

ABBOTT LABORATORIES  
Form 10-K  
February 21, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D. C. 20549

---

**FORM 10-K**

(MARK ONE)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934  
OR  
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

---

For the fiscal year ended December 31, 2013

Commission file number 1-2189

**Abbott Laboratories**

An Illinois Corporation  
100 Abbott Park Road  
Abbott Park, Illinois 60064-6400

**36-0698440**  
(I.R.S. employer identification number)  
**(847) 937-6100**  
(telephone number)

Securities Registered Pursuant to Section 12(b) of the Act:

| Title of Each Class              | Name of Each Exchange on Which Registered         |
|----------------------------------|---------------------------------------------------|
| Common Shares, Without Par Value | New York Stock Exchange<br>Chicago Stock Exchange |

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☒ Accelerated Filer ☐ Non-accelerated Filer ☐ Smaller Reporting Company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

The aggregate market value of the 1,516,025,819 shares of voting stock held by nonaffiliates of the registrant, computed by reference to the closing price as reported on the New York Stock Exchange, as of the last business day of Abbott Laboratories' most recently completed second fiscal quarter (June 30, 2013), was \$52,878,980,567. Abbott has no non-voting common equity.

Number of common shares outstanding as of January 31, 2014: 1,543,070,300

### DOCUMENTS INCORPORATED BY REFERENCE

Portions of the 2014 Abbott Laboratories Proxy Statement are incorporated by reference into Part III. The Proxy Statement will be filed on or about March 14, 2014.

---

**PART I**

**ITEM 1. BUSINESS**

**GENERAL DEVELOPMENT OF BUSINESS**

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's\* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.

**FINANCIAL INFORMATION RELATING TO INDUSTRY SEGMENTS, GEOGRAPHIC AREAS, AND CLASSES OF SIMILAR PRODUCTS**

Incorporated herein by reference is Note 14 entitled "Segment and Geographic Area Information" of the Notes to Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data."

**NARRATIVE DESCRIPTION OF BUSINESS**

Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Prior to January 1, 2013, Abbott had five reportable segments, which included Proprietary Pharmaceutical Products.

On January 1, 2013, Abbott completed the separation of its research-based proprietary pharmaceuticals business through the distribution of the issued and outstanding common stock of AbbVie Inc. (AbbVie) to Abbott's shareholders. AbbVie was formed to hold Abbott's research-based proprietary pharmaceuticals business and, as a result of the distribution, is now an independent public company trading under the symbol "ABBV" on the New York Stock Exchange.

The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line in Abbott's Consolidated Statement of Earnings. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013.

---

\*

As used throughout the text of this report on Form 10-K, the term "Abbott" refers to Abbott Laboratories, an Illinois corporation, or Abbott Laboratories and its consolidated subsidiaries, as the context requires.

## Established Pharmaceutical Products

These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States, and are generally sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with other companies.

The principal products included in the broad therapeutic area portfolios of the Established Pharmaceutical Products segment are:

gastroenterology products, including Creon®, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal® and Dicetel®, for the treatment of irritable bowel syndrome or biliary spasm; Adomet®, Heptral®, Transmetil®, Samyr®, and Donamet®, for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and Duphalac®, for regulation of the physiological rhythm of the colon;

women's health products, including Duphaston®, for the treatment of many different gynecological disorders; and Femoston®, a hormone replacement therapy for postmenopausal women;

cardiovascular and metabolic products, including Lipanthyl® and TriCor®, for the treatment of dyslipidemia; Teveten® and Teveten® Plus, for the treatment of essential hypertension, and Physiotens®, for the treatment of hypertension; and Synthroid®, for the treatment of hypothyroidism;

pain and central nervous system products, including Serc®, for the treatment of Ménière's disease and vestibular vertigo; and Brufen®, for the treatment of pain, fever, and inflammation; and

respiratory drugs and vaccines, including the anti-infective clarithromycin (sold under the trademarks Biaxin®, Klacid®, and Klaricid®); and Influvac®, an influenza vaccine available during flu season.

The Established Pharmaceutical Products segment directs its primary marketing efforts toward building a strong brand with key stakeholders, including, in certain markets, consumers, as well as securing the prescription, or recommendation, of Abbott's brand of products by physicians, pharmacists and other healthcare providers. Government agencies are also important customers.

Competition in the Established Pharmaceutical Products segment is generally from other health care and pharmaceutical companies. Changes to government tenders and reimbursement schemes are significant factors with respect to pricing. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors have increased competitive pressures.

## Diagnostic Products

These products include a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies. In the United States, the segment's products are generally marketed and sold directly from Abbott-owned distribution centers, public warehouses and third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.

The principal products included in the Diagnostic Products segment are:

immunoassay and clinical chemistry systems, including ARCHITECT® and ABBOTT PRISM®;



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases such as hepatitis and HIV;

a full line of hematology systems and reagents known as the Cell-Dyn® series;

the m2000 , an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents including HIV, HBV, HCV, HPV, and CT/NG;

the Vysis® product line of genomic-based tests, including the PathVysion® HER-2 DNA probe kit; the UroVysion® bladder cancer recurrence kit; and the Vysis ALK Break Apart FISH Probe Kit, the only FDA-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI®;

informatics and automation solutions for use in the laboratory; and

the i-STAT® point-of-care diagnostic systems and tests for blood analysis.

The Diagnostic Products segment's products are subject to competition in technological innovation, price, convenience of use, service, instrument warranty provisions, product performance, long-term supply contracts, and product potential for overall cost-effectiveness and productivity gains. Some products in this segment can be subject to rapid product obsolescence or regulatory changes. Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.

### Nutritional Products

These products include a broad line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. These products are generally marketed and sold directly to customers and to institutions, wholesalers, retailers, health care facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-party distributors.

The principal products included in the Nutritional Products segment are:

various forms of prepared infant formula and follow-on formula, including Similac®, Similac®Advance®, Similac® Advance® with EarlyShield®, Similac® with Iron, Similac Sensitive®, Similac Sensitive® RS, Similac Go&Grow®, Similac® NeoSure®, Similac® Organic, Similac Special Care®, Similac Total Comfort , Similac® For Supplementation, Isomil® Advance®, Isomil®, Alimentum®, Gain , and Grow ;

adult and other pediatric nutritional products, including Ensure®, Ensure Plus®, Ensure® Muscle Health, Ensure® (with Nutrivigor®), Glucerna®, Glucerna Hunger Smart®, ProSure®, PediaSure®, PediaSure Sidekicks®, EleCare®, Juven®, Abound®, and Pedialyte®;

nutritional products used in enteral feeding in health care institutions, including Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Osmolite®, Oxepa®, Freego (Enteral Pump) and Freego® sets, and Nepro®; and

Zone Perfect® bars and the EAS® family of nutritional brands, including Myoplex® and AdvantEdge®.

Primary marketing efforts for nutritional products are directed toward securing the recommendation of Abbott's brand of products by physicians or other health care professionals. In addition, certain nutritional products sold as Gain , Grow , PediaSure®, PediaSure Sidekicks®, Pedialyte®, Ensure®, Zone Perfect®, EAS®/Myoplex®, and Glucerna® are also promoted directly to the public by consumer marketing efforts in select markets.



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Competition for nutritional products in the segment is generally from other diversified consumer and health care manufacturers. Competitive factors include consumer advertising, formulation, packaging, scientific innovation, intellectual property, price, retail distribution, and availability of product forms. A significant aspect of competition is the search for ingredient innovations. The introduction of new products by competitors, changes in medical practices and procedures, and regulatory changes can result in product obsolescence. In addition, private label and local manufacturers' products may increase competitive pressure.

### Vascular Products

These products include a broad line of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease manufactured, marketed and sold worldwide. In the United States, the segment's products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.

The principal products included in the Vascular Products segment are:

Xience Xpedition®, Xience Prime®, Xience nano®, Xience V®, and Xience Pro , drug-eluting coronary stent systems developed on the Multi-Link Vision® platform;

Absorb , a drug-eluting coronary bioresorbable vascular scaffold;

Multi-Link 8®, Multi-Link Vision® and Multi-Link Mini Vision®, coronary metallic stents;

TREK® and Voyager®, coronary balloon dilatation products;

Hi-Torque Balance Middleweight Elite® and ASAHI® coronary guidewires (licensed from Asahi Intecc Co., Ltd.);

MitraClip®, a percutaneous mitral valve repair system;

Supera Veritas, a stent system for the treatment of biliary strictures related to cancer in the United States and peripheral artery disease outside the United States;

StarClose SE® and Perclose® vessel closure devices; and

Acculink®/Accunet® and Xact®/Emboshield NAV<sup>6</sup>®, carotid stent systems.

The Vascular Products segment's products are subject to competition in technological innovation, price, convenience of use, service, product performance, long-term supply contracts, and product potential for overall cost-effectiveness and productivity gains. Some products in this segment can be subject to rapid product obsolescence or regulatory changes. Although Abbott has benefited from technological advantages of certain of its current products, these advantages may be reduced or eliminated as competitors introduce new products.

### Other Products

The principal products in Abbott's other businesses include blood glucose and continuous glucose monitoring systems, test strips, data management software and accessories for people with diabetes, including the FreeStyle® product line, and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. These products are marketed worldwide and generally sold directly to wholesalers, government agencies, health care facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring systems, contact lens care products, and dry eye products are also marketed and sold over-the-counter to consumers. These





## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

products are subject to regulatory changes and competition in technological innovation, price, convenience of use, service, and product performance.

### INFORMATION WITH RESPECT TO ABBOTT'S BUSINESS IN GENERAL

#### Sources and Availability of Raw Materials

Abbott purchases, in the ordinary course of business, raw materials and supplies essential to Abbott's operations from numerous suppliers in the United States and abroad. There have been no recent significant availability problems or supply shortages for raw materials or supplies.

#### Patents, Trademarks, and Licenses

Abbott is aware of the desirability for patent and trademark protection for its products. Accordingly, where possible, patents and trademarks are sought and obtained for Abbott's products in the United States and countries of interest to Abbott. Abbott owns and is licensed under a substantial number of patents and patent applications. Principal trademarks and the products they cover are discussed in the Narrative Description of Business on pages 1 through 4. These, and various patents which expire during the period 2014 to 2034, in the aggregate, are believed to be of material importance in the operation of Abbott's business. Abbott believes that no single patent, license, or trademark is material in relation to Abbott's business as a whole. Patent-related litigation is discussed in Legal Proceedings on pages 17 through 18.

#### Seasonal Aspects, Customers, Backlog, and Renegotiation

There are no significant seasonal aspects to Abbott's business. Abbott has no single customer that, if the customer were lost, would have a material adverse effect on Abbott. Orders for Abbott's products are generally filled on a current basis, and order backlog is not material to Abbott's business. No material portion of Abbott's business is subject to renegotiation of profits or termination of contracts at the election of a government.

#### Research and Development

Abbott spent approximately \$1.5 billion per year in 2013, 2012, and 2011 on research to discover and develop new products and processes and to improve existing products and processes.

#### Environmental Matters

Abbott believes that its operations comply in all material respects with applicable laws and regulations concerning environmental protection. Regulations under federal and state environmental laws impose stringent limitations on emissions and discharges to the environment from various manufacturing operations. Abbott's capital and operating expenditures for pollution control in 2013 were approximately \$9 million and \$35 million, respectively. Capital and operating expenditures for pollution control in 2014 are estimated to be \$11 million and \$36 million, respectively.

Abbott has been identified as one of many potentially responsible parties in investigations and/or remediations at several locations in the United States, including Puerto Rico, under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund. Abbott is also engaged in remediation at several other sites, some of which are owned by Abbott, in cooperation with the Environmental Protection Agency (EPA) or similar agencies. While it is not feasible to predict with certainty the final costs related to those investigations and remediation activities, Abbott believes that such costs, together with other expenditures to maintain compliance with applicable laws and regulations concerning environmental protection, should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

## Employees

Abbott employed approximately 69,000 persons as of December 31, 2013.

## Regulation

The development, manufacture, marketing, sale, promotion, and distribution of Abbott's products are subject to comprehensive government regulation by the U.S. Food and Drug Administration and similar international regulatory agencies. Government regulation by various international, supranational, federal and state agencies addresses (among other matters) the development and approval to market Abbott's products, as well as the inspection of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, labeling, packaging, supply chains, marketing and promotion, pricing and reimbursement, sampling, distribution, quality control, post-market surveillance, record keeping, storage, and disposal practices. Abbott's international operations are also affected by trade and investment regulations in many countries. These may require local investment, restrict Abbott's investments, or limit the import of raw materials and finished products. In addition, Abbott is subject to laws and regulations pertaining to health care fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. Prescription drug, nutrition, and medical device manufacturers such as Abbott are also subject to taxes, as well as application, product, user, establishment, and other fees. Governmental agencies can also invalidate intellectual property rights.

Compliance with these laws and regulations is costly and materially affects Abbott's business. Among other effects, health care regulations substantially increase the time, difficulty, and costs incurred in obtaining and maintaining approval to market newly developed and existing products. Abbott expects this regulatory environment will continue to require significant technical expertise and capital investment to ensure compliance. Failure to comply can delay the release of a new product or result in regulatory and enforcement actions, the seizure or recall of a product, the suspension or revocation of the authority necessary for a product's production and sale, and other civil or criminal sanctions, including fines and penalties.

Abbott's business can also be affected by ongoing studies of the utilization, safety, efficacy, and outcomes of health care products and their components that are regularly conducted by industry participants, government agencies, and others. These studies can call into question the utilization, safety, and efficacy of previously marketed products. In some cases, these studies have resulted, and may in the future result, in the discontinuance of marketing of such products in one or more countries, and may give rise to claims for damages from persons who believe they have been injured as a result of their use.

Access to human health care products continues to be a subject of investigation and action by governmental agencies, legislative bodies, and private organizations in many countries. A major focus is cost containment. Efforts to reduce health care costs are also being made in the private sector, notably by health care payors and providers, which have instituted various cost reduction and containment measures. Abbott expects insurers and providers to continue attempts to reduce the cost of health care products. Many countries control the price of health care products directly or indirectly, through reimbursement, payment, pricing, coverage limitations, or compulsory licensing. Budgetary pressures on health care payors may also heighten the scope and severity of pricing pressures on Abbott's products for the foreseeable future.

In the United States, the federal government follows a diagnosis-related group (DRG) payment system for certain institutional services provided under Medicare or Medicaid and has implemented a prospective payment system (PPS) for services delivered in hospital outpatient, nursing home, and home health settings. DRG and PPS entitle a health care facility to a fixed reimbursement based on the diagnosis and/or procedure rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products. The Centers for Medicare and Medicaid Services have announced plans to reevaluate reimbursement levels to diagnostic

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

laboratories. Under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (together, the Affordable Care Act), Abbott must pay an excise tax on sales of certain medical devices. Medicare also implemented a competitive bidding system for durable medical equipment (including diabetes products), enteral nutrition products, and supplies.

In the United States, governmental cost containment efforts also affect Abbott's nutrition business. Under regulations governing the federally funded Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), all states must have a cost containment program for infant formula. As a result, through competitive bidding states obtain rebates from manufacturers of infant formula whose products are used in the program.

The Affordable Care Act also includes provisions known as the Physician Payments Sunshine Act, which require manufacturers of drugs, devices, and medical supplies covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data, beginning in 2014, to the Centers for Medicare and Medicaid Services for subsequent public disclosure. Similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with health care professionals. Failure to report appropriate data may result in civil or criminal fines and/or penalties.

The regulation of data privacy and security and the protection of the confidentiality of certain patient health information, is increasing. For example, the European Union continues to contemplate enacting stricter laws with enhanced financial penalties for noncompliance. Similarly, in 2013, the U.S. Department of Health and Human Services issued stricter rules governing the use, disclosure, and security of protected health information. Failure to comply with data privacy and security regulations can result in enforcement actions, which could include civil or criminal penalties. Transferring and managing protected health information will become more challenging as new laws and regulations are enacted, and Abbott expects there will be increasing regulatory complexity in this area.

Abbott expects debate to continue during 2014 at all government levels worldwide over the marketing, availability, method of delivery, and payment for health care products and services, as well as data privacy and security. Abbott believes that future legislation and regulation in the markets it serves could affect access to health care products and services, increase rebates, reduce prices or reimbursements or the rate of price increases for health care products and services, change health care delivery systems, create new fees and obligations for the pharmaceutical, nutrition, diagnostic, and medical device industries, or require additional reporting and disclosure. It is not possible to predict the extent to which Abbott or the health care industry in general might be affected by the matters discussed above.

### INTERNATIONAL OPERATIONS

As discussed in greater detail in the section captioned, "Narrative Description of Business," Abbott markets products worldwide through affiliates and distributors. Most of the products discussed in the preceding sections of this report are also sold outside the United States. In addition, certain products of a local nature and variations of product lines to meet local regulatory requirements and marketing preferences are manufactured and marketed to customers outside the United States. International operations are subject to certain additional risks inherent in conducting business outside the United States, including price and currency exchange controls, changes in currency exchange rates, limitations on foreign participation in local enterprises, expropriation, nationalization, and other governmental action.

### INTERNET INFORMATION

Copies of Abbott's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are available free of charge through Abbott's investor relations website

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

([www.abbottinvestor.com](http://www.abbottinvestor.com)) as soon as reasonably practicable after Abbott electronically files the material with, or furnishes it to, the Securities and Exchange Commission.

Abbott's corporate governance guidelines, outline of directorship qualifications, code of business conduct and the charters of Abbott's audit committee, compensation committee, nominations and governance committee, and public policy committee are all available on Abbott's investor relations website ([www.abbottinvestor.com](http://www.abbottinvestor.com)).

## ITEM 1A. RISK FACTORS

In addition to the other information in this report, the following risk factors should be considered before deciding to invest in any of Abbott's securities. Additional risks and uncertainties not presently known to Abbott, or risks Abbott currently considers immaterial, could also affect Abbott's actual results. Abbott's business, financial condition, results of operations, or prospects could be materially adversely affected by any of these risks.

**Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.**

Abbott may pursue acquisitions, licensing arrangements, and strategic alliances, or dispose of or spin-off some of its businesses, as part of its business strategy. Abbott may not complete these transactions in a timely manner, on a cost-effective basis, or at all, and may not realize the expected benefits. If Abbott is successful in making an acquisition, the products and technologies that are acquired may not be successful or may require significantly greater resources and investments than originally anticipated. Abbott may not be able to integrate acquisitions successfully into its existing business and could incur or assume significant debt and unknown or contingent liabilities. Abbott could also experience negative effects on its reported results of operations from acquisition or disposition-related charges, amortization of expenses related to intangibles and charges for impairment of long-term assets. These effects could cause a deterioration of Abbott's credit rating and result in increased borrowing costs and interest expense.

**Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating income.**

In the United States and other countries, Abbott's businesses have experienced downward pressure on product pricing. Cost containment efforts by governments and private organizations are described in greater detail in the section captioned "Regulation." To the extent these cost containment efforts are not offset by greater patient access to health care or other factors, Abbott's future revenues and operating income will be reduced.

**Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and processes.**

Abbott's products are subject to rigorous regulation by the U.S. Food and Drug Administration (FDA) and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a drug or medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, future products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs.

In addition, no assurance can be given that Abbott will remain in compliance with applicable FDA and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and postmarketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns. Many of Abbott's facilities and procedures and those of Abbott's suppliers are subject to ongoing regulation, including periodic inspection by the FDA and other regulatory authorities. Abbott must incur expense and spend time and effort to ensure compliance with these complex regulations. Possible regulatory actions for non-compliance could include warning letters, fines, damages, injunctions, civil penalties, recalls, seizures of Abbott's products, and criminal prosecution. These actions could result in, among other things, substantial modifications to Abbott's business practices

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

and operations; refunds, recalls, or seizures of Abbott's products; a total or partial shutdown of production in one or more of Abbott's facilities while Abbott or Abbott's suppliers remedy the alleged violation; the inability to obtain future pre-market approvals or marketing authorizations; and withdrawals or suspensions of current products from the market. Any of these events could disrupt Abbott's business and have a material adverse effect on Abbott's revenues, profitability and financial condition.

### **Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations in the future.**

Abbott's industry is subject to various international, supranational, federal, and state laws and regulations pertaining to government benefit program reimbursement, price reporting and regulation, and health care fraud and abuse, including anti-kickback and false claims laws, and international and individual state laws relating to pricing and sales and marketing practices. Violations of these laws may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, imprisonment, and exclusion from participation in government health care programs, including Medicare, Medicaid, and Veterans Administration health programs in the U.S. These laws and regulations are broad in scope and they are subject to evolving interpretations, which could require Abbott to incur substantial costs associated with compliance or to alter one or more of its sales or marketing practices. In addition, violations of these laws, or allegations of such violations, could disrupt Abbott's business and result in a material adverse effect on Abbott's revenues, profitability, and financial condition.

### **Changes in the health care regulatory environment may adversely affect Abbott's business.**

A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 change access to health care products and services and establish new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. Abbott cannot predict the timing or impact of any future rulemaking.

### **The expiration or loss of patent protection and licenses may affect Abbott's future revenues and operating income.**

Many of Abbott's businesses rely on patent and trademark and other intellectual property protection. Although most of the challenges to Abbott's intellectual property have come from other businesses, governments may also challenge intellectual property protections. To the extent Abbott's intellectual property is successfully challenged, invalidated, or circumvented or to the extent it does not allow Abbott to compete effectively, Abbott's business will suffer. To the extent that countries do not enforce Abbott's intellectual property rights or to the extent that countries require compulsory licensing of its intellectual property, Abbott's future revenues and operating income will be reduced. Litigation regarding Abbott's patents and trademarks is described in the section captioned "Legal Proceedings."

### **Competitors' intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott's future profitability and financial condition.**

Competitors may claim that an Abbott product infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require Abbott to enter into license agreements. Abbott cannot guarantee that it would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject Abbott to significant damages or an injunction preventing the manufacture, sale or use of affected Abbott products. Any of these events could have a material adverse effect on Abbott's profitability and financial condition.

**Abbott's research and development efforts may not succeed in developing commercially successful products and technologies, which may cause Abbott's revenue and profitability to decline.**

To remain competitive, Abbott must continue to launch new products and technologies. To accomplish this, Abbott commits substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. Abbott must make ongoing substantial expenditures without any assurance that its efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested.

Promising new product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if Abbott successfully develops new products or enhancements or new generations of Abbott's existing products, they may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations. Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. Abbott cannot state with certainty when or whether any of its products under development will be launched, whether it will be able to develop, license, or otherwise acquire compounds or products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause Abbott's products to become obsolete, causing Abbott's revenues and operating results to suffer.

**New products and technological advances by Abbott's competitors may negatively affect Abbott's results of operations.**

Abbott's products face intense competition from its competitors' products. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than Abbott's products. Abbott cannot predict with certainty the timing or impact of the introduction of competitors' products.

**The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott's business could suffer.**

The manufacture of many of Abbott's products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters, and environmental factors. In addition, single suppliers are currently used for certain products and materials. If problems arise during the production of a batch of product, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. To the extent Abbott or one of its suppliers experiences significant manufacturing problems, this could have a material adverse effect on Abbott's revenues and profitability.

**Significant safety concerns could arise for Abbott's products, which could have a material adverse effect on Abbott's revenues and financial condition.**

Health care products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive,



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

studies. If new safety issues are reported, Abbott may be required to amend the conditions of use for a product. For example, Abbott may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with an Abbott product, sales of the product could be halted by Abbott or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of Abbott's products.

In addition, in the ordinary course of business, Abbott is the subject of product liability claims and lawsuits alleging that its products or the products of other companies that Abbott promotes have resulted or could result in an unsafe condition for or injury to patients. Product liability claims and lawsuits, safety alerts or product recalls, and other allegations of product safety or quality issues, regardless of their validity or ultimate outcome, may have a material adverse effect on Abbott's business and reputation and on Abbott's ability to attract and retain customers. Consequences may also include additional costs, a decrease in market share for the products, lower income or exposure to other claims. Product liability losses are self-insured. Product liability claims could have a material adverse effect on Abbott's profitability and financial condition.

### **Deterioration in the economic position and credit quality of certain countries may negatively affect Abbott's results of operations.**

Unfavorable economic conditions in certain countries may increase the time it takes to collect outstanding trade receivables. Financial instability and fiscal deficits in these countries may result in additional austerity measures to reduce costs, including health care. Deterioration in the quality of sovereign debt, including credit downgrades, could increase Abbott's collection risk where a significant amount of Abbott's receivables in these countries are with governmental health care systems.

### **Abbott depends on sophisticated information technology systems to operate its business and a cyber attack or other breach of these systems could have a material adverse effect on Abbott's results of operations.**

Similar to other large multi-national companies, the size and complexity of Abbott's information technology systems makes them vulnerable to a cyber attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Abbott's systems have been and are expected to continue to be the target of malware and other cyber attacks. Abbott has invested in its systems and the protection of its data to reduce the risk of an invasion or interruption and monitors its systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns that could have a significant effect on Abbott's business.

### **Abbott may incur operational difficulties or be exposed to claims and liabilities as a result of the separation.**

AbbVie and Abbott entered into a separation and distribution agreement and various other agreements to govern the separation of AbbVie from Abbott and the relationship between the two companies going forward. Certain of these agreements provide for the performance of services by each company for the benefit of the other for a period of time. If AbbVie is unable to satisfy its obligations under these agreements, including its indemnification obligations, Abbott could incur operational difficulties or losses. These arrangements could also lead to disputes between Abbott and AbbVie over Abbott's rights to certain shared property and rights and over the allocation of costs and revenues for products and operations.

The separation and distribution agreement also provides for, among other things, indemnification obligations designed to make AbbVie financially responsible for substantially all liabilities that may exist relating to its business activities, whether incurred prior to or after AbbVie's separation from Abbott, as well as those obligations of Abbott assumed by AbbVie pursuant to the separation and distribution

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

agreement. It is possible that a court would disregard the allocation agreed to between Abbott and AbbVie and require Abbott to assume responsibility for obligations allocated to AbbVie. Third parties could also seek to hold Abbott responsible for any of these liabilities or obligations. The indemnity rights Abbott has under the separation agreement may not be sufficient to protect Abbott. Even if Abbott is successful in obtaining indemnification, Abbott may have to bear losses temporarily. In addition, Abbott's indemnity obligations to AbbVie may be significant. These risks could negatively affect Abbott's results of operations.

### **There could be significant liability if the distribution of AbbVie common stock to Abbott shareholders is determined to be a taxable transaction.**

Abbott received a private letter ruling from the Internal Revenue Service (IRS) to the effect that, among other things, the separation and the distribution of AbbVie qualifies as a transaction that is tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code (the Code). In addition, Abbott received an opinion from outside tax counsel to the effect that the separation and distribution qualifies as a transaction that is described in Sections 355(a) and 368(a)(1)(D) of the Code. The ruling and the opinion rely on certain facts, assumptions, representations and undertakings from Abbott and AbbVie regarding the past and future conduct of the companies' respective businesses and other matters. If any of these facts, assumptions, representations or undertakings are incorrect or not satisfied, Abbott and its shareholders may not be able to rely on the ruling or the opinion of tax counsel and could be subject to significant tax liabilities. Notwithstanding the receipt by Abbott of the private letter ruling from the IRS and opinion of tax counsel, the IRS could determine on audit that the separation is taxable if it determines that any of these facts, assumptions, representations or undertakings are not correct or have been violated or if it disagrees with the conclusions in the opinion that are not covered by the private letter ruling, or for other reasons, including as a result of certain significant changes in the share ownership of Abbott or AbbVie after the separation. If the separation is determined to be taxable for U.S. federal income tax purposes, Abbott and its shareholders that are subject to U.S. federal income tax could incur significant U.S. federal income tax liabilities.

### **The international nature of Abbott's business subjects it to additional business risks that may cause its revenue and profitability to decline.**

Abbott's business is subject to risks associated with doing business internationally. Sales outside of the United States make up approximately 70 percent of Abbott's net sales. Additional risks associated with Abbott's international operations include:

fluctuations in currency exchange rates;

differing local product preferences and product requirements;

trade protection measures and import or export licensing requirements;

difficulty in establishing, staffing, and managing operations;

differing labor regulations;

potentially negative consequences from changes in or interpretations of tax laws;

political and economic instability, including sovereign debt issues;

price and currency exchange controls, limitations on participation in local enterprises, expropriation, nationalization, and other governmental action;

inflation, recession, and fluctuations in interest rates;

compulsory licensing or diminished protection of intellectual property; and



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

potential penalties or other adverse consequences for violations of anti-corruption, anti-bribery, and other similar laws and regulations, including the Foreign Corrupt Practices Act and the U.K. Bribery Act.

Events contemplated by these risks may, individually or in the aggregate, have a material adverse effect on Abbott's revenues and profitability.

### **Other factors can have a material adverse effect on Abbott's future profitability and financial condition.**

Many other factors can affect Abbott's profitability and its financial condition, including:

changes in or interpretations of laws and regulations, including changes in accounting standards, taxation requirements, product marketing application standards, product labeling, source and use laws, and environmental laws;

differences between the fair value measurement of assets and liabilities and their actual value, particularly for pensions, retiree health care, stock compensation, intangibles, and goodwill; and for contingent liabilities such as litigation, the absence of a recorded amount, or an amount recorded at the minimum, compared to the actual amount;

changes in the rate of inflation (including the cost of raw materials, commodities, and supplies), interest rates, market value of Abbott's equity investments, and the performance of investments held by Abbott or Abbott's employee benefit trusts;

changes in the creditworthiness of counterparties that transact business with or provide services to Abbott or Abbott's employee benefit trusts;

changes in business, economic, and political conditions, including: war, political instability, terrorist attacks, the threat of future terrorist activity and related military action; natural disasters; the cost and availability of insurance due to any of the foregoing events; labor disputes, strikes, slow-downs, or other forms of labor or union activity; and pressure from third-party interest groups;

changes in Abbott's business units and investments and changes in the relative and absolute contribution of each to earnings and cash flow resulting from evolving business strategies, changing product mix, changes in tax laws or tax rates both in the U.S. and abroad and opportunities existing now or in the future;

changes in the buying patterns of a major distributor, retailer, or wholesale customer resulting from buyer purchasing decisions, pricing, seasonality, or other factors, or other problems with licensors, suppliers, distributors, and business partners;

changes in credit markets impacting Abbott's ability to obtain financing for its business operations; and

legal difficulties, any of which could preclude or delay commercialization of products or adversely affect profitability, including claims asserting statutory or regulatory violations, and adverse litigation decisions.

### **CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This Form 10-K contains forward-looking statements that are based on management's current expectations, estimates, and projections. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "forecasts," variations of these words, and similar expressions are intended to identify these forward-looking statements. Certain factors, including but not limited to those identified under "Item 1A. Risk Factors" of this Form 10-K, may cause actual results to differ materially from current expectations, estimates, projections, forecasts, and from past results. No assurance can be made that any expectation, estimate, or projection contained in a forward-looking statement will be



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

achieved or will not be affected by the factors cited above or other future events. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments, except as required by law.

### **ITEM 1B. UNRESOLVED STAFF COMMENTS**

None.

**ITEM 2. PROPERTIES**

Abbott's corporate offices are located at 100 Abbott Park Road, Abbott Park, Illinois 60064. The locations of Abbott's principal plants, as of December 31, 2013, are listed below.

| <b>Location</b>           | <b>Segments of Products Produced</b>             |
|---------------------------|--------------------------------------------------|
| Abbott Park, Illinois     | Diagnostic Products                              |
| Alajuela, Costa Rica      | Vascular Products                                |
| Alcobendas, Spain         | Non-Reportable                                   |
| Altavista, Virginia       | Nutritional Products                             |
| Anasco, Puerto Rico*      | Non-Reportable                                   |
| Baddi, India              | Established Pharmaceutical Products              |
| Barceloneta, Puerto Rico* | Established Pharmaceutical and Vascular Products |
| Beringen, Switzerland*    | Vascular Products                                |
| Buenos Aires, Argentina   | Established Pharmaceutical Products              |
| Casa Grande, Arizona      | Nutritional Products                             |
| Chatillon, France         | Established Pharmaceutical Products              |
| Clonmel, Ireland          | Vascular Products                                |
| Columbus, Ohio            | Nutritional Products                             |
| Cootehill, Ireland        | Nutritional Products                             |
| Dartford, England         | Diagnostic Products                              |
| Des Plaines, Illinois     | Diagnostic Products                              |
| Donegal, Ireland          | Non-Reportable                                   |
| Fairfield, California*    | Nutritional Products                             |
| Goa, India                | Established Pharmaceutical Products              |
| Granada, Spain            | Nutritional Products                             |
| Hangzhou, China           | Non-Reportable                                   |
| Irving, Texas             | Diagnostic Products                              |
| Karachi, Pakistan         | Established Pharmaceutical Products              |
| Katsuyama, Japan          | Established Pharmaceutical Products              |
| Longford, Ireland         | Diagnostic Products                              |
| Menlo Park, California    | Vascular Products                                |
| Milpitas, California*     | Non-Reportable                                   |
| Murrieta, California      | Vascular Products                                |
| Neustadt, Germany         | Established Pharmaceutical Products              |
| Olst, the Netherlands     | Established Pharmaceutical Products              |
| Ottawa, Canada*           | Diagnostic Products                              |
| Princeton, New Jersey*    | Diagnostic Products                              |
| Redwood City, California* | Vascular Products                                |
| Rio de Janeiro, Brazil    | Established Pharmaceutical Products              |
| Singapore                 | Nutritional Products                             |
| Sligo, Ireland            | Nutritional and Diagnostic Products              |
| Sturgis, Michigan         | Nutritional Products                             |
| Temecula, California      | Vascular Products                                |
| Tlalpan, Mexico           | Established Pharmaceutical Products              |
| Uppsala, Sweden           | Non-Reportable                                   |
| Weesp, the Netherlands    | Established Pharmaceutical Products              |
| Wiesbaden, Germany        | Diagnostic Products                              |
| Witney, England           | Non-Reportable                                   |
| Zwolle, the Netherlands   | Nutritional Products                             |

---

\*

Leased property

In addition to the above, as of December 31, 2013, Abbott had manufacturing facilities in four other locations in the United States and in six countries outside the United States. Abbott's facilities are deemed suitable and provide adequate productive capacity.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Abbott's research and development facilities in the United States are primarily located in California, Illinois, New Jersey, and Ohio. Abbott also has research and development facilities in various other countries including China, India, Singapore, Spain, and Switzerland.



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Except as noted, the corporate offices, and those principal plants in the United States listed above, are owned by Abbott or subsidiaries of Abbott. The remaining manufacturing plants and all other facilities are owned or leased by Abbott or subsidiaries of Abbott. There are no material encumbrances on the properties.

### ITEM 3. LEGAL PROCEEDINGS

Abbott is involved in various claims, legal proceedings and investigations, including (as of January 31, 2014, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

Seven shareholder derivative lawsuits are pending in a consolidated proceeding, *In Re Abbott-Depakote Shareholder Derivative Litigation*, in the United States District Court for the Northern District of Illinois against certain of Abbott's current and former directors and members of senior management. The lawsuits allege a breach of fiduciary duty in relation to certain business practices regarding the sales and marketing of Depakote. In each case, the plaintiffs request damages nominally on behalf of Abbott, attorneys' fees, and other forms of relief. *In Re Abbott-Depakote Shareholder Derivative Litigation* includes: *Chester County Employees' Retirement Fund*, *Warren Pinchuck and Roy Sapir*, and *Jacksonville Police & Fire Pension Fund*, all filed in November 2011; *Louisiana Municipal Police Employees' Retirement System* and *Pipefitters Local Union 537 Pension Fund*, both filed in December 2011; *Public School Retirement System of the School District of Kansas City, Missouri*, filed in January 2012; and *Pipefitters Local Union No. 120 Pension Fund*, filed in April 2012. On January 21, 2014, Abbott and the lead plaintiff entered into a Memorandum of Understanding in which they reached an agreement to settle. The agreement to settle is subject to court approval of a final settlement agreement. In November 2013, the Montini Family Trust and West Virginia Pipe Trades Health & Welfare Fund filed a related shareholder derivative action in the United States District Court for the Northern District of Illinois.

In January 2008, Cordis Corporation and Wyeth filed suit against Abbott in the United States District Court for the District of New Jersey alleging that the Xience V stent infringes three patents and seeking an injunction, damages, and a determination of willful infringement. In January 2012, the court issued an order invalidating the plaintiff's patents and dismissing the case against Abbott. Cordis and Wyeth withdrew one patent from the case and in June 2012 appealed the court's order invalidating the remaining two patents. On June 26, 2013, the appeals court affirmed the district court's order invalidating the two patents, and on October 11, 2013, the appeals court denied Cordis and Wyeth's petition for rehearing or rehearing en banc. The time for further appeals has expired. In a separate action, in September 2009, Wyeth, Cordis Corporation, and Cordis LLC filed suit against Abbott in the United States District Court for the District of New Jersey alleging the Xience V (and later the Xience Prime) stent systems infringe an additional patent, and in August 2010 the plaintiffs amended their lawsuit to add a second related patent to this case. The plaintiffs in this case seek an injunction and damages. In February 2012, the court stayed the litigation pending the completion of *inter partes* reexamination of the two patents at issue by the United States Patent and Trademark Office and any resulting appeals.

In December 2008, Medinol Limited (Medinol) sued Abbott in the Netherlands and in Germany asserting that certain of Abbott's coronary bare metal and all of its metal-based drug eluting stent products infringe one or more of Medinol's European and German stent design patents. In December 2009, the Dutch court found that Abbott's stents do not infringe the only patent asserted in The Netherlands. In October 2012, the Dutch appeals court affirmed. In January 2013, Medinol appealed its loss to the Dutch Supreme Court. In March 2010, a German court, which assesses questions of patent infringement, issued mixed infringement/non-infringement rulings, which both Abbott and Medinol have appealed. The infringement cases have been stayed pending further developments with respect to other Abbott-initiated actions relating to patent validity. In January 2011, a different German court, which assesses questions of

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

patent invalidity, found two of the Medinol patents invalid, but concluded that the modified claims of one of Medinol's German patents were valid. The question of validity of these patents has been appealed to the Federal Supreme Court. In June 2011, Medinol asserted another, related European patent against Abbott. The question of validity of this additional patent, along with other validity questions, is subject to continued lower court proceedings. Medinol seeks damages and injunctions in The Netherlands and seeks damages in Germany.

As previously mentioned, the Texas State Attorney General is investigating the sales and marketing activities of Abbott's biliary stent products and United States Attorney's Office for the District of Maryland is investigating the sales and marketing activities for Abbott's coronary stents products. The government is seeking to determine whether any of these activities violated civil and/or criminal laws, including the Federal False Claims Act, the Food and Drug Cosmetic Act, and the Anti-Kickback Statute in connection with Medicare and/or Medicaid reimbursement paid to third parties. An investigation by the United States Department of Justice through the United States Attorney's Office for the Eastern District of Tennessee relating to the sales and marketing activities for Abbott's biliary and carotid stents and stent related products was closed and a related qui tam case was settled and dismissed in December 2013.

Pursuant to the separation and distribution agreement, AbbVie is responsible for certain investigations, claims and litigation matters relating to Abbott's former research-based pharmaceuticals business. In some cases, AbbVie has been substituted for Abbott, and Abbott is no longer a party to such investigations, claims and litigation matters. In addition, AbbVie has assumed the liabilities associated with, and has agreed to indemnify Abbott for any damages incurred in connection with, certain investigations, claims and litigation matters, including the following:

Several cases are pending that generally allege that Abbott and numerous other pharmaceutical companies reported false pricing information in connection with certain drugs that are reimbursable under Medicare and Medicaid. These cases, brought by state Attorneys General, generally seek monetary damages and/or injunctive relief and attorneys' fees. The following previously reported cases have been settled: *Commonwealth of Kentucky*, filed in September 2003 in the Circuit Court of Franklin County, Kentucky; and *State of Louisiana*, filed in October 2010 in the Nineteenth Judicial District, Parish of Baton Rouge, Louisiana. The following cases are pending in state courts: *State of Wisconsin*, filed in June 2004 in the Circuit Court of Dane County, Wisconsin; and *State of Illinois*, filed in February 2005 in the Circuit Court of Cook County, Illinois. These cases are no longer material to Abbott, and Abbott will no longer report on these cases.

In April 2012, Roxane Laboratories, Inc. (Roxane) filed a declaratory judgment action in the United States District Court for the Southern District of Ohio alleging that two Abbott patents (which were contributed to AbbVie in connection with the separation of the research-based pharmaceuticals business) relating to ritonavir tablets (a drug AbbVie sells under the trademark Norvir®) are invalid and not infringed by Roxane proposed generic product. In November 2012, Roxane filed an amended declaratory judgment complaint in the United States District Court for the Southern District of Ohio, naming AbbVie as a defendant along with Abbott. This case is no longer material to Abbott, and Abbott will no longer report on this case.

### ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

## EXECUTIVE OFFICERS OF THE REGISTRANT

Executive officers of Abbott are elected annually by the board of directors. All other officers are elected by the board or appointed by the chairman of the board. All officers are either elected at the first meeting of the board of directors held after the annual shareholder meeting or appointed by the chairman after that board meeting. Each officer holds office until a successor has been duly elected or appointed and qualified or until the officer's death, resignation, or removal. Vacancies may be filled at any time by the board. Any officer may be removed by the board of directors when, in its judgment, removal would serve the best interests of Abbott. Any officer appointed by the chairman of the board may be removed by the chairman whenever, in the chairman's judgment, removal would serve the best interests of Abbott. A vacancy in any office appointed by the chairman of the board may be filled by the chairman.

Abbott's executive officers, their ages as of February 21, 2014, and the dates of their first election as officers of Abbott are listed below. The executive officers' principal occupations and employment for the past five years and the year of appointment to the earliest reported office are also shown. Unless otherwise stated, employment was by Abbott. There are no family relationships between any corporate officers or directors.

### **Miles D. White, 58**

1999 to present Chairman of the Board and Chief Executive Officer, and Director.

Elected Corporate Officer 1993.

### **Hubert L. Allen, 48**

2013 to present Executive Vice President, General Counsel and Secretary.

2010 to 2012 Divisional Vice President and Associate General Counsel, Established Pharmaceuticals.

2009 to 2010 Divisional Vice President and Associate General Counsel, Proprietary Pharmaceuticals.

2007 to 2009 Section Head, Legal, Abbott Nutrition.

Elected Corporate Officer 2012.

### **Richard W. Ashley, 70**

2004 to present Executive Vice President, Corporate Development.

Elected Corporate Officer 2004.

### **Brian J. Blaser, 49**

2012 to present Executive Vice President, Diagnostics Products.

2010 to 2012 Senior Vice President, Diagnostics.

2008 to 2010 Vice President, Diagnostics, Operations.

Elected Corporate Officer 2008.

### **John M. Capek, 52**

2007 to present Executive Vice President, Medical Devices.

Elected Corporate Officer 2006.



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

### **Thomas C. Freyman, 59**

2004 to present Executive Vice President, Finance and Chief Financial Officer.

Elected Corporate Officer 1991.

### **Stephen R. Fussell, 56**

2013 to present Executive Vice President, Human Resources.

2005 to 2013 Senior Vice President, Human Resources.

Elected Corporate Officer 1999.

### **John C. Landgraf, 61**

2013 to present Executive Vice President, Nutritional Products.

2011 to 2013 Executive Vice President, Nutritional Products.

2004 to 2010 Senior Vice President, Pharmaceuticals, Manufacturing and Supply.

Elected Corporate Officer 2013. (Mr. Landgraf was also an Abbott corporate officer from 2000 until February 2013, and retired from Abbott at the end of March 2013. Mr. Landgraf returned to Abbott in October 2013.)

### **Michael J. Warmuth, 51**

2012 to present Executive Vice President, Established Pharmaceuticals.

2010 to 2012 Senior Vice President, Established Products, Pharmaceutical Products Group.

2008 to 2010 Senior Vice President, Diagnostics.

Elected Corporate Officer 2007.

### **Jaime Contreras, 57**

2013 to present Senior Vice President, Core Laboratory Diagnostics, Commercial Operations.

2008 to 2013 Vice President, Diagnostics, Global Commercial Operations.

Elected Corporate Officer 2003.

### **Georges H. De Vos, 54**

2013 to present Senior Vice President, Established Pharmaceuticals, Emerging Markets.

2011 to 2013 Managing Director, Limestone NV (a healthcare consulting firm).

2009 to 2011 Global Chief Operating Officer, Omega Pharma NV (a Belgian-based pharmaceutical company).

2007 to 2009 CEO Pharmaceuticals Russia, Novartis AG (a Swiss multinational pharmaceutical company).

Elected Corporate Officer 2013.

### **Katherine C. Doyle, 46**

Edgar Filing: ABBOTT LABORATORIES - Form 10-K

2013 to present Senior Vice President, U.S. Nutrition.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

2011 to 2013 Vice President, Pediatric Products.

2000 to 2011 Principal, McKinsey and Company (a management consulting firm).

Elected Corporate Officer 2011.

### **Charles D. Foltz, 53**

2013 to present Senior Vice President, Abbott Vascular.

2006 to 2013 Vice President, Vascular Product Operations.

Elected Corporate Officer 2006.

### **Heather L. Mason, 53**

2008 to present Senior Vice President, Diabetes Care.

Elected Corporate Officer 2001.

### **Jean-Yves F. Pavee, 50**

2013 to present Senior Vice President, Established Pharmaceuticals, Developed Markets.

2011 to 2013 Divisional Vice President, Established Pharmaceuticals, EMEA East.

2008 to 2011 Divisional Vice President, Europe South.

Elected Corporate Officer 2013.

### **Murthy V. Simhambhatla, 48**

2013 to present Senior Vice President, Abbott Medical Optics.

2012 Divisional Vice President and General Manager, Abbott Medical Optics.

2011 to 2012 Divisional Vice President and General Manager, Ibis.

2008 to 2011 General Manager, Australia and New Zealand, Vascular.

Elected Corporate Officer 2013.

### **J. Scott White, 46**

2013 to present Senior Vice President, International Nutrition.

2010 to 2013 Senior Vice President, U.S. Nutrition.

2007 to 2009 Division Vice President and Regional Director for Latin America, Abbott Nutrition International.

Elected Corporate Officer 2010.

### **Robert E. Funck, 52**

2013 to present Vice President, Controller.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

2009 to 2013 Vice President, Chief Ethics and Compliance Officer.

2007 to 2009 Vice President, Internal Audit.

Elected Corporate Officer 2005.



## PART II

## ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

## Principal Market

The principal market for Abbott's common shares is the New York Stock Exchange. Shares are also listed on the Chicago Stock Exchange and traded on various regional and electronic exchanges. Outside the United States, Abbott's shares are listed on the London Stock Exchange and the SIX Swiss Exchange.

|                | Market Price Per Share |          |          |          | Adjusted Market Price Per Share (1) |          |
|----------------|------------------------|----------|----------|----------|-------------------------------------|----------|
|                | 2013                   |          | 2012     |          | 2012                                |          |
|                | high                   | low      | high     | low      | high                                | low      |
| First Quarter  | \$ 35.34               | \$ 31.64 | \$ 61.49 | \$ 53.96 | \$ 29.42                            | \$ 25.82 |
| Second Quarter | 38.77                  | 34.69    | 64.47    | 59.04    | 30.85                               | 28.25    |
| Third Quarter  | 37.16                  | 32.70    | 70.41    | 63.51    | 33.69                               | 30.39    |
| Fourth Quarter | 38.81                  | 32.75    | 72.47    | 62.62    | 34.67                               | 29.96    |

(1)

The 2012 adjusted market prices per share reflect historical share prices that have been adjusted to reflect the separation of AbbVie.

## Shareholders

There were 57,854 shareholders of record of Abbott common shares as of December 31, 2013.

## Dividends

Abbott declared quarterly dividends of \$.14 per share on common shares in the first, second, and third quarters of 2013. In the fourth quarter of 2013, Abbott declared a quarterly dividend of \$.22 per share on common shares.

Abbott declared quarterly dividends of \$.51 per share on common shares in the first, second, and third quarters of 2012. In the fourth quarter of 2012, Abbott declared a quarterly dividend of \$.14 per share on common shares, reflecting the impact of the separation of AbbVie. On January 4, 2013, AbbVie reported that its board of directors had declared a quarterly dividend of \$.40 per share of AbbVie common stock.

On January 1, 2013, Abbott distributed the issued and outstanding common stock of AbbVie to Abbott's shareholders. Abbott's shareholders of record as of the close of business on December 12, 2012, the record date for the distribution, received one share of AbbVie common stock for each Abbott common share held as of the record date. Abbott shareholders received cash in lieu of any fractional shares of AbbVie common stock.

## Tax Information for Shareholders

In 2001, the Illinois Department of Commerce and Economic Opportunity designated Abbott as an Illinois High Impact Business ("HIB") for a period not to exceed twenty years. Dividends paid by a corporation that is designated as a HIB and conducts business in a foreign trade zone may be eligible for a subtraction from base income for Illinois income tax purposes. Abbott certified that the HIB requirements were met for the calendar year ending December 31, 2013.

If you have any questions, please contact your tax advisor.

## Issuer Purchases of Equity Securities

| Period                               | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|--------------------------------------|-------------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| October 1, 2013 – October 31, 2013   | 97,509(1)                                       | \$ 37.080                                  | 0                                                                                               | \$ 2,650,000,001(2)                                                                                                         |
| November 1, 2013 – November 30, 2013 | 49,986(1)                                       | \$ 38.100                                  | 0                                                                                               | \$ 2,650,000,001(2)                                                                                                         |
| December 1, 2013 – December 31, 2013 | 1,065,953(1)                                    | \$ 38.310                                  | 1,000,000                                                                                       | \$ 2,611,604,501(2)                                                                                                         |
| Total                                | 1,213,448(1)                                    | \$ 38.203                                  | 1,000,000                                                                                       | \$ 2,611,604,501(2)                                                                                                         |

(1)

These shares include:

(i)

the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options 97,509 in October, 16,756 in November, and 22,729 in December; and

(ii)

the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan 0 in October, 33,230 in November, and 43,224 in December.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(2)

On June 14, 2013, Abbott announced that its board of directors approved the purchase of up to \$3 billion of its common shares, from time to time.

**ITEM 6. SELECTED FINANCIAL DATA**

|                                                              | Year Ended December 31                              |           |           |           |           |
|--------------------------------------------------------------|-----------------------------------------------------|-----------|-----------|-----------|-----------|
|                                                              | 2013                                                | 2012      | 2011      | 2010      | 2009      |
|                                                              | <i>(dollars in millions, except per share data)</i> |           |           |           |           |
| Net sales (1)                                                | \$ 21,848                                           | \$ 21,494 | \$ 21,407 | \$ 19,529 | \$ 16,551 |
| Earnings from continuing operations                          | 2,383                                               | 579       | 1,126     | 281       | 975       |
| Net earnings                                                 | 2,576                                               | 5,963     | 4,728     | 4,626     | 5,746     |
| Basic earnings per common share from continuing operations   | 1.52                                                | 0.36      | 0.72      | 0.18      | 0.63      |
| Basic earnings per common share                              | 1.64                                                | 3.76      | 3.03      | 2.98      | 3.71      |
| Diluted earnings per common share from continuing operations | 1.50                                                | 0.36      | 0.72      | 0.18      | 0.63      |
| Diluted earnings per common share                            | 1.62                                                | 3.72      | 3.01      | 2.96      | 3.69      |
| Total assets                                                 | 42,953                                              | 67,235    | 60,277    | 60,574    | 52,582    |
| Long-term debt, including current portion                    | 3,397                                               | 18,394    | 13,067    | 14,568    | 11,477    |
| Cash dividends declared per common share                     | 0.64                                                | 1.67(2)   | 1.92      | 1.76      | 1.60      |

(1) Net sales for 2012 and prior years have been adjusted to reflect the presentation of Abbott's former research-based pharmaceuticals business as a discontinued operation.

(2) The \$1.67 dividend for 2012 reflects a quarterly dividend of \$.14 per share in the fourth quarter of 2012, which contemplated the impact of the separation of AbbVie. On January 4, 2013, AbbVie reported that its board of directors had declared a quarterly dividend of \$.40 per share of AbbVie common stock.

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Financial Review**

Abbott's revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott's products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott's primary products are nutritional products, branded generic pharmaceuticals, diagnostic testing products and vascular products. Sales in international markets comprise approximately 70 percent of consolidated net sales.

In October 2011, Abbott announced a plan to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. To accomplish the separation, Abbott created a new company, AbbVie Inc. ("AbbVie") for its research-based pharmaceuticals business which consists primarily of Abbott's historical Proprietary Pharmaceutical Products segment. On January 1, 2013, Abbott distributed all of the outstanding shares of AbbVie to Abbott's shareholders and AbbVie became an independent company trading under the symbol "ABBV". The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line in Abbott's Consolidated Statement of Earnings. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013.

Sales growth and margin improvement in the nutritional and diagnostics businesses and the challenging economic and fiscal environment in many countries around the world have impacted Abbott's sales, costs and financial position over the last three years. Sales in emerging markets increased 11 percent per year in 2013 and 2012, excluding foreign exchange, despite the slowdown in several emerging economies and a weakening of key emerging market currencies in 2013. (Emerging markets include all countries except the United States, Western Europe, Japan, Canada, and Australia.)

In Abbott's worldwide nutritional products business, sales over the last three years were positively impacted by demographics such as an aging population and an increasing rate of chronic disease in developed markets and the rise of a middle class in many emerging markets, as well as by numerous new product introductions that leveraged Abbott's strong brands. At the same time, manufacturing and distribution process changes and other cost reductions drove margin improvements across the business. Operating margins for this business increased from 13.2 percent in 2011 to 18.7 percent in 2013.

In 2013 sales growth in International Pediatric Nutrition was affected by a product recall initiated in August 2013 in China and two other markets for certain pediatric nutritional products supplied to Abbott by a third-party manufacturer. While there were no health issues associated with the recalled products, and the supplier subsequently determined that the products had been safe for consumption, the recall created significant disruption in these markets. As a result, International Pediatric Nutrition sales were significantly lower than Abbott's previous expectations for this business for the second half of 2013. While Abbott initiated investments in the third quarter of 2013 in these markets to rebuild consumer confidence, Abbott expects the recall to continue to have a negative impact on sales in the first half of 2014.

In Abbott's worldwide diagnostics business, margin improvement continued to be a key focus in 2013. Operating margins increased from 19.2 percent of sales in 2011 to 22.2 percent in 2013 as the business continued to execute on efficiency initiatives in the manufacturing and supply chain functions. In addition to continued margin improvement, unit growth across geographical regions positively impacted worldwide

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

diagnostic sales. Worldwide sales for this business increased 8.3 percent in 2013 and 7.3 percent in 2012, excluding foreign exchange.

In the Established Pharmaceutical Products segment, macroeconomic and market pressures in certain emerging markets impacted this business in 2013. Nevertheless, sales in this segment's 14 key emerging markets increased 6.3 percent in 2013 excluding the effect of foreign exchange. However, the growth in emerging markets was largely offset by declines in developed markets where austerity measures have continued to impact performance.

Over the last three years in the vascular business, Abbott continued to build its *Xience* drug-eluting stent franchise with the receipt of approval to market *Xience Xpedition* in various countries, including Japanese approval in the third quarter of 2013 and U.S. approval in the fourth quarter of 2012. *Xience Pro* received CE Mark approval in the second quarter of 2012. Abbott's market share also benefited from the U.S. launches of *Xience nano* and *Xience PRIME* in 2011, and the Japanese launches of *Xience PRIME* small vessel DES in 2013 and *Xience PRIME* in April 2012. *Xience*, which includes *Xience V*, *PRIME*, *nano*, *Pro*, and *Xpedition*, ended 2013 as the market-leading drug eluting stent globally. In 2013, *ABSORB* and *MitraClip* also contributed to sales growth. In 2011, the third party distributor of the Promus product began transitioning away from the product and that supply agreement ended in 2012. The effect of the winding down of the agreement continued into the first quarter of 2013.

Abbott's short- and long-term debt totaled \$6.6 billion at December 31, 2013. At December 31, 2013, Abbott's long-term debt rating was A+ by Standard and Poor's Corporation and A1 by Moody's Investors Service. In the fourth quarter of 2012, Abbott extinguished \$7.7 billion of long-term debt and incurred a charge of \$1.35 billion related to the early repayment, net of gains from the unwinding of interest rate swaps related to the debt. In October 2013 Abbott announced a 57 percent increase in Abbott's quarterly dividend to \$0.22 per share from \$0.14 per share, effective with the dividend paid in February 2014.

In 2014, Abbott will focus on several key initiatives. In the nutritional business, Abbott will continue to build its product portfolio with the introduction of new science-based products, expand in high-growth emerging markets and implement additional margin improvement initiatives. In the established pharmaceuticals business, Abbott will continue to focus on obtaining additional product approvals across numerous countries and expanding its presence in emerging markets. In the diagnostics business, Abbott will focus on the development of next-generation instrument platforms and other advanced technologies, expansion in emerging markets, and further improvements in the segment's operating margin. In the vascular business, Abbott will continue to focus on marketing products in the *Xience* and endovascular franchises, and increasing *MitraClip* sales, as well as further clinical development of *ABSORB*, its bioresorbable vascular scaffold (BVS) device and a further penetration of *ABSORB* in numerous countries. In Abbott's other segments, Abbott will focus on developing differentiated technologies in higher growth markets.

### Critical Accounting Policies

**Sales Rebates** In 2013, approximately 49 percent of Abbott's consolidated gross revenues were subject to various forms of rebates and allowances that Abbott recorded as reductions of revenues at the time of sale. Most of these rebates and allowances are in the Established Pharmaceuticals and Nutritional Products segments. Abbott provides rebates to state agencies that administer the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), wholesalers, group purchasing organizations, and other government agencies and private entities. Rebate amounts are usually based upon the volume of purchases using contractual or statutory prices for a product. Factors used in the rebate calculations include the identification of which products have been sold subject to a rebate, which customer or government agency price terms apply, and the estimated lag time between sale and payment of a rebate. Using historical trends, adjusted for current changes, Abbott estimates the amount of the rebate that will be paid, and records the liability as a reduction of gross sales when Abbott records its sale of the product.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Settlement of the rebate generally occurs from one to six months after sale. Abbott regularly analyzes the historical rebate trends and makes adjustments to reserves for changes in trends and terms of rebate programs. Rebates and chargebacks charged against gross sales in 2013, 2012 and 2011 amounted to approximately \$2.0 billion, \$1.9 billion and \$1.7 billion, respectively, or 16.1 percent, 16.0 percent and 16.8 percent, respectively, based on gross sales of approximately \$12.5 billion, \$11.8 billion and \$10.1 billion, respectively, subject to rebate. A one-percentage point increase in the percentage of rebates to related gross sales would decrease net sales by approximately \$125 million in 2013. Abbott considers a one-percentage point increase to be a reasonably likely increase in the percentage of rebates to related gross sales. Other allowances charged against gross sales were approximately \$150 million, \$149 million and \$117 million for cash discounts in 2013, 2012 and 2011, respectively, and \$208 million, \$199 million and \$170 million for returns in 2013, 2012 and 2011, respectively. Cash discounts are known within 15 to 30 days of sale, and therefore can be reliably estimated. Returns can be reliably estimated because Abbott's historical returns are low, and because sales returns terms and other sales terms have remained relatively unchanged for several periods.

Management analyzes the adequacy of ending rebate accrual balances each quarter. In the domestic nutritional business, management uses both internal and external data available to estimate the level of inventory in the distribution channel. Management has access to several large customers' inventory management data, and for other customers, utilizes data from a third party that measures time on the retail shelf. These sources allow management to make reliable estimates of inventory in the distribution channel. Except for a transition period before or after a change in the supplier for the WIC business in a state, inventory in the distribution channel does not vary substantially. Management also estimates the states' processing lag time based on claims data. In addition, internal processing time is a factor in estimating the accrual. In the WIC business, the state where the sale is made, which is the determining factor for the applicable price, is reliably determinable. Estimates are required for the amount of WIC sales within each state where Abbott has the WIC business. External data sources utilized for that estimate are participant data from the U.S. Department of Agriculture (USDA), which administers the WIC program, participant data from some of the states, and internally administered market research. The USDA has been making its data available for many years. Internal data includes historical redemption rates and pricing data. At December 31, 2013, Abbott had WIC business in 23 states.

Historically, adjustments to prior years' rebate accruals have not been material to net income. Abbott employs various techniques to verify the accuracy of claims submitted to it, and where possible, works with the organizations submitting claims to gain insight into changes that might affect the rebate amounts. For government agency programs, the calculation of a rebate involves interpretations of relevant regulations, which are subject to challenge or change in interpretation.

*Income Taxes* Abbott operates in numerous countries where its income tax returns are subject to audits and adjustments. Because Abbott operates globally, the nature of the audit items are often very complex, and the objectives of the government auditors can result in a tax on the same income in more than one country. Abbott employs internal and external tax professionals to minimize audit adjustment amounts where possible. In accordance with the accounting rules relating to the measurement of tax contingencies, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50 percent likely to be realized upon resolution of the benefit. Application of these rules requires a significant amount of judgment. In the U.S., Abbott's federal income tax returns through 2010 are settled except for three items, and the income tax returns for years after 2010 are open. Abbott does not record deferred income taxes on earnings reinvested indefinitely in foreign subsidiaries.

*Pension and Post-Employment Benefits* Abbott offers pension benefits and post-employment health care to many of its employees. Abbott engages outside actuaries to assist in the determination of the obligations and costs under these programs. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

assets. The discount rates used to measure liabilities were determined based on high-quality fixed income securities that match the duration of the expected retiree benefits. The health care cost trend rates represent Abbott's expected annual rates of change in the cost of health care benefits and is a forward projection of health care costs as of the measurement date. A difference between the assumed rates and the actual rates, which will not be known for decades, can be significant in relation to the obligations and the annual cost recorded for these programs. Low interest rates have significantly increased actuarial losses for these plans. At December 31, 2013, pretax net actuarial losses and prior service costs and (credits) recognized in Accumulated other comprehensive income (loss) for Abbott's defined benefit plans and medical and dental plans were losses of \$1.8 billion and \$82 million, respectively. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method, in accordance with the rules for accounting for post-employment benefits. Differences between the expected long-term return on plan assets and the actual annual return are amortized over a five-year period. Note 12 to the consolidated financial statements describes the impact of a one-percentage point change in the health care cost trend rate; however, there can be no certainty that a change would be limited to only one percentage point.

*Valuation of Intangible Assets* Abbott has acquired and continues to acquire significant intangible assets that Abbott records at fair value. Transactions involving the purchase or sale of intangible assets occur with some frequency between companies in the health care field and valuations are usually based on a discounted cash flow analysis. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Each of these factors can significantly affect the value of the intangible asset. Abbott engages independent valuation experts who review Abbott's critical assumptions and calculations for acquisitions of significant intangibles. Abbott reviews definite-lived intangible assets for impairment each quarter using an undiscounted net cash flows approach. If the undiscounted cash flows of an intangible asset are less than the carrying value of an intangible asset, the intangible asset is written down to its fair value, which is usually the discounted cash flow amount. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest group level for which cash flows are identifiable. Goodwill and indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, are reviewed for impairment annually or when an event that could result in an impairment occurs. At December 31, 2013, goodwill amounted to \$9.8 billion and intangibles amounted to \$5.7 billion, and amortization expense for intangible assets amounted to \$791 million in 2013, \$795 million in 2012 and \$884 million in 2011. There were no impairments of goodwill in 2013, 2012 or 2011. In 2012 and 2011, Abbott recorded impairment charges of \$69 million and \$125 million, respectively, for certain research and development assets due to changes in the projected development and regulatory timelines for the projects.

*Litigation* Abbott accounts for litigation losses in accordance with FASB Accounting Standards Codification No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. These estimates are often initially developed substantially earlier than the ultimate loss is known, and the estimates are refined each accounting period as additional information becomes known. Accordingly, Abbott is often initially unable to develop a best estimate of loss, and therefore the minimum amount, which could be zero, is recorded. As information becomes known, either the minimum loss amount is increased, resulting in additional loss provisions, or a best estimate can be made, also resulting in additional loss provisions. Occasionally, a best estimate amount is changed to a lower amount when events result in an expectation of a more favorable outcome than previously expected. Abbott estimates the range of possible loss to be from approximately \$70 million to \$90 million for its legal proceedings and environmental exposures. Accruals of approximately \$80 million have been recorded at December 31, 2013 for these proceedings and exposures. These accruals represent management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies."

**Results of Operations****Sales**

The following table details the components of sales growth by reportable segment for the last two years:

|                                                    | <b>Total<br/>% Change</b> | <b>Components of % Change</b> |               |                 |
|----------------------------------------------------|---------------------------|-------------------------------|---------------|-----------------|
|                                                    |                           | <b>Price</b>                  | <b>Volume</b> | <b>Exchange</b> |
| <b>Total Net Sales</b>                             |                           |                               |               |                 |
| 2013 vs. 2012                                      | 1.6                       | (0.8)                         | 4.5           | (2.1)           |
| 2012 vs. 2011                                      | 0.4                       | (0.4)                         | 4.0           | (3.2)           |
| <b>Total U.S.</b>                                  |                           |                               |               |                 |
| 2013 vs. 2012                                      | (0.8)                     | (1.0)                         | 0.2           |                 |
| 2012 vs. 2011                                      | 0.7                       | 0.8                           | (0.1)         |                 |
| <b>Total International</b>                         |                           |                               |               |                 |
| 2013 vs. 2012                                      | 2.7                       | (0.8)                         | 6.5           | (3.0)           |
| 2012 vs. 2011                                      | 0.3                       | (0.9)                         | 5.7           | (4.5)           |
| <b>Established Pharmaceutical Products Segment</b> |                           |                               |               |                 |
| 2013 vs. 2012                                      | (2.9)                     | (0.4)                         | 1.1           | (3.6)           |
| 2012 vs. 2011                                      | (4.4)                     | (1.3)                         | 3.4           | (6.5)           |
| <b>Nutritional Products Segment</b>                |                           |                               |               |                 |
| 2013 vs. 2012                                      | 4.3                       | 3.2                           | 2.2           | (1.1)           |
| 2012 vs. 2011                                      | 7.9                       | 4.5                           | 4.4           | (1.0)           |
| <b>Diagnostic Products Segment</b>                 |                           |                               |               |                 |
| 2013 vs. 2012                                      | 5.9                       | (2.5)                         | 10.8          | (2.4)           |
| 2012 vs. 2011                                      | 4.0                       | (1.4)                         | 8.7           | (3.3)           |
| <b>Vascular Products Segment</b>                   |                           |                               |               |                 |
| 2013 vs. 2012                                      | (1.9)                     | (6.2)                         | 6.2           | (1.9)           |
| 2012 vs. 2011                                      | (7.9)                     | (5.2)                         | (0.4)         | (2.3)           |

The increases in Total Net Sales in 2013 and 2012 reflect unit growth, partially offset by the impact of unfavorable foreign exchange. The price declines related to Vascular Products sales in 2013 and 2012 primarily reflect pricing pressure on drug eluting stents and other coronary products as a result of market competition in major markets.



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

A comparison of significant product and product group sales is as follows. Percent changes are versus the prior year and are based on unrounded numbers.

|                                                                              | 2013     | Percent<br>Change | 2012     | Percent<br>Change |
|------------------------------------------------------------------------------|----------|-------------------|----------|-------------------|
| <i>(dollars in millions)</i>                                                 |          |                   |          |                   |
| <b>Total Established Pharmaceuticals</b>                                     |          |                   |          |                   |
| Key Emerging Markets                                                         | \$ 2,358 | 1                 | \$ 2,324 | 4                 |
| Other Markets                                                                | 2,616    | (7)               | 2,797    | (10)              |
| <b>Nutritionals</b>                                                          |          |                   |          |                   |
| International Pediatric Nutritionals                                         | 2,257    | 9                 | 2,075    | 8                 |
| U.S. Pediatric Nutritionals                                                  | 1,508    |                   | 1,505    | 14                |
| International Adult Nutritionals                                             | 1,601    | 8                 | 1,489    | 4                 |
| U.S. Adult Nutritionals                                                      | 1,374    | (1)               | 1,392    | 6                 |
| <b>Diagnostics</b>                                                           |          |                   |          |                   |
| Immunochemistry                                                              | 3,458    | 5                 | 3,279    | 4                 |
| <b>Vascular Products (1)</b>                                                 |          |                   |          |                   |
| Drug Eluting Stents (DES) and Bioresorbable Vascular Scaffold (BVS) products | 1,563    | (2)               | 1,599    | 3                 |
| Other Coronary Products                                                      | 579      | (3)               | 598      | (1)               |
| Endovascular                                                                 | 475      | 5                 | 452      | 1                 |

(1)

Other Coronary Products include primarily guidewires and balloon catheters. Endovascular includes vessel closure, carotid stents and other peripheral products.

Excluding the unfavorable effect of exchange, total Established Pharmaceutical Products sales increased 0.7 percent in 2013 and 2.1 percent in 2012. The Established Pharmaceutical Products segment is focused on 14 key emerging markets including India, Russia, China and Brazil. Excluding the effect of exchange, sales in these 14 key emerging markets increased 6.3 percent in 2013 and 12.8 percent in 2012 as macroeconomic and market pressures in various emerging markets negatively affected 2013 growth. Excluding the effect of exchange, sales in Established Pharmaceuticals' other markets decreased 4 percent in 2013 and 5.6 percent in 2012. These declines in the Other Markets category reflect unfavorable market conditions, including the continued effects of European austerity measures and 2012 Japanese pricing actions.

Excluding the unfavorable effect of exchange, total Nutritional Products sales increased 5.4 percent in 2013 and 8.9 percent in 2012. International Pediatric Nutritional sales increased in 2013 and 2012 due primarily to volume growth in developing countries. A supplier's recall of product in August 2013 in certain international markets negatively impacted International Pediatric Nutritional sales in the third and fourth quarters of 2013. While there were no health issues associated with this supplier recall and the supplier subsequently determined that the product had been safe for consumption, this event created significant disruption in these markets. Abbott expects this sales disruption to continue to negatively impact International Pediatric Nutritional growth in the first half of 2014. U.S. Pediatric sales were flat in 2013 due to lower formula share, partially offset by higher shipments of toddler products. U.S. Pediatric Nutritional sales in 2012 reflect market share gains for *Similac* and unit growth for *PediaSure*.

The 2013 and 2012 increases in International Adult Nutritional sales are due primarily to volume growth in developing countries and were negatively impacted by the effect of the relatively stronger U.S. dollar. The 1 percent decline in 2013 U.S. Adult Nutritional sales reflects Abbott's exit from certain non-core business lines as part of the business' margin improvement initiative; most of the sales decline

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

resulting from this exit was offset by higher *Ensure* revenues. The increase in 2012 U.S. Adult Nutritional sales reflects unit growth for the *Ensure* and *Glucerna* products.

Excluding the unfavorable effect of exchange, total Diagnostic Products sales increased 8.3 percent in 2013 and 7.3 percent in 2012. The sales increases reflect unit growth across geographical regions. 2013 and 2012 sales of immunochemistry products, the largest category in this segment, reflect continued execution of Abbott's strategy to deliver integrated solutions to large healthcare customers.

Excluding the unfavorable effect of exchange, total Vascular Products sales were flat in 2013 and decreased 5.6 percent in 2012. In 2013, growth in international markets, driven by continued share gains in key geographies of XIENCE Xpedition and Absorb, was offset by declines in the U.S. market due to the negative impact of pricing pressure and a decline in procedures due to market conditions, as well as the expected decline of certain royalty revenues. In 2012, the decrease in Vascular Products sales was due to pricing pressure, as well as the expected winding down of royalty and supply agreements related to certain third-party products, including Promus. Excluding this royalty and supply agreement revenue in both periods and the unfavorable effect of exchange, Vascular Products sales increased 3.4 percent in 2012.

Abbott has periodically sold product rights to non-strategic products and has recorded the related gains in net sales in accordance with Abbott's revenue recognition policies as discussed in Note 1 to the consolidated financial statements. Related net sales were not significant in 2013, 2012 and 2011.

The expiration of licenses and patent protection can affect the future revenues and operating income of Abbott. There are currently no significant patent or license expirations in the next three years that are expected to affect Abbott.

### Operating Earnings

Gross profit margins were 50.4 percent of net sales in 2013, 50.6 percent in 2012 and 49.1 percent in 2011. The gross profit margin in 2013 remained relatively unchanged versus the prior year as improved margins in the Nutritional and Diagnostics Products segments were offset by margin declines in Established Pharmaceuticals and Vascular Products due to pricing pressures and unfavorable product mix as well as the impact of unfavorable foreign exchange across segments. The increase in the gross profit margin in 2012 was impacted by improved gross margins across all reportable segments as a result of cost reduction initiatives, the impact of exchange and favorable product mix.

In the U.S., states receive price rebates from manufacturers of infant formula under the federally subsidized Special Supplemental Nutrition Program for Women, Infants, and Children. There are also rebate programs for pharmaceutical products in numerous countries. These rebate programs continue to have a negative effect on the gross profit margins of the Nutritional and Established Pharmaceutical Products segments.

Research and development expense was \$1.452 billion in 2013, \$1.544 billion in 2012 and \$1.512 billion in 2011 and represented a 6.0 percent decrease in 2013, and a 2.1 percent increase in 2012. The 2013 decrease primarily reflects the incurrence of restructuring and asset impairment charges in 2012 which did not recur in 2013. In 2013, research and development expenditures totaled \$336 million for the Vascular Products segment, \$416 million for the Diagnostics Products segment, \$239 million for the Established Pharmaceutical Products segment and \$188 million for the Nutritional Products segment.

Selling, general and administrative expenses decreased 6.8 percent in 2013 and increased 1.1 percent in 2012. The 2013 decrease reflects the transfer of certain 2012 corporate costs to AbbVie in the separation as well as certain information technology and other back office support costs that are being charged to AbbVie in 2013 under transition services agreements. Prudent cost management and a reduction in restructuring costs also contributed to the decrease. The 2012 increase primarily reflects increased selling and marketing support for new products and geographical expansion, largely offset by prudent cost management.

## Business Acquisitions

In August 2013, Abbott acquired 100 percent of IDEV Technologies, net of debt, for \$310 million, in cash. The acquisition of IDEV Technologies expands Abbott's endovascular portfolio. The allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately \$170 million which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible definite-lived intangible assets of approximately \$66 million, non-deductible goodwill of approximately \$123 million and net deferred tax liabilities of \$56 million. Acquired intangible assets consist of developed technology and are being amortized over 11 years.

In August 2013, Abbott acquired 100 percent of OptiMedica for \$260 million, in cash, plus additional payments up to \$150 million to be made upon completion of certain development, regulatory and sales milestones. The acquisition of OptiMedica provides Abbott with an immediate entry point into the laser assisted cataract surgery market. The allocation of the fair value of the acquisition resulted in non-deductible definite-lived intangible assets of approximately \$160 million, non-deductible acquired in-process research and development of approximately \$60 million which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately \$151 million, net deferred tax liabilities of \$70 million and contingent consideration of approximately \$70 million. The fair value of the contingent consideration was determined based on an independent appraisal. Acquired intangible assets consist primarily of developed technology that is being amortized over 18 years.

The preliminary allocations of the fair value of these acquisitions will be finalized when valuations are completed. Had the above acquisitions taken place on January 1 of the previous year, consolidated net sales and income would not have been significantly different from reported amounts.

## Restructurings

In 2013, Abbott management approved a plan to reduce costs and improve efficiencies across various functional areas as well as a plan to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott's established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceutical and nutritional businesses. Abbott recorded employee related severance charges of approximately \$78 million in 2013 and \$167 million in 2012. Additional charges of approximately \$4 million and \$22 million were also recorded in 2013 and 2012, respectively, primarily for asset impairments. Approximately \$35 million in 2013 and \$70 million in 2012 is recorded in Cost of products sold and approximately \$47 million in 2013 and \$119 million in 2012 is recorded as Selling, general and administrative expense.

In 2013 and prior years, Abbott management approved plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. In 2013, Abbott recorded employee severance charges of approximately \$11 million. In 2011, Abbott recorded charges of approximately \$194 million reflecting the impairment of manufacturing facilities and other assets, employee severance and other related charges. Approximately \$11 million in 2013 and \$18 million in 2011 is classified as Cost of products sold. The remaining 2011 charge of \$176 million related to businesses transferred to AbbVie and is being recognized in the results of discontinued operations. An additional \$41 million, \$110 million and \$25 million were recorded in 2013, 2012 and 2011, respectively, relating to these restructurings, primarily for accelerated depreciation.

In 2012, Abbott recorded a charge of approximately \$150 million for employee severance and contractual obligations, primarily related to the exit from a research and development facility. These charges related to businesses transferred to AbbVie and have been recognized in the results of discontinued operations.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

In 2011, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs, and improve efficiencies in Abbott's core diagnostic business. In 2011, a charge of \$28 million was recorded in Cost of products sold. In addition, charges of approximately \$16 million and \$42 million were recorded in 2012 and 2011, primarily for accelerated depreciation and product transfer costs.

### Interest expense

In 2013, interest expense decreased due to a lower level of borrowings, which resulted from the transfer of approximately \$14.6 billion of debt to AbbVie as part of the separation. In 2012, interest expense included bridge facility fees related to the separation of AbbVie from Abbott.

### Change in Accounting Principle and Other (income) expense, net

Prior to January 1, 2011, the accounts of foreign subsidiaries were consolidated based on a fiscal year ended November 30 due to the time needed to consolidate these subsidiaries. Effective January 1, 2011, the one month lag in the consolidation of the accounts of foreign subsidiaries was eliminated and the year-end of foreign subsidiaries was changed to December 31. Abbott believes that the change in accounting principle related to the elimination of the one month reporting lag is preferable because it results in more contemporaneous reporting of the results of foreign subsidiaries. In accordance with applicable accounting literature, a change in subsidiaries' year-end is treated as a change in accounting principle and requires retrospective application. A charge of \$100 million was recorded to Other (income) expense, net in 2011 to recognize the cumulative immaterial impacts to 2009 and 2010.

Other (income) expense, net, for 2013 includes gains on sales of investments; 2012 includes income of approximately \$40 million from the resolution of a contractual agreement.

### Net Loss on Extinguishment of Debt

In 2012, Abbott extinguished \$7.7 billion of long-term debt and incurred a cost of \$1.35 billion to extinguish this debt, net of gains from the unwinding of interest rate swaps related to the debt.

### Taxes on Earnings

The income tax rates on earnings from continuing operations were 5.5 percent in 2013, (89.7) percent in 2012 and 8.9 percent in 2011. 2013 taxes on earnings from continuing operations include \$234 million of tax benefit related to the resolution of various tax positions from previous years. In addition, as a result of the American Taxpayer Relief Act of 2012 signed into law in January 2013, Abbott recorded a tax benefit to taxes on continuing operations of approximately \$103 million in 2013 for the retroactive extension of the research tax credit and the look-through rules of section 954(c)(6) of the Internal Revenue Code to the beginning of 2012. Taxes on earnings from continuing operations in 2012 reflect the \$472 million effect of the tax rate applied to Abbott's net debt extinguishment loss, as well as the recognition of \$212 million of tax benefits as a result of the favorable resolution of various tax positions pertaining to a prior year. Taxes on earnings from continuing operations in 2011 reflect the recognition of \$168 million of tax benefits as a result of the favorable resolution of various tax positions pertaining to prior years. Exclusive of these discrete items, the effective rates are lower than the U.S. federal statutory rate of 35 percent due primarily to the benefit of lower tax rates and tax exemptions on foreign income that reduced the tax rates by 18.0, 75.7, and 14.9 percentage points in 2013, 2012 and 2011, respectively. The tax rate reductions are primarily derived from operations in Puerto Rico, Switzerland, Ireland and Singapore where Abbott benefits from a combination of favorable statutory tax rules, tax rulings, grants, and exemptions. See Note 13 to the consolidated financial statements for a full reconciliation of the effective tax rate to the U.S. federal statutory rate.

In 2014 Abbott expects to repatriate approximately \$2 billion of 2014 earnings generated outside the U.S. Abbott also expects to be able to accelerate the utilization of deferred tax assets and thereby reduce

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

the cash taxes due in the U.S. on this repatriation to no more than \$150 million. This repatriation is projected to result in approximately \$550 to \$600 million of additional tax expense in Abbott's 2014 Statement of Earnings. Excluding the tax effect of this repatriation, Abbott expects to apply an annual effective rate of approximately 19 percent to 2014 results.

### Separation of AbbVie Inc.

On November 28, 2012, Abbott's board of directors declared a special dividend distribution of all of the outstanding shares of common stock of AbbVie Inc. (AbbVie), the company formed to hold Abbott's research-based proprietary pharmaceuticals business. For each Abbott common share held at the close of business on December 12, 2012, Abbott shareholders received one share of AbbVie stock on January 1, 2013. Abbott has received a ruling from the Internal Revenue Service that the separation qualifies as a tax-free distribution to Abbott and its U.S. shareholders for U.S. federal income tax purposes.

The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line. Discontinued operations include the results of AbbVie's business except for certain corporate overhead costs and certain costs associated with transition services that will be provided by Abbott to AbbVie. Discontinued operations also include other costs incurred by Abbott to separate AbbVie as well as an allocation of interest assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013.

The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013: *(in billions)*

|                                                                        |        |
|------------------------------------------------------------------------|--------|
| Assets:                                                                |        |
| Cash and cash equivalents                                              | \$ 5.9 |
| Investments                                                            | 2.2    |
| Trade receivables, less allowances                                     | 3.2    |
| Inventories                                                            | 0.7    |
| Prepaid expenses, deferred income taxes, and other current receivables | 2.9    |
| Net property and equipment                                             | 2.2    |
| Intangible assets, net of amortization                                 | 2.3    |
| Goodwill                                                               | 6.1    |
| Deferred income taxes and other assets                                 | 1.1    |

26.6

|                                                                                    |      |
|------------------------------------------------------------------------------------|------|
| Liabilities:                                                                       |      |
| Short-term borrowings                                                              | 1.0  |
| Trade accounts payable and other current liabilities                               | 5.2  |
| Long-term debt                                                                     | 14.6 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1  |

23.9

Net Assets Transferred to AbbVie Inc. \$ 2.7

In addition, approximately \$1 billion of accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation was transferred to AbbVie.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

In 2013, discontinued operations includes a favorable adjustment to tax expense of \$193 million as a result of the resolution of various tax positions pertaining to 2010 related to AbbVie's operations. Summarized financial information for discontinued operations for 2012 and 2011 is as follows:

|                       | Year Ended December 31 |           |
|-----------------------|------------------------|-----------|
| (in millions)         | 2012                   | 2011      |
| Net sales             | \$ 18,380              | \$ 17,444 |
| Earnings before taxes | 5,958                  | 3,963     |
| Taxes on earnings     | 574                    | 361       |
| Net earnings          | 5,384                  | 3,602     |

Abbott and AbbVie entered into transitional services agreements prior to the separation pursuant to which Abbott and AbbVie are providing various services to each other on an interim transitional basis. Transition services may be provided for up to 24 months with an option for a one-year extension by the recipient. Services being provided by Abbott include certain information technology and back office support. Billings by Abbott under these transitional services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Consolidated Statement of Earnings. This transitional support will enable AbbVie to establish its stand-alone processes for various activities that were previously provided by Abbott and does not constitute significant continuing support of AbbVie's operations.

For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 with the remainder expected to be transferred in 2014. These assets and liabilities have been presented as held for disposition in the Consolidated Balance Sheet. At December 31, 2013, the assets and liabilities held for disposition consist of inventories of \$243 million, trade accounts receivable of \$163 million, other current assets of \$32 million, equipment of \$28 million, other assets of \$38 million, trade accounts payable and accrued liabilities of \$386 million and other liabilities of \$7 million. Abbott's obligation to transfer the net assets held for disposition to AbbVie of \$111 million is included in Other accrued liabilities.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. In connection with the separation, Abbott has adjusted its employee stock compensation awards and separated its defined benefit programs for pensions and post-employment medical and dental benefit plans. See notes 8 and 12 for additional information.

### Research and Development Programs

Abbott currently has numerous pharmaceutical, medical device, diagnostic and nutritional products in development.

### Research and Development Process

In the Established Pharmaceuticals segment, the development process focuses on the geographic expansion and continuous improvement of the segment's existing products to provide benefits to patients and customers. As Established Pharmaceuticals does not actively pursue primary research, development usually begins with work on existing products or after the acquisition of an advanced stage licensing opportunity.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Depending upon the product, the phases of development may include:

Drug product development

Phase I bioequivalence studies to compare a future Established Pharmaceutical's brand with an already marketed compound with the same active pharmaceutical ingredient (API).

Phase II studies to test the efficacy of benefits in a small group of patients.

Phase III studies to broaden the testing to a wider population that reflects the actual medical use.

Phase IV and other post-marketing studies to obtain new clinical use data on existing products within approved indications.

The specific requirements (e.g. scope of clinical trials) for obtaining regulatory approval vary across different countries and geographic regions. The process may range from one year for a bioequivalence study project to 6 or more years for complex formulations, new indications, or geographic expansion in specific countries such as China.

In the Diagnostics segment, the phases of the research and development process include:

Discovery which focuses on identification of a product that will address a specific therapeutic area, platform, or unmet clinical need,

Concept/Feasibility during which the materials and manufacturing processes are evaluated, testing may include product characterization and analysis is performed to confirm clinical utility, and

Development during which extensive testing is performed to demonstrate that the product meets specified design requirements and that the design specifications conform to user needs and intended uses.

The regulatory requirements for diagnostic products vary across different countries and geographic regions. In the U.S., the FDA classifies diagnostic products into classes (I, II, or III) and the classification determines the regulatory process for approval. While the Diagnostics segment has products in all three classes, the vast majority of its products are categorized as Class I or Class II. Submission of a separate regulatory filing is not required for Class I products. Class II devices typically require pre-market notification to the FDA through a regulatory filing known as a 510(k) submission. Most Class III products are subject to the FDA's Pre-Marketing Approval (PMA) requirements. Other Class III products, such as those used to screen blood, require the submission and approval of a Biological License Application (BLA).

In the EU, diagnostic products are also categorized into different categories and the regulatory process, which is governed by the European InVitro Diagnostic Medical Device Directive, depends upon the category. Certain product categories require review and approval by an independent company, known as a Notified Body, before the manufacturer can affix a CE mark to the product to show compliance with the Directive. Other products only require a self-certification process.

In the Vascular segment, the research and development process begins with research on a specific technology that is evaluated for feasibility and commercial viability. If the research program passes that hurdle, it moves forward into development. The development process includes evaluation and selection of a product design, completion of clinical trials to test the product's safety and efficacy, and validation of the manufacturing process to demonstrate its repeatability and ability to consistently meet pre-determined specifications.

Similar to the diagnostic products discussed above, in the U.S., vascular products are classified as Class I, II, or III. Most of Abbott's vascular products are classified as Class II devices that follow the 510(k) regulatory process or Class III devices that are subject to the PMA process.





## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

In the EU, vascular products are also categorized into different classes and the regulatory process, which is governed by the European Medical Device Directive, varies by class. Each product must bear a CE mark to show compliance with the Directive. Some products require submission of a design dossier to the appropriate regulatory authority for review and approval prior to CE marking of the device. For other products, the company is required to prepare a technical file which includes testing results and clinical evaluations but can self-certify its ability to apply the CE mark to the product. Outside the U.S. and the EU, the regulatory requirements vary across different countries and regions.

After approval and commercial launch of some vascular products, post-market trials may be conducted either due to a conditional requirement of the regulatory market approval or with the objective of proving product superiority.

In the Nutritional segment, the research and development process generally focuses on identifying and developing ingredients and products that address the nutritional needs of particular populations (e.g., infants, athletes) or patients (e.g., people with diabetes). Depending upon the country and/or region, if claims regarding a product's efficacy will be made, clinical studies typically must be conducted. Most other product development, such as a product form change from liquid to powder, generally does not necessitate clinical studies.

In the U.S., the FDA requires that it be notified of proposed new formulations and formulation or packaging changes related to infant formula products. Prior to the launch of an infant formula or product packaging change, the company is required to obtain the FDA's confirmation that it has no objections to the proposed product or packaging. For other nutrition products, notification or pre-approval from the FDA is not required unless the product includes a new food additive. In some countries, regulatory approval may be required for certain nutritional products, including infant formula and medical nutritional products.

### ***Areas of Focus***

In 2014 and beyond, Abbott's significant areas of therapeutic focus will include the following:

**Established Pharmaceuticals** Abbott is actively working on development plans for about 20 - 30 key brands. Depending on the product, the development activities focus on new data, markets, formulations, combinations, or indications. Abbott focuses on building country-specific portfolios made up of global and local pharmaceutical brands that best meet each local market's needs. Over the next several years, Established Pharmaceuticals will work to expand its product portfolio in its key markets through further geographic expansion of existing brands, new product enhancements, and strategic licensing activities.

**Vascular** Ongoing projects in the pipeline include:

*XIENCE Xpedition*, our latest drug-eluting stent (DES) with enhanced deliverability and an expanded size matrix. It utilizes the *XIENCE PRIME* stent, everolimus and biocompatible coating technology but incorporates new catheter technology for improved deliverability. *XIENCE Xpedition* received U.S. regulatory approval in December 2012 and is also available in Europe and parts of Asia and Latin America. In 2013, Abbott continued to expand DES size offerings. *XIENCE Xpedition* 48 received CE regulatory approval in May 2013, making it the longest length DES among major brands. *XIENCE Xpedition* 2.0 mm diameter received CE regulatory approval in December 2013, making it the smallest diameter DES among major brands.

*Absorb*, the world's first drug eluting bioresorbable vascular scaffold (BVS) device for the treatment of coronary artery disease that is gradually resorbed into the vessel wall. In 2013 Abbott made significant progress in enrolling patients in clinical trials for regulatory approval in the United States and China, and completed enrollment in trials in Japan in December 2013.

*MitraClip* device for the treatment of mitral regurgitation (MR). In October 2013 *MitraClip* received U.S. regulatory approval for patients with significant symptomatic degenerative MR who are at prohibitive risk for mitral valve surgery. *MitraClip* is also available in Europe, parts of Asia, the Middle East and Latin America. Abbott expects to seek product approval in additional markets in 2014. In addition, Abbott will continue clinical development of the *MitraClip* therapy including the COAPT trial, a landmark, prospective, randomized trial in the United States that will evaluate the impact of *MitraClip* treatment on the progression of heart failure.

*SUPERA Veritas* self-expanding nitinol stent system which was acquired as part of the acquisition of IDEV Technologies in August 2013. With its proprietary interwoven wire technology, *SUPERA Veritas* is designed based on biomimetic principles to mimic the body's natural movement. It received CE Mark in Europe for treating blockages in blood vessels due to peripheral artery disease (PAD). In the U.S., *SUPERA Veritas* is cleared only for the treatment of biliary strictures (narrowing of a bile duct) related to cancer. It is currently being reviewed by the U.S. Food and Drug Administration under a Premarket Approval application for treatment of the superficial femoral and proximal popliteal arteries, which are the main arteries in the thigh that supply blood to lower extremities. Abbott plans to continue development of *SUPERA*'s size matrix and next generation delivery system.

Coronary and endovascular guide wires. Abbott's HT Pilot and HT Progress guide wire families received FDA clearance for the Chronic Total Occlusions (CTO) indication in January 2013.

**Medical Optics** Abbott is developing a number of new products for patients undergoing cataract surgery, which are designed to improve physician efficiency and patient outcomes. In 2013 Abbott's Tecnis Toric monofocal intraocular lens, which combines the optical qualities of the Tecnis design with astigmatism correction, was approved in the U.S., China and Japan. In addition, a preloaded version of the Tecnis 1 piece monofocal IOL was approved in the U.S., Canada and India and a preloaded version of the Tecnis 1 piece multifocal IOL was approved in Canada, Europe and Japan. Preloaded technology enables insertion of the Tecnis 1 piece IOL with an easy to use, disposable insertion system. Other products that received regulatory approval in Japan included the Tecnis OptiBlue monofocal IOL in a standard cartridge insertion system as well as the preloaded version. The iDesign advanced vision diagnostic and LASIK treatment planning system, previously approved in Europe in 2012, received approval in Canada and a number of Latin American and Asian countries. In 2014, Abbott plans to continue to work to introduce new products, including the launch of new pre-loaded IOLs, which are designed to improve the ease of use for the cataract surgeon.

**Molecular Diagnostics** Various new molecular in vitro diagnostic (IVD) products, including oncology and infectious disease assays and a next generation instrument system are in various stages of development and commercialization. Abbott's companion diagnostic test for an ALK gene rearrangement test for non-small-cell lung cancer has been approved in more than 69 countries around the world and now includes options for automated processing and image analysis. Abbott's companion diagnostic program continues to expand and includes collaborative efforts with multiple major pharmaceutical companies. An automated assay to genotype HCV-infected patients to aid in the choice of an appropriate therapy was approved by the FDA. In addition, automated IVD assays for Flu A/B/RSV, *C.difficile*, and VanR were launched in many countries around the world. Assays for infectious diseases including MTB and MTB drug resistance and for oncology including KRAS and BRAF mutation detection are in development.

**Core Laboratory Diagnostics** Abbott is working on the development of next-generation blood screening, hematology, and immunochemistry instrument systems, as well as assays in various areas including infectious disease, cardiac care, metabolics, oncology, and automation solutions to increase efficiency in laboratories.

**Diabetes Care** In the third quarter of 2013, Abbott received CE Mark in Europe for its *FreeStyle Precision Neo* monitoring system, a new icon-driven system with visual glucose trend indicators and insulin

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

logging. In the second half of 2013, Abbott received both CE Mark in Europe and FDA approval for *Precision Pro*, a hospital glucose monitoring system which provides improved accuracy and dual-band wireless access to immediate test results. Abbott is also developing a new sensor based system that it expects to submit for approval in Europe in 2014.

**Nutrition** Abbott is focusing its research and development spend on six benefit platforms that span the pediatric, adult and performance nutrition areas: immunity, cognition, lean body mass, inflammation, metabolism and tolerance. Numerous new products that build on advances in these benefit platforms are currently under development, including clinical outcome testing, and are expected to be launched over the coming years.

Given the diversity of Abbott's business, its intention to remain a broad-based healthcare company and the numerous sources for potential future growth, no individual project is expected to be material to cash flows or results of operations over the next five years. Factors considered included research and development expenses projected to be incurred for the project over the next year relative to Abbott's total research and development expenses as well as qualitative factors, such as marketplace perceptions and impact of a new product on Abbott's overall market position. There were no delays in Abbott's 2013 research and development activities that are expected to have a material impact on operations.

While the aggregate cost to complete the numerous projects currently in development is expected to be material, the total cost to complete will depend upon Abbott's ability to successfully complete each project, the rate at which each project advances, and the ultimate timing for completion. Given the potential for significant delays and the high rate of failure inherent in the development of pharmaceutical and medical device products and technologies, it is not possible to accurately estimate the total cost to complete all projects currently in development. Abbott plans to manage its portfolio of projects to achieve research and development spend equal to approximately 6 percent to 7 percent of sales each year. Abbott does not regularly accumulate or make management decisions based on the total expenses incurred for a particular development phase in a given period.

### **Goodwill**

At December 31, 2013, goodwill recorded as a result of business combinations totaled \$9.8 billion. Goodwill is reviewed for impairment annually in the third quarter or when an event that could result in an impairment occurs. The results of the last impairment test indicated that the fair value of each reporting unit was substantially in excess of its carrying value except for the Medical Optics unit. While the fair value of the Medical Optics business exceeds its carrying value, extended economic pressure on government-reimbursed cataract procedures in Europe and on the global LASIK surgery business as well as longer regulatory approval timelines for products currently under development, the integration of OptiMedica and the negative impact of foreign currency movements could result in a valuation in the future where the fair value of the Medical Optics unit has declined below its carrying value, thereby triggering the requirement to estimate the implied fair value of the goodwill and measure for impairment.

### **Financial Condition**

#### **Cash Flow**

Net cash from operating activities amounted to \$3.3 billion, \$9.3 billion and \$9.0 billion in 2013, 2012 and 2011, respectively. The decrease in Net cash from operating activities in 2013 was due to the separation of AbbVie on January 1, 2013. Net cash from operating activities in 2013 reflects approximately \$435 million of one-time net cash outflows related to the separation of AbbVie and \$724 million of contributions to defined benefit pension plans. The income tax component of operating cash flow in 2013, 2012 and 2011 includes \$427 million, \$408 million and \$580 million, respectively, of noncash tax benefits related to the favorable resolution of various tax positions pertaining to prior years and 2013 also includes a \$103 million tax benefit for the retroactive impact of U.S. tax law changes, which is expected to be

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

realized in future years. Trade accounts payable and other liabilities in Net cash from operating activities in 2012 includes the payment of approximately \$1.5 billion related to a litigation accrual recorded in 2011 related to the business operations of AbbVie. This was partially offset by increases in other liabilities, primarily restructuring reserves.

While substantially all cash and cash equivalents at December 31, 2013, 2012 and 2011 is considered reinvested indefinitely in foreign subsidiaries, Abbott does not expect such reinvestment to affect its liquidity and capital resources. If these funds were needed for operations in the U.S., Abbott would be required to accrue and pay U.S. income taxes to repatriate these funds. Abbott believes that it has sufficient sources of liquidity to support its assumption that the disclosed amount of undistributed earnings at December 31, 2013 can be considered to be reinvested indefinitely.

Abbott funded \$724 million in 2013, \$379 million in 2012 and \$394 million in 2011 to defined benefit pension plans. Abbott expects pension funding of approximately \$400 million in 2014 for its pension plans, of which approximately \$300 million relates to its main domestic pension plans. Abbott expects annual cash flow from operating activities to continue to exceed Abbott's capital expenditures and cash dividends.

### Debt and Capital

At December 31, 2013 Abbott's long-term debt rating was A+ by Standard & Poor's Corporation and A1 by Moody's Investors Service. Abbott has readily available financial resources, including unused lines of credit of \$5.0 billion that support commercial paper borrowing arrangements which expire in 2017.

In 2012, Abbott redeemed \$7.7 billion of long-term notes in preparation for the separation of AbbVie from Abbott and repaid \$1 billion of long-term notes that were due in 2012. In addition, AbbVie Inc., a wholly owned subsidiary of Abbott, issued \$14.7 billion of long-term notes that were guaranteed by Abbott until AbbVie's separation from Abbott on January 1, 2013. In 2011, Abbott repaid \$2.0 billion of long-term notes using primarily short-term borrowings.

In October 2008, the board of directors authorized the purchase of up to \$5 billion of Abbott's common shares from time to time. Under this authorization, 33.0 million and 37.0 million shares were purchased in 2013 and 2012 at a cost of approximately \$1.2 billion and \$2.2 billion, respectively. No additional purchases of common shares will be made from this authorization. In June 2013, the board of directors authorized the purchase of up to \$3.0 billion of Abbott's common shares from time to time and 10.5 million shares were purchased under this authorization at a cost of \$388 million in 2013. Abbott has indicated that it plans to purchase over \$2 billion of additional shares from time to time in 2014.

Abbott declared dividends of \$0.64 per share in 2013 compared to \$1.67 per share in 2012. Dividends paid were \$882 million in 2013 compared to \$3.2 billion in 2012. The year-over-year change in dividends reflects the impact of the separation of AbbVie in January 2013. In October 2013, Abbott announced an increase in the company's quarterly dividend to \$0.22 per share from \$0.14 per share, representing an increase of 57 percent. This increase took effect with the dividend paid in February 2014 to shareholders of record at the close of business on January 15, 2014.

### Working Capital

The reduction of cash and cash equivalents from \$10.8 billion at December 31, 2012 to \$3.5 billion at December 31, 2013 reflects the transfer of \$5.9 billion of cash and cash equivalents to AbbVie as part of the separation on January 1, 2013. Working capital was \$9.7 billion at December 31, 2013 and \$18.0 billion at December 31, 2012. The decrease in working capital in 2013 was due to the transfer of approximately \$9 billion of working capital to AbbVie on January 1, 2013 as part of the separation. See note 2 Separation of AbbVie for additional information.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

Substantially all of Abbott's trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. The collection of outstanding receivables in these countries held steady or improved in 2013 depending upon the country. As a result, governmental receivables in these four countries accounted for approximately 1 percent of Abbott's total assets and 12 percent of total net trade receivables as of December 31, 2013. The latter is down from 16 percent as of December 31 2012.

With the exception of Greece, Abbott historically has collected almost all of the outstanding receivables in these countries. Abbott continues to monitor the credit worthiness of customers located in these and other geographic areas and establishes an allowance against a trade receivable when it is probable that the balance will not be collected. In addition to closely monitoring economic conditions and budgetary and other fiscal developments in these countries, Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate credit risk although the receivables included in such arrangements have historically not been a material amount of total outstanding receivables. If government funding were to become unavailable in these countries or if significant adverse changes in their reimbursement practices were to occur, Abbott may not be able to collect the entire balance.

### Capital Expenditures

Capital expenditures of \$1.1 billion in 2013, \$1.8 billion in 2012 and \$1.5 billion in 2011 were principally for upgrading and expanding manufacturing and research and development facilities and equipment in various segments, investments in information technology, and laboratory instruments placed with customers. The 2013 decrease reflects the separation of AbbVie at the beginning of 2013.

### Contractual Obligations

The table below summarizes Abbott's estimated contractual obligations as of December 31, 2013.

|                                              | Payments Due By Period |                 |                 |               | 2019 and<br>Thereafter |
|----------------------------------------------|------------------------|-----------------|-----------------|---------------|------------------------|
|                                              | Total                  | 2014            | 2015-2016       | 2017-2018     |                        |
|                                              | <i>(in millions)</i>   |                 |                 |               |                        |
| Long-term debt, including current maturities | \$ 3,397               | \$ 9            | \$ 13           | \$ 2          | \$ 3,373               |
| Interest on debt obligations                 | 2,977                  | 181             | 350             | 349           | 2,097                  |
| Operating lease obligations                  | 628                    | 140             | 219             | 131           | 138                    |
| Capitalized auto lease obligations           | 40                     | 13              | 27              |               |                        |
| Purchase commitments (a)                     | 2,295                  | 2,118           | 158             | 15            | 4                      |
| Other long-term liabilities                  | 1,272                  |                 | 771             | 354           | 147                    |
| <b>Total (b)</b>                             | <b>\$ 10,609</b>       | <b>\$ 2,461</b> | <b>\$ 1,538</b> | <b>\$ 851</b> | <b>\$ 5,759</b>        |

(a) Purchase commitments are for purchases made in the normal course of business to meet operational and capital expenditure requirements.

(b) Unrecognized tax benefits totaling \$1.3 billion are excluded from the table above as Abbott is unable to reasonably estimate the period of cash settlement with the respective taxing authorities on such items. See Note 13 Taxes on Income for further details. The company has employee benefit obligations consisting of pensions and other postemployment benefits, including medical and life, which have been excluded from the table. A discussion of the company's pension and postretirement plans, including funding matters is included in Note 12 Post-employment Benefits.

### **Contingent Obligations**

Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. In addition, Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events.

### **Legislative Issues**

Abbott's primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, to the Annual Report on Form 10-K.

### **Private Securities Litigation Reform Act of 1995    A Caution Concerning Forward-Looking Statements**

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to the Annual Report on Form 10-K.

**ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Financial Instruments and Risk Management**

**Market Price Sensitive Investments**

Abbott holds available-for-sale equity securities from strategic technology acquisitions. The market value of these investments was approximately \$26 million and \$76 million as of December 31, 2013 and 2012, respectively. The decrease is due to the sale of securities. Abbott monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in value occurs. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at December 31, 2013 by approximately \$5 million. (A 20 percent decrease is believed to be a reasonably possible near-term change in share prices.)

**Non-Publicly Traded Equity Securities**

Abbott holds equity securities from strategic technology acquisitions that are not traded on public stock exchanges. The carrying value of these investments was approximately \$67 million and \$137 million as of December 31, 2013 and 2012, respectively. The decrease of non-publicly traded securities is due to the separation of AbbVie on January 1, 2013. No individual investment is recorded at a value in excess of \$20 million. Abbott monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in estimated value occurs.

**Interest Rate Sensitive Financial Instruments**

At December 31, 2013 and 2012, Abbott had interest rate hedge contracts totaling \$1.5 billion and \$9.5 billion, respectively, to manage its exposure to changes in the fair value of debt. \$8.0 billion of these contracts related to debt issued by AbbVie Inc. in the fourth quarter of 2012 and were transferred to AbbVie as part of the separation on January 1, 2013. The effect of these hedges is to change the fixed interest rate to a variable rate. Abbott does not use derivative financial instruments, such as interest rate swaps, to manage its exposure to changes in interest rates for its investment securities. At December 31, 2013, Abbott had \$2.5 billion of domestic commercial paper outstanding with an average annual interest rate of 0.13% with an average remaining life of 34 days. The fair value of long-term debt at December 31, 2013 and 2012 amounted to \$3.9 billion and \$19.6 billion, respectively (average interest rates of 5.3% and 2.9% as of December 31, 2013 and 2012, respectively) with maturities through 2040. At December 31, 2013 and 2012, the fair value of current and long-term investment securities amounted to approximately \$4.7 billion. A hypothetical 100-basis point change in the interest rates would not have a material effect on cash flows, income or market values. (A 100-basis point change is believed to be a reasonably possible near-term change in rates.)

**Foreign Currency Sensitive Financial Instruments**

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts are designated as cash flow hedges of the variability of the cash flows due to changes in foreign currency exchange rates and are marked-to-market with the resulting gains or losses reflected in Accumulated other comprehensive income (loss). Gains or losses will be included in Cost of products sold at the time the products are sold, generally within the next twelve months. At December 31, 2013 and 2012, Abbott held \$137 million and \$1.6 billion, respectively, of such contracts, which all mature in the following calendar year. Contracts totaling \$1.0 billion were transferred to AbbVie as part of the separation on January 1, 2013.

Abbott enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated intercompany loans and trade payables and third-party trade payables and

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

receivables. The contracts are marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or gains on the foreign currency exposure being managed. At December 31, 2013 and 2012, Abbott held \$13.8 billion and \$18.2 billion, respectively, of such contracts, which mature in the next twelve months. \$4.3 billion of these contracts were transferred to AbbVie as part of the separation on January 1, 2013.

Abbott has designated foreign denominated short-term debt of approximately \$505 million and approximately \$615 million as of December 31, 2013 and 2012, respectively, as a hedge of the net investment in a foreign subsidiary. Accordingly, changes in the fair value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

The following table reflects the total foreign currency forward contracts outstanding at December 31, 2013 and 2012: *(dollars in millions)*

|                                                                                             | 2013             |          |                          | 2012             |          |                          |
|---------------------------------------------------------------------------------------------|------------------|----------|--------------------------|------------------|----------|--------------------------|
|                                                                                             | Contract         | Weighted | Fair and                 | Contract         | Weighted | Fair and                 |
|                                                                                             | Amount           | Average  | Carrying                 | Amount           | Average  | Carrying                 |
|                                                                                             |                  | Exchange | Value                    |                  | Exchange | Value                    |
|                                                                                             |                  | Rate     | Receivable/<br>(Payable) |                  | Rate     | Receivable/<br>(Payable) |
| <b>Receive primarily U.S.<br/>Dollars<br/>in exchange for<br/>the following currencies:</b> |                  |          |                          |                  |          |                          |
| Euro                                                                                        | \$ 6,208         | 1.3735   | \$ (4)                   | \$ 11,349        | 1.317    | \$ (4)                   |
| British Pound                                                                               | 1,181            | 1.624    | 1                        | 1,318            | 1.621    | 1                        |
| Japanese Yen                                                                                | 1,865            | 99.0     | 12                       | 2,624            | 81.2     | 9                        |
| Canadian Dollar                                                                             | 191              | 1.06     | 1                        | 332              | .992     | 1                        |
| All other currencies                                                                        | 4,446            | N/A      | (1)                      | 4,169            | N/A      | (33)                     |
| <b>Total</b>                                                                                | <b>\$ 13,891</b> |          | <b>\$ 9</b>              | <b>\$ 19,792</b> |          | <b>\$ (26)</b>           |



**ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

|                                                                       | <b>Page</b> |
|-----------------------------------------------------------------------|-------------|
| <u>Consolidated Statement of Earnings</u>                             | <u>46</u>   |
| <u>Consolidated Statement of Comprehensive Income</u>                 | <u>47</u>   |
| <u>Consolidated Statement of Cash Flows</u>                           | <u>48</u>   |
| <u>Consolidated Balance Sheet</u>                                     | <u>49</u>   |
| <u>Consolidated Statement of Shareholders' Investment</u>             | <u>51</u>   |
| <u>Notes to Consolidated Financial Statements</u>                     | <u>52</u>   |
| <u>Management Report on Internal Control Over Financial Reporting</u> | <u>84</u>   |
| <u>Reports of Independent Registered Public Accounting Firm</u>       | <u>85</u>   |

## Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings  
(in millions except per share data)

|                                                   | Year Ended December 31 |           |           |
|---------------------------------------------------|------------------------|-----------|-----------|
|                                                   | 2013                   | 2012      | 2011      |
| Net Sales                                         | \$ 21,848              | \$ 21,494 | \$ 21,407 |
| Cost of products sold                             | 10,040                 | 9,817     | 10,017    |
| Amortization of intangible assets                 | 791                    | 795       | 884       |
| Research and development                          | 1,452                  | 1,544     | 1,512     |
| Selling, general and administrative               | 6,936                  | 7,444     | 7,365     |
| Total Operating Cost and Expenses                 | 19,219                 | 19,600    | 19,778    |
| Operating Earnings                                | 2,629                  | 1,894     | 1,629     |
| Interest expense                                  | 157                    | 347       | 359       |
| Interest income                                   | (67)                   | (59)      | (65)      |
| Net loss on extinguishment of debt                |                        | 1,351     |           |
| Net foreign exchange (gain) loss                  | 50                     | (25)      | (20)      |
| Other (income) expense, net                       | (32)                   | (25)      | 119       |
| Earnings from Continuing Operations Before Taxes  | 2,521                  | 305       | 1,236     |
| Taxes on Earnings from Continuing Operations      | 138                    | (274)     | 110       |
| Earnings from Continuing Operations               | 2,383                  | 579       | 1,126     |
| Earnings from Discontinued Operations, net of tax | 193                    | 5,384     | 3,602     |
| Net Earnings                                      | \$ 2,576               | \$ 5,963  | \$ 4,728  |
| Basic Earnings Per Common Share                   |                        |           |           |
| Continuing Operations                             | \$ 1.52                | \$ 0.36   | \$ 0.72   |
| Discontinued Operations                           | 0.12                   | 3.40      | 2.31      |
| Net Earnings                                      | \$ 1.64                | \$ 3.76   | \$ 3.03   |
| Diluted Earnings Per Common Share                 |                        |           |           |
| Continuing Operations                             | \$ 1.50                | \$ 0.36   | \$ 0.72   |
| Discontinued Operations                           | 0.12                   | 3.36      | 2.29      |
| Net Earnings                                      |                        |           |           |

# Edgar Filing: ABBOTT LABORATORIES - Form 10-K

|                                                                                           |    |       |    |       |    |       |
|-------------------------------------------------------------------------------------------|----|-------|----|-------|----|-------|
|                                                                                           | \$ | 1.62  | \$ | 3.72  | \$ | 3.01  |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share      |    | 1,558 |    | 1,575 |    | 1,557 |
| Dilutive Common Stock Options and Awards                                                  |    | 16    |    | 17    |    | 10    |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards |    | 1,574 |    | 1,592 |    | 1,567 |
| Outstanding Common Stock Options Having No Dilutive Effect                                |    | 1     |    | 1     |    | 27    |

The accompanying notes to consolidated financial statements are an integral part of this statement.

## Abbott Laboratories and Subsidiaries

Consolidated Statement of Comprehensive Income  
(in millions)

|                                                                                                                                                                                                                 | Year Ended December 31 |          |          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|----------|----------|
|                                                                                                                                                                                                                 | 2013                   | 2012     | 2011     |
| Net Earnings                                                                                                                                                                                                    | \$ 2,576               | \$ 5,963 | \$ 4,728 |
| Less: Earnings from Discontinued Operations, net of tax                                                                                                                                                         | 193                    | 5,384    | 3,602    |
| Earnings from Continuing Operations                                                                                                                                                                             | 2,383                  | 579      | 1,126    |
| Foreign currency translation (loss) adjustments                                                                                                                                                                 | (239)                  | (181)    | (523)    |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of \$393 in 2013, \$(253) in 2012 and \$(380) in 2011 | 882                    | (715)    | (503)    |
| Unrealized (losses) gains on marketable equity securities, net of taxes of \$(10) in 2013, \$11 in 2012 and \$(1) in 2011                                                                                       | (18)                   | 19       | (2)      |
| Net adjustments for derivative instruments designated as cash flow hedges, net of taxes of \$(13) in 2013, \$(21) in 2012 and \$28 in 2011                                                                      | (53)                   | (91)     | 111      |
| Other Comprehensive Income (Loss) from Continuing Operations                                                                                                                                                    | 572                    | (968)    | (917)    |
| Comprehensive Income (Loss) from Continuing Operations                                                                                                                                                          | 2,955                  | (389)    | 209      |
| Comprehensive Income from Discontinued Operations                                                                                                                                                               | 193                    | 5,355    | 3,289    |
| Comprehensive Income                                                                                                                                                                                            | \$ 3,148               | \$ 4,966 | \$ 3,498 |

## Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31:

|                                                                           |          |         |         |
|---------------------------------------------------------------------------|----------|---------|---------|
| Cumulative foreign currency translation loss adjustments                  | \$ (718) | \$ (79) | \$ (72) |
| Net actuarial (losses) and prior service (cost) and credits               | (1,312)  | (3,596) | (2,731) |
| Cumulative unrealized gains on marketable equity securities               | 13       | 31      | 38      |
| Cumulative gains on derivative instruments designated as cash flow hedges | 5        | 50      | 168     |

The accompanying notes to consolidated financial statements are an integral part of this statement.

## Abbott Laboratories and Subsidiaries

Consolidated Statement of Cash Flows  
(in millions)

|                                                                                    | Year Ended December 31 |          |          |
|------------------------------------------------------------------------------------|------------------------|----------|----------|
|                                                                                    | 2013                   | 2012     | 2011     |
| Cash Flow From (Used in) Operating Activities:                                     |                        |          |          |
| Net earnings                                                                       | \$ 2,576               | \$ 5,963 | \$ 4,728 |
| Adjustments to reconcile earnings to net cash from operating activities            |                        |          |          |
| Depreciation                                                                       | 928                    | 1,363    | 1,395    |
| Amortization of intangible assets                                                  | 791                    | 1,419    | 1,649    |
| Share-based compensation                                                           | 262                    | 433      | 383      |
| Acquired in-process and collaborations research and development                    |                        | 288      | 672      |
| Investing and financing (gains) losses, net                                        | 4                      | 356      | 142      |
| Net loss on extinguishment of debt                                                 |                        | 1,351    |          |
| Trade receivables                                                                  | (113)                  | 36       | (670)    |
| Inventories                                                                        | (154)                  | (417)    | (130)    |
| Prepaid expenses and other assets                                                  | 131                    | (35)     | 413      |
| Trade accounts payable and other liabilities                                       | (436)                  | (134)    | 1,790    |
| Income taxes                                                                       | (665)                  | (1,309)  | (1,402)  |
| Net Cash From Operating Activities                                                 | 3,324                  | 9,314    | 8,970    |
| Cash Flow From (Used in) Investing Activities:                                     |                        |          |          |
| Acquisitions of property and equipment                                             | (1,145)                | (1,795)  | (1,491)  |
| Acquisitions of businesses and technologies, net of cash acquired                  | (580)                  | (706)    | (273)    |
| Purchases of investment securities                                                 | (10,064)               | (11,998) | (5,110)  |
| Proceeds from sales of investment securities                                       | 7,839                  | 8,936    | 5,649    |
| Release of restricted funds                                                        |                        |          | 1,870    |
| Other                                                                              | 21                     | 3        | 16       |
| Net Cash (Used in) From Investing Activities                                       | (3,929)                | (5,560)  | 661      |
| Cash Flow From (Used in) Financing Activities:                                     |                        |          |          |
| Proceeds from issuance of (repayments of) short-term debt and other                | 2,086                  | 784      | (1,965)  |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months    | 9                      | 14,700   | 1,000    |
| Repayments of long-term debt and debt with maturities over 3 months                | (303)                  | (11,071) | (3,012)  |
| Acquisition and contingent consideration payments related to business acquisitions | (495)                  | (521)    | (400)    |
| Transfer of cash and cash equivalents to AbbVie Inc.                               | (5,901)                |          |          |
| Purchases of common shares                                                         | (1,605)                | (2,364)  | (77)     |
| Proceeds from stock options exercised, including income tax benefit                | 395                    | 1,850    | 969      |
| Dividends paid                                                                     | (882)                  | (3,183)  | (2,938)  |
| Net Cash (Used in) From Financing Activities                                       | (6,696)                | 195      | (6,423)  |
| Effect of exchange rate changes on cash and cash equivalents                       | (26)                   | 40       | (43)     |

# Edgar Filing: ABBOTT LABORATORIES - Form 10-K

|                                                      |         |       |       |
|------------------------------------------------------|---------|-------|-------|
| Net (Decrease) Increase in Cash and Cash Equivalents | (7,327) | 3,989 | 3,165 |
| Cash and Cash Equivalents, Beginning of Year         | 10,802  | 6,813 | 3,648 |

|                                        |          |           |          |
|----------------------------------------|----------|-----------|----------|
| Cash and Cash Equivalents, End of Year | \$ 3,475 | \$ 10,802 | \$ 6,813 |
|----------------------------------------|----------|-----------|----------|

## Supplemental Cash Flow Information:

|                   |          |          |          |
|-------------------|----------|----------|----------|
| Income taxes paid | \$ 1,039 | \$ 1,367 | \$ 1,782 |
| Interest paid     | 148      | 576      | 545      |

The accompanying notes to consolidated financial statements are an integral part of this statement.

**Abbott Laboratories and Subsidiaries**

**Consolidated Balance Sheet**  
(dollars in millions)

|                                                                   | December 31 |           |
|-------------------------------------------------------------------|-------------|-----------|
|                                                                   | 2013        | 2012      |
| Assets                                                            |             |           |
| Current Assets:                                                   |             |           |
| Cash and cash equivalents                                         | \$ 3,475    | \$ 10,802 |
| Investments, primarily bank time deposits and U.S. treasury bills | 4,623       | 4,372     |
| Trade receivables, less allowances of 2013: \$312; 2012: \$406    | 3,986       | 7,613     |
| Inventories:                                                      |             |           |
| Finished products                                                 | 1,866       | 2,346     |
| Work in process                                                   | 349         | 629       |
| Materials                                                         | 478         | 818       |
| Total inventories                                                 | 2,693       | 3,793     |
| Deferred income taxes                                             | 2,528       | 2,986     |
| Other prepaid expenses and receivables                            | 1,504       | 1,757     |
| Current assets held for disposition                               | 438         |           |
| Total Current Assets                                              | 19,247      | 31,323    |
| Investments                                                       | 119         | 274       |
| Property and Equipment, at Cost:                                  |             |           |
| Land                                                              | 502         | 605       |
| Buildings                                                         | 2,994       | 4,259     |
| Equipment                                                         | 8,506       | 13,111    |
| Construction in progress                                          | 868         | 954       |
|                                                                   | 12,870      | 18,929    |
| Less: accumulated depreciation and amortization                   | 6,965       | 10,866    |
| Net Property and Equipment                                        | 5,905       | 8,063     |
| Intangible Assets, net of amortization                            | 5,735       | 8,588     |
| Goodwill                                                          | 9,772       | 15,774    |
| Deferred Income Taxes and Other Assets                            | 2,109       | 3,213     |
| Non-current Assets Held for Disposition                           | 66          |           |
|                                                                   | \$ 42,953   | \$ 67,235 |





## Abbott Laboratories and Subsidiaries

Consolidated Balance Sheet  
(dollars in millions)

|                                                                                                          | December 31 |           |
|----------------------------------------------------------------------------------------------------------|-------------|-----------|
|                                                                                                          | 2013        | 2012      |
| Liabilities and Shareholders' Investment                                                                 |             |           |
| Current Liabilities:                                                                                     |             |           |
| Short-term borrowings                                                                                    | \$ 3,164    | \$ 2,082  |
| Trade accounts payable                                                                                   | 1,026       | 1,797     |
| Salaries, wages and commissions                                                                          | 906         | 1,428     |
| Other accrued liabilities                                                                                | 3,500       | 6,788     |
| Dividends payable                                                                                        | 341         | 221       |
| Income taxes payable                                                                                     | 175         | 655       |
| Current portion of long-term debt                                                                        | 9           | 309       |
| Current liabilities held for disposition                                                                 | 386         |           |
| Total Current Liabilities                                                                                | 9,507       | 13,280    |
| Long-term Debt                                                                                           | 3,388       | 18,085    |
| Post-employment Obligations and Other Long-term Liabilities                                              | 4,784       | 9,057     |
| Non-current Liabilities Held for Disposition                                                             | 7           |           |
| Commitments and Contingencies                                                                            |             |           |
| Shareholders' Investment:                                                                                |             |           |
| Preferred shares, one dollar par value Authorized 1,000,000 shares, none issued                          |             |           |
| Common shares, without par value Authorized 2,400,000,000 shares Issued at stated capital amount Shares: |             |           |
| 2013: 1,685,827,096; 2012: 1,675,930,484;                                                                | 12,048      | 11,755    |
| Common shares held in treasury, at cost Shares: 2013: 137,728,810; 2012: 99,262,992                      | (6,844)     | (5,591)   |
| Earnings employed in the business                                                                        | 21,979      | 24,151    |
| Accumulated other comprehensive income (loss)                                                            | (2,012)     | (3,594)   |
| Total Abbott Shareholders' Investment                                                                    | 25,171      | 26,721    |
| Noncontrolling Interests in Subsidiaries                                                                 | 96          | 92        |
| Total Shareholders' Investment                                                                           | 25,267      | 26,813    |
|                                                                                                          | \$ 42,953   | \$ 67,235 |

The accompanying notes to consolidated financial statements are an integral part of this statement.



## Abbott Laboratories and Subsidiaries

Consolidated Statement of Shareholders' Investment  
(in millions except shares and per share data)

|                                                                                               | Year Ended December 31 |            |            |
|-----------------------------------------------------------------------------------------------|------------------------|------------|------------|
|                                                                                               | 2013                   | 2012       | 2011       |
| <b>Common Shares:</b>                                                                         |                        |            |            |
| Beginning of Year                                                                             |                        |            |            |
| Shares: 2013: 1,675,930,484; 2012: 1,638,870,201; 2011: 1,619,689,876                         | \$ 11,755              | \$ 9,817   | \$ 8,745   |
| Issued under incentive stock programs                                                         |                        |            |            |
| Shares: 2013: 9,896,612; 2012: 37,060,283; 2011: 19,180,325                                   | 393                    | 1,854      | 954        |
| Share-based compensation                                                                      | 261                    | 435        | 382        |
| Issuance of restricted stock awards                                                           | (361)                  | (351)      | (264)      |
| End of Year                                                                                   |                        |            |            |
| Shares: 2013: 1,685,827,096; 2012: 1,675,930,484; 2011: 1,638,870,201                         | \$ 12,048              | \$ 11,755  | \$ 9,817   |
| <b>Common Shares Held in Treasury:</b>                                                        |                        |            |            |
| Beginning of Year                                                                             |                        |            |            |
| Shares: 2013: 99,262,992; 2012: 68,491,382; 2011: 72,705,928                                  | \$ (5,591)             | \$ (3,688) | \$ (3,917) |
| Issued under incentive stock programs                                                         |                        |            |            |
| Shares: 2013: 5,718,575; 2012: 6,691,748; 2011: 4,638,841                                     | 310                    | 363        | 250        |
| Purchased                                                                                     |                        |            |            |
| Shares: 2013: 44,184,393; 2012: 37,463,358; 2011: 424,295                                     | (1,563)                | (2,266)    | (21)       |
| End of Year                                                                                   |                        |            |            |
| Shares: 2013: 137,728,810; 2012: 99,262,992; 2011: 68,491,382                                 | \$ (6,844)             | \$ (5,591) | \$ (3,688) |
| <b>Earnings Employed in the Business:</b>                                                     |                        |            |            |
| Beginning of Year                                                                             | \$ 24,151              | \$ 20,907  | \$ 19,216  |
| Net earnings                                                                                  | 2,576                  | 5,963      | 4,728      |
| Separation of AbbVie Inc.                                                                     | (3,735)                |            |            |
| Cash dividends declared on common shares (per share 2013: \$0.64; 2012: \$1.67; 2011: \$1.92) | (1,002)                | (2,650)    | (3,012)    |
| Effect of common and treasury share transactions                                              | (11)                   | (69)       | (25)       |
| End of Year                                                                                   | \$ 21,979              | \$ 24,151  | \$ 20,907  |
| <b>Accumulated Other Comprehensive Income (Loss):</b>                                         |                        |            |            |
| Beginning of Year                                                                             | \$ (3,594)             | \$ (2,597) | \$ (1,367) |

# Edgar Filing: ABBOTT LABORATORIES - Form 10-K

|                                   |       |       |         |
|-----------------------------------|-------|-------|---------|
| Separation of AbbVie Inc.         | 1,010 |       |         |
| Other comprehensive income (loss) | 572   | (997) | (1,230) |

End of Year \$ (2,012) \$ (3,594) \$ (2,597)

|                                                                                                              |       |       |       |
|--------------------------------------------------------------------------------------------------------------|-------|-------|-------|
| Noncontrolling Interests in Subsidiaries:                                                                    |       |       |       |
| Beginning of Year                                                                                            | \$ 92 | \$ 86 | \$ 88 |
| Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases | 4     | 6     | (2)   |

End of Year \$ 96 \$ 92 \$ 86

The accompanying notes to consolidated financial statements are an integral part of this statement.

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements**

**Note 1 Summary of Significant Accounting Policies**

**NATURE OF BUSINESS** Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products.

**CHANGES IN PRESENTATION DUE TO ABBVIE SEPARATION** On January 1, 2013, Abbott completed the separation of AbbVie Inc., which was formed to hold Abbott's research-based proprietary pharmaceuticals business. The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line in Abbott's Consolidated Statement of Earnings. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013. See Note 2 for additional information.

**BASIS OF CONSOLIDATION AND CHANGE IN ACCOUNTING PRINCIPLE** The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. Prior to January 1, 2011, the accounts of foreign subsidiaries were consolidated based on a fiscal year ended November 30 due to the time needed to consolidate these subsidiaries. Effective January 1, 2011, the one month lag in the consolidation of the accounts of foreign subsidiaries was eliminated and the year-end of foreign subsidiaries was changed to December 31. Abbott believes that the change in accounting principle related to the elimination of the one month reporting lag is preferable because it results in more contemporaneous reporting of the results of foreign subsidiaries. In accordance with applicable accounting literature, a change in subsidiaries' year-end is treated as a change in accounting principle and requires retrospective application. The impact of the change was not material to the results of operations for the previously reported annual and interim periods after January 1, 2009, and thus, those results have not been revised. A charge of \$137 million was recorded in 2011 to recognize the cumulative immaterial impacts to 2009 and 2010 of which \$37 million is recognized in the results of discontinued operations.

The Consolidated Statements of Cash Flows for 2012 and 2011 have been appropriately revised to reflect acquisition and contingent consideration payments related to certain business acquisitions as cash flow used in financing activities. The amounts had been previously reflected as cash flow used in investing activities.

**USE OF ESTIMATES** The financial statements have been prepared in accordance with generally accepted accounting principles in the United States and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for sales rebates, income taxes, pension and other post-employment benefits, valuation of intangible assets, litigation, derivative financial instruments, and inventory and accounts receivable exposures.

**FOREIGN CURRENCY TRANSLATION** The statements of earnings of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using average exchange rates for the period. The net assets of foreign subsidiaries whose functional currencies are other than the U.S. dollar are translated into U.S. dollars using exchange rates as of the balance sheet date. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in the foreign currency translation adjustment account, which is included in equity as a component of *accumulated other comprehensive income (loss)*. Transaction gains and losses are recorded in earnings and were not significant for any of the periods presented.

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 1 Summary of Significant Accounting Policies (Continued)**

**REVENUE RECOGNITION** Revenue from product sales is recognized upon passage of title and risk of loss to customers. Provisions for discounts, rebates and sales incentives to customers, and returns and other adjustments are provided for in the period the related sales are recorded. Sales incentives to customers are not material. Historical data is readily available and reliable, and is used for estimating the amount of the reduction in gross sales. Revenue from the launch of a new product, from an improved version of an existing product, or for shipments in excess of a customer's normal requirements are recorded when the conditions noted above are met. In those situations, management records a returns reserve for such revenue, if necessary. In certain of Abbott's businesses, primarily within diagnostics and medical optics, Abbott participates in selling arrangements that include multiple deliverables (e.g., instruments, reagents, procedures, and service agreements). Under these arrangements, Abbott recognizes revenue upon delivery of the product or performance of the service and allocates the revenue based on the relative selling price of each deliverable, which is based primarily on vendor specific objective evidence. Sales of product rights for marketable products are recorded as revenue upon disposition of the rights. Revenue from license of product rights, or for performance of research or selling activities, is recorded over the periods earned.

**INCOME TAXES** Deferred income taxes are provided for the tax effect of differences between the tax bases of assets and liabilities and their reported amounts in the financial statements at the enacted statutory rate to be in effect when the taxes are paid. U.S. income taxes are provided on those earnings of foreign subsidiaries which are intended to be remitted to the parent company. Deferred income taxes are not provided on undistributed earnings reinvested indefinitely in foreign subsidiaries as working capital and plant and equipment. Interest and penalties on income tax obligations are included in taxes on income.

**EARNINGS PER SHARE** Unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares in 2013, 2012 and 2011 were \$2.366 billion, \$575 million and \$1.123 billion, respectively. Net earnings allocated to common shares in 2013, 2012 and 2011 were \$2.558 billion, \$5.917 billion and \$4.714 billion, respectively.

**PENSION AND POST-EMPLOYMENT BENEFITS** Abbott accrues for the actuarially determined cost of pension and post-employment benefits over the service attribution periods of the employees. Abbott must develop long-term assumptions, the most significant of which are the health care cost trend rates, discount rates and the expected return on plan assets. Differences between the expected long-term return on plan assets and the actual return are amortized over a five-year period. Actuarial losses and gains are amortized over the remaining service attribution periods of the employees under the corridor method.

**FAIR VALUE MEASUREMENTS** For assets and liabilities that are measured using quoted prices in active markets, total fair value is the published market price per unit multiplied by the number of units held without consideration of transaction costs. Assets and liabilities that are measured using significant other observable inputs are valued by reference to similar assets or liabilities, adjusted for contract restrictions and other terms specific to that asset or liability. For these items, a significant portion of fair value is derived by reference to quoted prices of similar assets or liabilities in active markets. For all remaining assets and liabilities, fair value is derived using a fair value model, such as a discounted cash flow model or Black-Scholes model. Purchased intangible assets are recorded at fair value. The fair value of

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 1 Summary of Significant Accounting Policies (Continued)**

significant purchased intangible assets is based on independent appraisals. Abbott uses a discounted cash flow model to value intangible assets. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital, terminal values and market participants. Intangible assets, goodwill and indefinite-lived intangible assets are reviewed for impairment at least on a quarterly and annual basis, respectively.

**SHARE-BASED COMPENSATION** The value of stock options and restricted stock awards and units are amortized over their service period, which could be shorter than the vesting period if an employee is retirement eligible, with a charge to compensation expense.

**LITIGATION** Abbott accounts for litigation losses in accordance with FASB ASC No. 450, "Contingencies." Under ASC No. 450, loss contingency provisions are recorded for probable losses at management's best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. Legal fees are recorded as incurred.

**CASH, CASH EQUIVALENTS AND INVESTMENTS** Cash equivalents consist of bank time deposits and U.S. treasury bills with original maturities of three months or less. Investments in marketable equity securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in Accumulated other comprehensive income (loss). Investments in equity securities that are not traded on public stock exchanges are recorded at cost. Investments in debt securities are classified as held-to-maturity, as management has both the intent and ability to hold these securities to maturity, and are reported at cost, net of any unamortized premium or discount. Income relating to these securities is reported as interest income.

Abbott reviews the carrying value of investments each quarter to determine whether an other than temporary decline in market value exists. Abbott considers factors affecting the investee, factors affecting the industry the investee operates in and general equity market trends. Abbott considers the length of time an investment's market value has been below carrying value and the near-term prospects for recovery to carrying value. When Abbott determines that an other than temporary decline has occurred, the investment is written down with a charge to Other (income) expense, net.

**TRADE RECEIVABLE VALUATIONS** Accounts receivable are stated at their net realizable value. The allowance against gross trade receivables reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Accounts receivable are charged off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.

**INVENTORIES** Inventories are stated at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs.

**PROPERTY AND EQUIPMENT** Depreciation and amortization are provided on a straight-line basis over the estimated useful lives of the assets. The following table shows estimated useful lives of property and equipment:

| Classification | Estimated Useful Lives            |
|----------------|-----------------------------------|
| Buildings      | 10 to 50 years (average 27 years) |
| Equipment      | 3 to 20 years (average 11 years)  |

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 1 Summary of Significant Accounting Policies (Continued)**

**PRODUCT LIABILITY** Abbott accrues for product liability claims when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. The liabilities are adjusted quarterly as additional information becomes available. Receivables for insurance recoveries for product liability claims are recorded as assets, on an undiscounted basis, when it is probable that a recovery will be realized. Product liability losses are self-insured.

**RESEARCH AND DEVELOPMENT COSTS** Internal research and development costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are achieved.

**ACQUIRED IN-PROCESS AND COLLABORATIONS RESEARCH AND DEVELOPMENT (IPR&D)** The initial costs of rights to IPR&D projects obtained in an asset acquisition are expensed as IPR&D unless the project has an alternative future use. These costs include initial payments incurred prior to regulatory approval in connection with research and development collaboration agreements that provide rights to develop, manufacture, market and/or sell pharmaceutical products. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-lived intangible assets.

**CONCENTRATION OF RISK AND GUARANTEES** Due to the nature of its operations, Abbott is not subject to significant concentration risks relating to customers, products or geographic locations. Governmental accounts in Italy, Spain, Greece and Portugal accounted for 12 percent and 16 percent of total net trade receivables as of December 31, 2013 and 2012 respectively. Product warranties are not significant.

Abbott has no material exposures to off-balance sheet arrangements; no special purpose entities; nor activities, that include non-exchange-traded contracts accounted for at fair value. Abbott has periodically entered into agreements in the ordinary course of business, such as assignment of product rights, with other companies, which has resulted in Abbott becoming secondarily liable for obligations that Abbott was previously primarily liable. Since Abbott no longer maintains a business relationship with the other parties, Abbott is unable to develop an estimate of the maximum potential amount of future payments, if any, under these obligations. Based upon past experience, the likelihood of payments under these agreements is remote. Abbott periodically acquires a business or product rights in which Abbott agrees to pay contingent consideration based on attaining certain thresholds or based on the occurrence of certain events.

**RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS** In February 2013, the FASB issued a standard pertaining to the reporting of amounts reclassified out of accumulated other comprehensive income (AOCI). The standard requires that an entity provide, by component, information regarding the amounts reclassified out of AOCI and the line items in the statement of operations to which the amounts were reclassified. This guidance is effective prospectively for reporting periods beginning after December 15, 2012. Abbott's adoption of this guidance in the first quarter of 2013 did not have a material impact on our results of operations or financial position.

**Note 2 Separation of AbbVie Inc.**

On November 28, 2012, Abbott's board of directors declared a special dividend distribution of all of the outstanding shares of common stock of AbbVie Inc. (AbbVie), the company formed to hold Abbott's



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 2 Separation of AbbVie Inc. (Continued)

research-based proprietary pharmaceuticals business. For each Abbott common share held at the close of business on December 12, 2012, Abbott shareholders received one share of AbbVie stock on January 1, 2013. Abbott has received a ruling from the Internal Revenue Service that the separation qualifies as a tax-free distribution to Abbott and its U.S. shareholders for U.S. federal income tax purposes.

The historical operating results of the research-based proprietary pharmaceuticals business prior to separation are excluded from Earnings from Continuing Operations and are presented on the Earnings from Discontinued Operations line. Discontinued operations include the results of AbbVie's business except for certain corporate overhead costs and certain costs associated with transition services that will be provided by Abbott to AbbVie. Discontinued operations also includes other costs incurred by Abbott to separate AbbVie as well as an allocation of interest assuming a uniform ratio of consolidated debt to equity for all of Abbott's historical operations. The assets, liabilities, and cash flows of the research-based proprietary pharmaceuticals business are included in Abbott's Consolidated Balance Sheet and its Consolidated Statements of Cash Flows for periods prior to January 1, 2013.

The following is a summary of the assets and liabilities transferred to AbbVie as part of the separation on January 1, 2013:

(in billions)

|                                                                        |        |
|------------------------------------------------------------------------|--------|
| Assets:                                                                |        |
| Cash and cash equivalents                                              | \$ 5.9 |
| Investments                                                            | 2.2    |
| Trade receivables, less allowances                                     | 3.2    |
| Inventories                                                            | 0.7    |
| Prepaid expenses, deferred income taxes, and other current receivables | 2.9    |
| Net property and equipment                                             | 2.2    |
| Intangible assets, net of amortization                                 | 2.3    |
| Goodwill                                                               | 6.1    |
| Deferred income taxes and other assets                                 | 1.1    |

26.6

Liabilities:

|                                                                                    |      |
|------------------------------------------------------------------------------------|------|
| Short-term borrowings                                                              | 1.0  |
| Trade accounts payable and other current liabilities                               | 5.2  |
| Long-term debt                                                                     | 14.6 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 3.1  |

23.9

Net Assets Transferred to AbbVie Inc. \$ 2.7

In addition, approximately \$1 billion of accumulated other comprehensive losses, net of income taxes, primarily related to the pension and other benefit plan net liabilities as well as foreign translation was transferred to AbbVie.

In 2013, there are no operating results related to discontinued operations other than a favorable adjustment to tax expense of \$193 million as a result of the resolution of various tax positions related to



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 2 Separation of AbbVie Inc. (Continued)**

AbbVie's operations prior to separation. Summarized financial information for discontinued operations for 2012 and 2011 is as follows:

|                       | Year Ended<br>December 31 |           |
|-----------------------|---------------------------|-----------|
| (in millions)         | 2012                      | 2011      |
| Net sales             | \$ 18,380                 | \$ 17,444 |
| Earnings before taxes | 5,958                     | 3,963     |
| Taxes on earnings     | 574                       | 361       |
| Net earnings          | 5,384                     | 3,602     |

Abbott and AbbVie entered into transitional services agreements prior to the separation pursuant to which Abbott and AbbVie are providing various services to each other on an interim transitional basis. Transition services may be provided for up to 24 months with an option for a one-year extension by the recipient. Services being provided by Abbott include certain information technology and back office support. Billings by Abbott under these transitional services agreements are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Consolidated Statement of Earnings. This transitional support will enable AbbVie to establish its stand-alone processes for various activities that were previously provided by Abbott and does not constitute significant continuing support of AbbVie's operations.

For a small portion of AbbVie's operations, the legal transfer of AbbVie's assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 with the remainder transferring in 2014. These assets and liabilities have been presented as held for disposition in the Consolidated Balance Sheet. At December 31, 2013, the assets and liabilities held for disposition consist of inventories of \$243 million, trade accounts receivable of \$163 million, other current assets of \$32 million, equipment of \$28 million, other assets of \$38 million, trade accounts payable and accrued liabilities of \$386 million and other liabilities of \$7 million. Abbott's obligation to transfer the net assets held for disposition to AbbVie of \$111 million is included in Other accrued liabilities.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie's business. AbbVie generally will be liable for all other taxes attributable to its business. In connection with the separation, Abbott has adjusted its employee stock compensation awards and separated its defined benefit programs for pensions and post-employment medical and dental benefit plans. See notes 8 and 12 for additional information.

**Note 3 Supplemental Financial Information**

Other (income) expense, net, for 2013 primarily relates to gains from the sales of equity securities. The loss on the extinguishment of debt of \$1.35 billion in 2012 relates to the early redemption of \$7.7 billion of long-term notes. The loss consists of the premium paid on the notes and the write off of deferred financing costs totaling \$1.83 billion and was partially offset by a gain of \$479 million related to the unwinding of interest rate swaps related to a portion of the debt. As discussed in Note 1, Other

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 3 Supplemental Financial Information (Continued)**

(income) expense, net, for 2011 includes a charge of \$100 million to recognize the cumulative immaterial impacts to 2009 and 2010 relating to the change in year end for foreign subsidiaries.

The detail of various balance sheet components is as follows:

|                        | 2013          | 2012   |
|------------------------|---------------|--------|
|                        | (in millions) |        |
| Long-term Investments: |               |        |
| Equity securities      | \$ 93         | \$ 213 |
| Other                  | 26            | 61     |
| Total                  | \$ 119        | \$ 274 |

The reduction in long-term investments from December 31, 2012 to December 31, 2013 is due primarily to the separation of AbbVie on January 1, 2013.

|                                                | 2013          | 2012     |
|------------------------------------------------|---------------|----------|
|                                                | (in millions) |          |
| Other Accrued Liabilities:                     |               |          |
| Accrued rebates payable to government agencies | \$ 136        | \$ 1,020 |
| Accrued other rebates (a)                      | 220           | 1,079    |
| All other (b)                                  | 3,144         | 4,689    |
| Total                                          | \$ 3,500      | \$ 6,788 |

- 
- (a) Accrued wholesaler chargeback rebates of approximately \$90 million and \$300 million at December 31, 2013 and 2012, respectively, are netted in trade receivables because Abbott's customers are invoiced at a higher catalog price but only remit to Abbott their contract price for the products. The reduction in the chargeback rebates from December 31, 2012 to December 31, 2013 is primarily due to the separation of AbbVie on January 1, 2013.
- (b) 2013 and 2012 includes acquisition consideration payable of approximately \$400 million related primarily to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business.

|                                                                                                  | 2013          | 2012     |
|--------------------------------------------------------------------------------------------------|---------------|----------|
|                                                                                                  | (in millions) |          |
| Post-employment Obligations and Other Long-term Liabilities:                                     |               |          |
| Defined benefit pension plans and post-employment medical and dental plans for significant plans | \$ 1,818      | \$ 4,871 |

Edgar Filing: ABBOTT LABORATORIES - Form 10-K

|                       |          |          |
|-----------------------|----------|----------|
| Deferred income taxes | 466      | 710      |
| All other (c)         | 2,500    | 3,476    |
| Total                 | \$ 4,784 | \$ 9,057 |

(c) 2013 includes \$1.3 billion of gross unrecognized tax benefits, as well as \$70 million of acquisition consideration payable. 2012 includes \$1.4 billion of gross unrecognized tax benefits, as well as acquisition consideration payable of \$385 million related to the acquisition of Piramal Healthcare Limited's Healthcare Solutions business.

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 4 Accumulated Other Comprehensive Income**

The components of the changes in accumulated other comprehensive income from continuing operation, net of income taxes, are as follows: (*in millions*)

|                                                                                    | Cumulative<br>Foreign<br>Currency<br>Translation<br>Adjustments | Net<br>Actuarial<br>Losses and<br>Prior<br>Service<br>Costs and<br>Credits | Cumulative<br>Unrealized<br>Gains on<br>Marketable<br>Equity<br>Securities | Cumulative<br>Gains on<br>Derivative<br>Instruments<br>Designated as<br>Cash Flow<br>Hedges | Total      |
|------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------|
| Balance at December 31, 2012                                                       | \$ (79)                                                         | \$ (3,596)                                                                 | \$ 31                                                                      | \$ 50                                                                                       | \$ (3,594) |
| Separation of AbbVie                                                               | (400)                                                           | 1,402                                                                      |                                                                            | 8                                                                                           | 1,010      |
| Other comprehensive income (loss) before reclassifications                         | (239)                                                           | 771                                                                        | 22                                                                         | (23)                                                                                        | 531        |
| Income (loss) amounts reclassified from accumulated other comprehensive income (a) |                                                                 | 111                                                                        | (40)                                                                       | (30)                                                                                        | 41         |
| Net current period comprehensive income (loss) from continuing operations          | (239)                                                           | 882                                                                        | (18)                                                                       | (53)                                                                                        | 572        |
| Balance at December 31, 2013                                                       | \$ (718)                                                        | \$ (1,312)                                                                 | \$ 13                                                                      | \$ 5                                                                                        | \$ (2,012) |

---

(a)

Reclassified amounts for foreign currency translation are recorded in the Consolidated Statement of Earnings as Net Foreign exchange loss (gain); gains on marketable equity securities are recorded as Other (income) expense and gains/losses related to cash flow hedges are recorded as Cost of product sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan cost see Note 12 for additional information.

**Note 5 Business Acquisitions**

In August 2013, Abbott acquired 100 percent of IDEV Technologies, net of debt, for \$310 million, in cash. The acquisition of IDEV Technologies expands Abbott's endovascular portfolio. The allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately \$170 million which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible definite-lived intangible assets of approximately \$66 million, non-deductible goodwill of approximately \$123 million and net deferred tax liabilities of \$56 million. Acquired intangible assets consist of developed technology and are being amortized over 11 years.

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 5 Business Acquisitions (Continued)**

In August 2013, Abbott acquired 100 percent of OptiMedica for \$260 million, in cash, plus additional payments up to \$150 million to be made upon completion of certain development, regulatory and sales milestones. The acquisition of OptiMedica provides Abbott with an immediate entry point into the laser assisted cataract surgery market. The allocation of the fair value of the acquisition resulted in non-deductible definite-lived intangible assets of approximately \$160 million; non-deductible acquired in-process research and development of approximately \$60 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation; non-deductible goodwill of approximately \$151 million, net deferred tax liabilities of \$70 million and contingent consideration of approximately \$70 million. The fair value of the contingent consideration was determined based on an independent appraisal. Acquired intangible assets consist primarily of developed technology that is being amortized over 18 years.

The preliminary allocations of fair value of these acquisitions will be finalized when valuations are completed. Had the above acquisitions taken place on January 1 of the previous year, consolidated net sales and income would not have been significantly different from reported amounts.

**Note 6 Goodwill and Intangible Assets**

Abbott recorded goodwill of approximately \$274 million in 2013 related to the acquisitions of IDEV Technologies and OptiMedica. Goodwill related to the IDEV acquisition was allocated to the Vascular Products segment and goodwill related to OptiMedica was allocated to a non-reportable segment. Foreign currency translation and other adjustments decreased goodwill in 2013 and 2011 by \$168 million and \$225 million, respectively, and increased goodwill in 2012 by \$69 million. In addition, in connection with the separation of AbbVie on January 1, 2013, Abbott transferred approximately \$6.1 billion of goodwill to AbbVie. The amount of goodwill related to reportable segments at December 31, 2013 was \$2.9 billion for the Established Pharmaceutical Products segment, \$286 million for the Nutritional Products segment, \$444 million for the Diagnostic Products segment, and \$3.1 billion for the Vascular Products segment. Other than the effects of the separation of AbbVie, there were no reductions of goodwill relating to the disposal of all or a portion of a business. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was \$12.2 billion and \$17.6 billion as of December 31, 2013 and 2012, respectively, and accumulated amortization was \$6.8 billion and \$9.7 billion as of December 31, 2013 and 2012, respectively. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately \$266 million and \$691 million at December 31, 2013 and 2012, respectively. Gross amortizable intangible assets, accumulated amortization and indefinite-lived intangible assets of \$5.7 billion, \$3.8 billion and \$417 million, respectively, were transferred to AbbVie as part of the separation on January 1, 2013. In 2012 and 2011, Abbott recorded impairment charges of \$69 million and \$125 million, respectively, for certain research and development assets due to changes in the projected development and regulatory timelines for the projects. The charges relate to non-reportable segments. Discounted cash flow analysis was used to analyze fair value and the charges are included in research and development expenses.

The estimated annual amortization expense for intangible assets recorded at December 31, 2013 is approximately \$711 million in 2014, \$652 million in 2015, \$636 million in 2016, \$635 million in 2017 and \$505 million in 2018. Amortizable intangible assets are amortized over 2 to 20 years (average 11 years).

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 7 Restructuring Plans**

In 2013, Abbott management approved a plan to reduce costs and improve efficiencies across various functional areas as well as a plan to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott's established pharmaceuticals business. In addition, in 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott's core diagnostics, established pharmaceutical and nutritional businesses. Abbott recorded employee related severance charges of approximately \$78 million in 2013 and \$167 million in 2012. Additional charges of approximately \$4 million in 2013 and \$22 million in 2012 were also recorded primarily for asset impairments. Approximately \$35 million in 2013 and \$70 million in 2012 are recorded in Cost of products sold and approximately \$47 million in 2013 and \$119 million as Selling, general and administrative expense in 2012. No significant cash payments were made during 2012 relating to the 2012 actions. The following summarizes the activity for these restructurings: *(in millions)*

|                                        |        |
|----------------------------------------|--------|
| Restructuring charges recorded in 2012 | \$ 167 |
| Restructuring charges recorded in 2013 | 78     |
| Payments and other adjustments         | (97)   |

|                                      |        |
|--------------------------------------|--------|
| Accrued balance at December 31, 2013 | \$ 148 |
|--------------------------------------|--------|

In 2013 and prior years, Abbott management approved plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. In 2013, Abbott recorded employee severance charges of approximately \$11 million. In 2011, Abbott recorded charges of approximately \$194 million reflecting the impairment of manufacturing facilities and other assets, employee severance and other related charges. Approximately \$11 million in 2013 and \$18 million in 2011 are classified as Cost of products sold. The remaining 2011 charge of \$176 million related to businesses transferred to AbbVie and is being recognized in the results of discontinued operations.

The following summarizes the activity for these restructurings: *(in millions)*

|                                             |       |
|---------------------------------------------|-------|
| Accrued balance at January 1, 2011          | \$ 77 |
| 2011 restructuring charges                  | 194   |
| Payments, impairments and other adjustments | (94)  |

|                                             |      |
|---------------------------------------------|------|
| Accrued balance at December 31, 2011        | 177  |
| Payments, impairments and other adjustments | (48) |

|                                      |      |
|--------------------------------------|------|
| Accrued balance at December 31, 2012 | 129  |
| Transfer of liability to AbbVie      | (62) |
| Restructuring charges                | 11   |
| Payments and other adjustments       | (58) |

|                                      |       |
|--------------------------------------|-------|
| Accrued balance at December 31, 2013 | \$ 20 |
|--------------------------------------|-------|



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

An additional \$41 million, \$110 million and \$25 million were recorded in 2013, 2012 and 2011, respectively, relating to these restructurings, primarily for accelerated depreciation.

In 2012 and 2010, Abbott management approved restructuring plans primarily related to the acquisition of Solvay's pharmaceuticals business. These plans streamline operations, improve efficiencies and reduce costs in certain Solvay sites and functions as well as in certain Abbott and Solvay commercial

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 7 Restructuring Plans (Continued)**

organizations in various countries. In 2012, Abbott recorded a charge of approximately \$150 million for employee severance and contractual obligations, primarily related to the exit from a research and development facility. These charges are related to businesses transferred to AbbVie and are being recognized in the results of discontinued operations. The accrued restructuring reserves of \$115 million at December 31, 2012 related to these actions were transferred to AbbVie on January 1, 2013 as part of the separation. As such, there are no remaining accruals being reported in Abbott's balance sheet as of December 31, 2013.

In 2011 and 2008, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs, and improve efficiencies in Abbott's core diagnostic business. In 2011, a charge of \$28 million was recorded in Cost of products sold. The following summarizes the activity for these restructurings: *(in millions)*

|                                    |       |
|------------------------------------|-------|
| Accrued balance at January 1, 2011 | \$ 88 |
| 2011 restructuring charge          | 28    |
| Payments and other adjustments     | (37)  |

|                                      |      |
|--------------------------------------|------|
| Accrued balance at December 31, 2011 | 79   |
| Payments and other adjustments       | (23) |

|                                      |      |
|--------------------------------------|------|
| Accrued balance at December 31, 2012 | 56   |
| Payments and other adjustments       | (15) |

|                                      |       |
|--------------------------------------|-------|
| Accrued balance at December 31, 2013 | \$ 41 |
|--------------------------------------|-------|

In addition, charges of approximately \$16 million and \$42 million were recorded in 2012 and 2011, primarily for accelerated depreciation and product transfer costs.

**Note 8 Incentive Stock Program**

The 2009 Incentive Stock Program authorizes the granting of nonqualified stock options, restricted stock awards, restricted stock units, performance awards, foreign benefits and other share-based awards. Stock options, replacement stock options and restricted stock awards and units comprise the majority of benefits that have been granted and are currently outstanding under this program and a prior program. In 2013, Abbott granted 4,733,378 stock options, 918,819 replacement stock options, 848,674 restricted stock awards and 6,412,867 restricted stock units under this program.

The purchase price of shares under option must be at least equal to the fair market value of the common stock on the date of grant, and the maximum term of an option is 10 years. Options generally vest equally over three years. Restricted stock awards generally vest between 3 and 5 years and for restricted stock awards that vest over 5 years, no more than one-third of the award vests in any one year upon Abbott reaching a minimum return on equity target. Restricted stock units vest over three years and upon vesting, the recipient receives one share of Abbott stock for each vested restricted stock unit. The aggregate fair market value of restricted stock awards and units is recognized as expense over the service period. Restricted stock awards and settlement of vested restricted stock units are issued out of treasury shares. Abbott generally issues new shares for exercises of stock options. Abbott does not have a policy of purchasing its shares relating to its share-based programs.

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 8 Incentive Stock Program (Continued)

In connection with the separation of AbbVie on January 1, 2013, Abbott modified its outstanding equity awards granted under incentive stock programs for its employees. The awards were generally modified such that immediately following the separation, the awardees held the same number of awards in Abbott stock and an equal number of awards in AbbVie stock. The exercise price on outstanding Abbott options was adjusted and the exercise price on the AbbVie options granted under this modification was established with the intention of generally preserving the value of the awards immediately prior to the separation. This modification did not result in additional compensation expense.

At December 31, 2013, approximately 130 million shares were reserved for future grants. Subsequent to year-end, the reserve was reduced by approximately 22 million shares for stock options and restricted stock awards and units granted by the Board of Directors.

The number of restricted stock awards and units outstanding and the weighted-average grant-date fair value at December 31, 2013 and January 1, 2013 was 14,385,221 and \$30.13 and 15,728,503 and \$25.51, respectively. The number of restricted stock awards and units, and the weighted-average grant-date fair value, that were granted, vested and lapsed during 2013 were 7,261,541 and \$34.92, 7,821,999 and \$25.36 and 782,824 and \$29.34, respectively. The fair market value of restricted stock awards and units vested in 2013, 2012 and 2011 was \$274 million, \$385 million and \$237 million, respectively.

|                   | Options Outstanding |                                          |                                                     | Exercisable Options |                                          |                                                     |
|-------------------|---------------------|------------------------------------------|-----------------------------------------------------|---------------------|------------------------------------------|-----------------------------------------------------|
|                   | Shares              | Weighted<br>Average<br>Exercise<br>Price | Weighted<br>Average<br>Remaining<br>Life<br>(Years) | Shares              | Weighted<br>Average<br>Exercise<br>Price | Weighted<br>Average<br>Remaining<br>Life<br>(Years) |
| December 31, 2012 |                     |                                          |                                                     |                     |                                          |                                                     |
| (a)               | 48,685,273          | \$ 24.97                                 | 4.0                                                 | 43,511,651          | \$ 24.68                                 | 3.7                                                 |
| Granted           | 5,652,197           | 34.91                                    |                                                     |                     |                                          |                                                     |
| Exercised         | (11,370,121)        | 25.37                                    |                                                     |                     |                                          |                                                     |
| Lapsed            | (210,009)           | 31.82                                    |                                                     |                     |                                          |                                                     |
| December 31, 2013 | 42,757,340          | \$ 26.15                                 | 4.0                                                 | 36,185,039          | \$ 25.02                                 | 3.1                                                 |

(a)

The amount of options outstanding and the weighted average exercise price have been revised to reflect the impact of the AbbVie separation.

The aggregate intrinsic value of options outstanding and exercisable at December 31, 2013 was \$525 million and \$487 million, respectively. The total intrinsic value of options exercised in 2013, 2012 and 2011 was \$120 million, \$528 million and \$94 million, respectively. The total unrecognized compensation cost related to all share-based compensation plans at December 31, 2013 amounted to approximately \$153 million, which is expected to be recognized over the next three years.

Total non-cash compensation expense charged against income from continuing operations in 2013, 2012 and 2011 for share-based plans totaled approximately \$262 million, \$284 million and \$256 million, respectively, and the tax benefit recognized was approximately \$84 million, \$87 million and \$71 million, respectively. Compensation cost capitalized as part of inventory is not significant.



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 8 Incentive Stock Program (Continued)

The fair value of an option granted in 2013, 2012 and 2011 was \$5.77, \$6.80, and \$6.23, respectively. The fair value of an option grant was estimated using the Black-Scholes option-pricing model with the following assumptions

|                                 | 2013  | 2012  | 2011  |
|---------------------------------|-------|-------|-------|
| Risk-free interest rate         | 1.1%  | 1.2%  | 2.7%  |
| Average life of options (years) | 6.0   | 6.0   | 6.0   |
| Volatility                      | 20.0% | 21.0% | 21.0% |
| Dividend yield                  | 1.6%  | 3.6%  | 4.1%  |

The risk-free interest rate is based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option's expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on Abbott's stock and historical volatility of Abbott's stock over the expected life of the option. Dividend yield is based on the option's exercise price and annual dividend rate at the time of grant.

## Note 9 Debt and Lines of Credit

The following is a summary of long-term debt at December 31: *(in millions)*

|                                                                                                                   | 2013     | 2012      |
|-------------------------------------------------------------------------------------------------------------------|----------|-----------|
| 1.2% Notes, due 2015 (1)                                                                                          | \$       | \$ 3,500  |
| Variable Rate Notes, due 2015 (1)                                                                                 |          | 500       |
| 1.75% Notes, due 2017 (1)                                                                                         |          | 4,000     |
| 2.0% Notes, due 2018 (1)                                                                                          |          | 1,000     |
| 5.125% Notes, due 2019                                                                                            | 947      | 947       |
| 4.125% Notes, due 2020                                                                                            | 597      | 597       |
| 2.9% Notes, due 2022 (1)                                                                                          |          | 3,100     |
| 6.15% Notes, due 2037                                                                                             | 547      | 547       |
| 6.0% Notes, due 2039                                                                                              | 515      | 515       |
| 5.3% Notes, due 2040                                                                                              | 694      | 694       |
| 4.4% Notes, due 2042 (1)                                                                                          |          | 2,600     |
| Other, including fair value adjustments relating to interest rate hedge contracts designated as fair value hedges | 88       | 85        |
| Total, net of current maturities                                                                                  | 3,388    | 18,085    |
| Current maturities of long-term debt                                                                              | 9        | 309       |
| Total carrying amount                                                                                             | \$ 3,397 | \$ 18,394 |

(1)

These notes were issued by AbbVie Inc. in November 2012. With the separation of AbbVie on January 1, 2013, Abbott no longer has any obligations related to this debt.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

In 2012, Abbott redeemed \$7.7 billion of its outstanding notes. Abbott incurred a cost of \$1.35 billion to extinguish this debt, net of gains from the unwinding of interest rate swaps related to the debt. In 2012, AbbVie Inc., a wholly owned subsidiary of Abbott, issued \$14.7 billion of long-term debt with maturities

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 9 Debt and Lines of Credit (Continued)**

ranging from 3 to 30 years. The debt issued by AbbVie Inc. was guaranteed by Abbott with the guarantee expiring when AbbVie Inc. separated from Abbott on January 1, 2013.

Principal payments required on long-term debt outstanding at December 31, 2013 are \$9 million in 2014, \$10 million in 2015, \$3 million in 2016, \$1 million in 2017, \$1 million in 2018 and \$3.3 billion in 2019 and thereafter.

At December 31, 2013, Abbott's long-term debt rating was A+ by Standard & Poor's Corporation and A1 by Moody's Investors Service. Abbott has readily available financial resources, including unused lines of credit of \$5.0 billion that support commercial paper borrowing arrangements which expire in 2017. Abbott's weighted-average interest rate on short-term borrowings was 0.2% at December 31, 2013 and 0.4% at December 31, 2012 and 2011.

**Note 10 Financial Instruments, Derivatives and Fair Value Measures**

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, totaling \$137 million at December 31, 2013, and \$1.6 billion at December 31, 2012, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Contracts totaling \$1.0 billion were transferred to AbbVie as part of the separation on January 1, 2013. Accumulated gains and losses as of December 31, 2013 will be included in Cost of products sold at the time the products are sold, generally through the next twelve months. The amount of hedge ineffectiveness was not significant in 2013, 2012 and 2011.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies and Japanese yen, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar, European currencies and Japanese yen. At December 31, 2013, 2012 and 2011, Abbott held \$13.8 billion, \$18.2 billion and \$15.7 billion, respectively, of such foreign currency forward exchange contracts. Contracts totaling \$4.3 billion were transferred to AbbVie as part of the separation on January 1, 2013.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately \$505 million, \$615 million and \$680 million as of December 31, 2013, 2012 and 2011, respectively. Accordingly, changes in the fair value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling \$1.5 billion, \$9.5 billion and \$6.8 billion at December 31, 2013, 2012 and 2011, respectively, to manage its exposure to changes in the fair value of fixed-rate debt. \$8.0 billion of the contracts outstanding at December 31, 2012 related to debt issued by AbbVie Inc. in the fourth quarter of 2012 and were transferred to AbbVie as part of the separation on January 1, 2013. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 10 Financial Instruments, Derivatives and Fair Value Measures (Continued)

contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No hedge ineffectiveness was recorded in income in 2013, 2012 and 2011 for these hedges.

Gross unrealized holding gains on available-for-sale equity securities totaled \$22 million, \$51 million and \$64 million at December 31, 2013, 2012 and 2011, respectively.

The following table summarizes the amounts and location of certain derivative financial instruments as of December 31:

|                                                                         | Fair Value           |        | Assets                                       | Fair Value |        | Liabilities                                                       |
|-------------------------------------------------------------------------|----------------------|--------|----------------------------------------------|------------|--------|-------------------------------------------------------------------|
|                                                                         | 2013                 | 2012   | Balance Sheet<br>Caption                     | 2013       | 2012   | Balance Sheet<br>Caption                                          |
|                                                                         | <i>(in millions)</i> |        |                                              |            |        |                                                                   |
| Interest rate swaps designated as fair value hedges                     | \$ 87                | \$ 185 | Deferred income<br>taxes and other<br>assets | \$         | \$ 80  | Post-employment<br>obligations and other<br>long-term liabilities |
| Foreign currency forward exchange contracts                             |                      |        |                                              |            |        |                                                                   |
| Hedging instruments                                                     | 14                   | 22     | Other prepaid<br>expenses and<br>receivables |            | 11     | Other accrued<br>liabilities                                      |
| Others not designated as hedges                                         | 70                   | 98     |                                              | 75         | 135    |                                                                   |
| Debt designated as a hedge of net investment in a<br>foreign subsidiary |                      |        | n/a                                          | 505        | 615    | Short-term borrowings                                             |
|                                                                         | \$ 171               | \$ 305 |                                              | \$ 580     | \$ 841 |                                                                   |

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and the amounts and location of income (expense) and gain (loss) reclassified into income and for certain other derivative financial instruments. The amount of hedge ineffectiveness was not significant in 2013, 2012 and 2011 for these hedges.

|                                                                               | Gain (loss) Recognized<br>in<br>Other Comprehensive<br>Income (loss) |       |       | Income (expense) and<br>Gain (loss) Reclassified<br>into Income |        |         | Income Statement<br>Caption         |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------|-------|-------|-----------------------------------------------------------------|--------|---------|-------------------------------------|
|                                                                               | 2013                                                                 | 2012  | 2011  | 2013                                                            | 2012   | 2011    |                                     |
|                                                                               | <i>(in millions)</i>                                                 |       |       |                                                                 |        |         |                                     |
| Foreign currency forward exchange contracts designated as<br>cash flow hedges | \$ 35                                                                | \$ 13 | \$ 67 | \$ 47                                                           | \$ 114 | \$ (44) | Cost of products sold               |
| Debt designated as a hedge of net investment in a foreign<br>subsidiary       | 110                                                                  | 65    | (30)  |                                                                 |        |         | n/a                                 |
| Interest rate swaps designated as fair value hedges                           | n/a                                                                  | n/a   | n/a   | (98)                                                            | 62     | 488     | Interest expense                    |
| Foreign currency forward exchange contracts not<br>designated as hedges       | n/a                                                                  | n/a   | n/a   | 88                                                              | 131    | (41)    | Net foreign exchange<br>(gain) loss |

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

The carrying values and fair values of certain financial instruments as of December 31 are shown in the table below. The carrying values of all other financial instruments approximate their estimated fair values.





## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 10 Financial Instruments, Derivatives and Fair Value Measures (Continued)**

The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

|                                              | 2013              |               | 2012              |               |
|----------------------------------------------|-------------------|---------------|-------------------|---------------|
|                                              | Carrying<br>Value | Fair<br>Value | Carrying<br>Value | Fair<br>Value |
| <i>(in millions)</i>                         |                   |               |                   |               |
| Long-term Investment Securities:             |                   |               |                   |               |
| Equity securities                            | \$ 93             | \$ 93         | \$ 213            | \$ 213        |
| Other                                        | 26                | 24            | 61                | 56            |
| Total Long-term Debt                         | (3,397)           | (3,930)       | (18,394)          | (19,588)      |
| Foreign Currency Forward Exchange Contracts: |                   |               |                   |               |
| Receivable position                          | 84                | 84            | 120               | 120           |
| (Payable) position                           | (75)              | (75)          | (146)             | (146)         |
| Interest Rate Hedge Contracts:               |                   |               |                   |               |
| Receivable position                          | 87                | 87            | 185               | 185           |
| (Payable) position                           |                   |               | (80)              | (80)          |

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 10 Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

|                                                           | Outstanding<br>Balances | Basis of Fair Value Measurement       |                                           |                                       |
|-----------------------------------------------------------|-------------------------|---------------------------------------|-------------------------------------------|---------------------------------------|
|                                                           |                         | Quoted<br>Prices in<br>Active Markets | Significant Other<br>Observable<br>Inputs | Significant<br>Unobservable<br>Inputs |
| (in millions)                                             |                         |                                       |                                           |                                       |
| December 31, 2013:                                        |                         |                                       |                                           |                                       |
| Equity securities                                         | \$ 26                   | \$ 26                                 | \$                                        | \$                                    |
| Interest rate swap financial instruments                  | 87                      |                                       | 87                                        |                                       |
| Foreign currency forward exchange contracts               | 84                      |                                       | 84                                        |                                       |
|                                                           |                         |                                       |                                           |                                       |
| Total Assets                                              | \$ 197                  | \$ 26                                 | \$ 171                                    | \$                                    |
|                                                           |                         |                                       |                                           |                                       |
| Fair value of hedged long-term debt                       | \$ 1,623                | \$                                    | \$ 1,623                                  | \$                                    |
| Foreign currency forward exchange contracts               | 75                      |                                       | 75                                        |                                       |
| Contingent consideration related to business combinations | 208                     |                                       |                                           | 208                                   |
|                                                           |                         |                                       |                                           |                                       |
| Total Liabilities                                         | \$ 1,906                | \$                                    | \$ 1,698                                  | \$ 208                                |
|                                                           |                         |                                       |                                           |                                       |
| December 31, 2012:                                        |                         |                                       |                                           |                                       |
| Equity securities                                         | \$ 76                   | \$ 76                                 | \$                                        | \$                                    |
| Interest rate swap financial instruments                  | 185                     |                                       | 185                                       |                                       |
| Foreign currency forward exchange contracts               | 120                     |                                       | 120                                       |                                       |
|                                                           |                         |                                       |                                           |                                       |
| Total Assets                                              | \$ 381                  | \$ 76                                 | \$ 305                                    | \$                                    |
|                                                           |                         |                                       |                                           |                                       |
| Fair value of hedged long-term debt                       | \$ 9,632                | \$                                    | \$ 9,632                                  | \$                                    |
| Interest rate swap financial instruments                  | 80                      |                                       | 80                                        |                                       |
| Foreign currency forward exchange contracts               | 146                     |                                       | 146                                       |                                       |
| Contingent consideration related to business combinations | 323                     |                                       |                                           | 323                                   |
|                                                           |                         |                                       |                                           |                                       |
| Total Liabilities                                         | \$ 10,181               | \$                                    | \$ 9,858                                  | \$ 323                                |

The fair value of the debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money, exchange and other changes in fair value.

**Note 11    Litigation and Environmental Matters**

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed \$4 million, and the aggregate cleanup exposure is not expected to exceed \$15 million.

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 11   Litigation and Environmental Matters (Continued)**

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately \$70 million to \$90 million. The recorded accrual balance at December 31, 2013 for these proceedings and exposures was approximately \$80 million. This accrual represents management's best estimate of probable loss, as defined by FASB ASC No. 450, "Contingencies." Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations.

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 12 Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for Abbott's major defined benefit plans and post-employment medical and dental benefit plans is as follows:

| (in millions)                                                                                                                                        | Defined Benefit Plans |            | Medical and Dental Plans |            |
|------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|------------|--------------------------|------------|
|                                                                                                                                                      | 2013                  | 2012       | 2013                     | 2012       |
| Projected benefit obligations, January 1                                                                                                             | \$ 11,322             | \$ 9,212   | \$ 1,889                 | \$ 1,657   |
| Service cost                                                                                                                                         | 303                   | 389        | 43                       | 61         |
| Interest cost on projected benefit obligations                                                                                                       | 276                   | 460        | 59                       | 81         |
| (Gains) losses, primarily changes in discount rates, plan design changes, law changes and differences between actual and estimated health care costs | (650)                 | 1,461      | (156)                    | 148        |
| Benefits paid                                                                                                                                        | (185)                 | (308)      | (60)                     | (63)       |
| Separation of AbbVie Inc.                                                                                                                            | (4,654)               |            | (450)                    |            |
| Other, including foreign currency translation                                                                                                        | 20                    | 108        | (28)                     | 5          |
| Projected benefit obligations, December 31                                                                                                           | \$ 6,432              | \$ 11,322  | \$ 1,297                 | \$ 1,889   |
| Plan assets at fair value, January 1                                                                                                                 | \$ 7,949              | \$ 6,961   | \$ 417                   | \$ 389     |
| Actual return on plans' assets                                                                                                                       | 727                   | 878        | 61                       | 48         |
| Company contributions                                                                                                                                | 724                   | 379        | 40                       | 40         |
| Benefits paid                                                                                                                                        | (185)                 | (302)      | (56)                     | (60)       |
| Separation of AbbVie Inc.                                                                                                                            | (3,107)               |            |                          |            |
| Other, primarily foreign currency translation                                                                                                        | 15                    | 33         |                          |            |
| Plan assets at fair value, December 31                                                                                                               | \$ 6,123              | \$ 7,949   | \$ 462                   | \$ 417     |
| Projected benefit obligations greater than plan assets, December 31                                                                                  | \$ (309)              | \$ (3,373) | \$ (835)                 | \$ (1,472) |
| Long-term assets                                                                                                                                     | \$ 685                | \$ 69      | \$                       | \$         |
| Short-term liabilities                                                                                                                               | (11)                  | (43)       |                          |            |
| Long-term liabilities                                                                                                                                | (983)                 | (3,399)    | (835)                    | (1,472)    |
| Net liability                                                                                                                                        | \$ (309)              | \$ (3,373) | \$ (835)                 | \$ (1,472) |

# Edgar Filing: ABBOTT LABORATORIES - Form 10-K

|                                                                      |    |       |    |       |               |
|----------------------------------------------------------------------|----|-------|----|-------|---------------|
| Amounts Recognized in Accumulated Other Comprehensive Income (loss): |    |       |    |       |               |
| Actuarial losses, net                                                | \$ | 1,791 | \$ | 4,923 | \$ 334 \$ 701 |
| Prior service cost (credits)                                         |    | 20    |    | 61    | (252) (322)   |
|                                                                      |    |       |    |       |               |
| Total                                                                | \$ | 1,811 | \$ | 4,984 | \$ 82 \$ 379  |

In connection with separation of AbbVie on January 1, 2013, Abbott transferred to AbbVie Accumulated other comprehensive losses, net of income taxes, of approximately \$1.4 billion. The projected benefit obligations for non-U.S. defined benefit plans was \$2.0 billion and \$3.1 billion at December 31,

**Abbott Laboratories and Subsidiaries**
**Notes to Consolidated Financial Statements (Continued)**
**Note 12 Post-Employment Benefits (Continued)**

2013 and 2012, respectively. The accumulated benefit obligations for all defined benefit plans were \$5.5 billion and \$9.6 billion at December 31, 2013 and 2012, respectively.

For plans where the accumulated benefit obligations exceeded plan assets at December 31, 2013 and 2012, the aggregate accumulated benefit obligations, the projected benefit obligations and the aggregate plan assets were as follows:

| (in millions)                  | 2013   | 2012     |
|--------------------------------|--------|----------|
| Accumulated benefit obligation | \$ 408 | \$ 8,100 |
| Projected benefit obligation   | 505    | 9,619    |
| Fair value of plan assets      |        | 6,243    |

In 2011, \$776 million of assets and liabilities of a plan sponsored by Abbott Healthcare BV, a Dutch subsidiary of Abbott Laboratories, were irrevocably transferred to a Dutch insurance company in full settlement of that plan. The assets were used to purchase an annuity contract to fulfill the plan's obligations.

The components of the net periodic benefit cost were as follows:

|                                                | Defined Benefit Plans |        |        | Medical and Dental Plans |       |       |
|------------------------------------------------|-----------------------|--------|--------|--------------------------|-------|-------|
|                                                | 2013                  | 2012   | 2011   | 2013                     | 2012  | 2011  |
|                                                | (in millions)         |        |        |                          |       |       |
| Service cost                                   | \$ 303                | \$ 389 | \$ 332 | \$ 43                    | \$ 61 | \$ 55 |
| Interest cost on projected benefit obligations | 276                   | 460    | 446    | 59                       | 81    | 88    |
| Expected return on plans' assets               | (396)                 | (611)  | (608)  | (36)                     | (33)  | (34)  |
| Settlement                                     |                       |        | 40     |                          |       |       |
| Amortization of actuarial losses               | 169                   | 244    | 163    | 34                       | 34    | 38    |
| Amortization of prior service cost (credits)   | 3                     | 2      | 4      | (35)                     | (42)  | (42)  |
| Total cost                                     | 355                   | 484    | 377    | 65                       | 101   | 105   |
| Less: Discontinued operations                  |                       | (206)  | (176)  |                          | (48)  | (49)  |
| Net cost continuing operations                 | \$ 355                | \$ 278 | \$ 201 | \$ 65                    | \$ 53 | \$ 56 |

Other comprehensive income (loss) for each respective year includes the amortization of actuarial losses and prior service costs (credits) as noted in the previous table. Other comprehensive income (loss) for each respective year also includes: net actuarial gains and prior service credits of \$995 million for defined benefit plans and \$201 million for medical and dental plans in 2013; net actuarial losses of \$1.2 billion for defined benefit plans and net actuarial losses of \$134 million for medical and dental plans in 2012; and net actuarial losses of \$1.1 billion for defined benefit plans and net actuarial gains of \$66 million for medical and dental plans in 2011. The actuarial losses for 2012 and 2011 related to the businesses transferred to AbbVie as part of the separation were \$167 million and \$19 million, respectively; prior service costs were not significant.

The pretax amount of actuarial losses and prior service cost (credits) included in Accumulated other comprehensive income (loss) at December 31, 2013 that is expected to be recognized in the net periodic benefit cost in 2014 is \$102 million and \$2 million of expense, respectively, for defined benefit pension plans and \$17 million of expense and \$37 million of income, respectively, for medical and dental plans.





## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 12 Post-Employment Benefits (Continued)

The weighted average assumptions used to determine benefit obligations for defined benefit plans and medical and dental plans are as follows:

|                                                             | 2013 | 2012 | 2011 |
|-------------------------------------------------------------|------|------|------|
| Discount rate                                               | 4.9% | 4.3% | 5.0% |
| Expected aggregate average long-term change in compensation | 5.0% | 5.3% | 5.3% |

The weighted average assumptions used to determine the net cost for defined benefit plans and medical and dental plans are as follows:

|                                                             | 2013 | 2012 | 2011 |
|-------------------------------------------------------------|------|------|------|
| Discount rate                                               | 4.2% | 5.0% | 5.4% |
| Expected return on plan assets                              | 7.8% | 8.0% | 7.8% |
| Expected aggregate average long-term change in compensation | 5.0% | 5.3% | 5.1% |

The assumed health care cost trend rates for medical and dental plans at December 31 were as follows:

|                                                       | 2013 | 2012 | 2011 |
|-------------------------------------------------------|------|------|------|
| Health care cost trend rate assumed for the next year | 7%   | 7%   | 7%   |
| Rate that the cost trend rate gradually declines to   | 5%   | 5%   | 5%   |
| Year that rate reaches the assumed ultimate rate      | 2019 | 2019 | 2019 |

The discount rates used to measure liabilities were determined based on high-quality fixed income securities that match the duration of the expected retiree benefits. The health care cost trend rates represent Abbott's expected annual rates of change in the cost of health care benefits and is a forward projection of health care costs as of the measurement date. A one-percentage point increase/(decrease) in the assumed health care cost trend rate would increase/(decrease) the accumulated post-employment benefit obligations as of December 31, 2013, by \$177 million /\$(146) million, and the total of the service and interest cost components of net post-employment health care cost for the year then ended by approximately \$18 million/\$(14) million.

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 12 Post-Employment Benefits (Continued)

The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value:

|                                    | Basis of Fair Value Measurement |                     |                      |                        |    |       |    |     |
|------------------------------------|---------------------------------|---------------------|----------------------|------------------------|----|-------|----|-----|
|                                    | Outstanding<br>Balances         | Quoted<br>Prices in | Significant<br>Other | Significant            |    |       |    |     |
|                                    |                                 | Active Markets      | Observable<br>Inputs | Unobservable<br>Inputs |    |       |    |     |
| <i>(in millions)</i>               |                                 |                     |                      |                        |    |       |    |     |
| December 31, 2013:                 |                                 |                     |                      |                        |    |       |    |     |
| Equities:                          |                                 |                     |                      |                        |    |       |    |     |
| U.S. large cap (a)                 | \$                              | 1,618               | \$                   | 741                    | \$ | 877   | \$ |     |
| U.S. mid cap (b)                   |                                 | 409                 |                      | 134                    |    | 275   |    |     |
| International (c)                  |                                 | 1,319               |                      | 608                    |    | 711   |    |     |
| Fixed income securities:           |                                 |                     |                      |                        |    |       |    |     |
| U.S. government securities (d)     |                                 | 453                 |                      | 61                     |    | 392   |    |     |
| Corporate debt instruments (e)     |                                 | 378                 |                      | 108                    |    | 270   |    |     |
| Non-U.S. government securities (f) |                                 | 536                 |                      | 305                    |    | 231   |    |     |
| Other (g)                          |                                 | 77                  |                      | 69                     |    | 8     |    |     |
| Absolute return funds (h)          |                                 | 1,474               |                      | 197                    |    | 791   |    | 486 |
| Commodities (i)                    |                                 | 170                 |                      | 6                      |    | 97    |    | 67  |
| Other (j)                          |                                 | 151                 |                      | 149                    |    |       |    | 2   |
|                                    | \$                              | 6,585               | \$                   | 2,378                  | \$ | 3,652 | \$ | 555 |

|                                    |          |          |          |        |
|------------------------------------|----------|----------|----------|--------|
| December 31, 2012:                 |          |          |          |        |
| Equities:                          |          |          |          |        |
| U.S. large cap (a)                 | \$ 1,831 | \$ 1,058 | \$ 773   | \$     |
| U.S. mid cap (b)                   | 491      | 133      | 358      |        |
| International (c)                  | 1,607    | 657      | 950      |        |
| Fixed income securities:           |          |          |          |        |
| U.S. government securities (d)     | 899      | 172      | 727      |        |
| Corporate debt instruments (e)     | 736      | 355      | 381      |        |
| Non-U.S. government securities (f) | 374      | 83       | 291      |        |
| Other (g)                          | 24       |          | 24       |        |
| Absolute return funds (h)          | 2,070    | 85       | 1,246    | 739    |
| Commodities (i)                    | 222      | 9        | 172      | 41     |
| Other (j)                          | 112      | 109      |          | 3      |
|                                    | \$ 8,366 | \$ 2,661 | \$ 4,922 | \$ 783 |

Prior year amounts have been revised to conform with the current year's asset classifications.

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

(a)

A mix of index funds that track the S&P 500 (60 percent in 2013 and 50 percent in 2012) and separate actively managed equity accounts that are benchmarked to the Russell 1000 (40 percent in 2013 and 50 percent in 2012).

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 12 Post-Employment Benefits (Continued)**

- (b) A mix of index funds (70 percent in 2013 and 75 percent in 2012) and separate actively managed equity accounts (30 percent in 2013 and 25 percent in 2012) that track or are benchmarked to the S&P 400 midcap index.
- (c) Primarily separate actively managed pooled investment accounts that are benchmarked to the MSCI and MSCI emerging market indices.
- (d) Index funds not actively managed (50 percent in 2013 and 2012) and separate actively managed accounts (50 percent in 2013 and 2012).
- (e) Index funds not actively managed (40 percent in 2013 and 20 percent in 2012) and separate actively managed accounts (60 percent in 2013 and 80 percent in 2012).
- (f) Primarily United Kingdom, Japan and Irish government-issued bonds.
- (g) Primarily mortgage backed securities.
- (h) Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets.
- (i) Primarily investments in liquid commodity future contracts and private energy funds.
- (j) Primarily cash and cash equivalents.

Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the net asset value (NAV) provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund minus its liabilities. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry-recognized vendors. Absolute return funds and commodities are valued at the NAV provided by the fund administrator. Private energy funds are valued at the NAV provided by the partnership on a one-quarter lag adjusted for known cash flows and significant events through the reporting date.

The following table summarizes the change in the value of assets that are measured using significant unobservable inputs:

|                                             | 2013                 | 2012   |
|---------------------------------------------|----------------------|--------|
|                                             | <i>(in millions)</i> |        |
| January 1                                   | \$ 783               | \$ 682 |
| Transfers in (out of) from other categories | 6                    | 6      |
| Separation of AbbVie, Inc.                  | (165)                |        |
| Actual return on plan assets:               |                      |        |
| Assets on hand at year end                  | 29                   | 59     |
| Assets sold during the year                 | 51                   | (4)    |
| Purchases, sales and settlements, net       | (149)                | 40     |

December 31

\$ 555 \$ 783

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 12 Post-Employment Benefits (Continued)**

The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, balancing higher return, more volatile equity securities, and lower return, less volatile fixed income securities. Investment allocations are made across a range of markets, industry sectors, capitalization sizes, and in the case of fixed income securities, maturities and credit quality. The plans do not directly hold any securities of Abbott. There are no known significant concentrations of risk in the plans' assets. Abbott's medical and dental plans' assets are invested in a similar mix as the pension plan assets. The actual asset allocation percentages at year end are consistent with the company's targeted asset allocation percentages.

The plans' expected return on assets, as shown above is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolios. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions.

Abbott funds its domestic pension plans according to IRS funding limitations. International pension plans are funded according to similar regulations. Abbott funded \$724 million in 2013 and \$379 million in 2012 to defined pension plans. Abbott expects to contribute approximately \$400 million to its pension plans in 2014, of which approximately \$300 million relates to its main domestic pension plan.

Total benefit payments expected to be paid to participants, which includes payments funded from company assets, as well as paid from the plans, are as follows:

| (in millions) | Defined<br>Benefit Plans | Medical and<br>Dental Plans |
|---------------|--------------------------|-----------------------------|
| 2014          | \$ 186                   | \$ 71                       |
| 2015          | 198                      | 73                          |
| 2016          | 213                      | 74                          |
| 2017          | 229                      | 76                          |
| 2018          | 249                      | 77                          |
| 2019 to 2023  | 1,578                    | 417                         |

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 12 Post-Employment Benefits (Continued)**

The Abbott Stock Retirement Plan is the principal defined contribution plan. Abbott's contributions to this plan were \$86 million in 2013, \$150 million in 2012 and \$151 million in 2011. The contribution amounts in 2012 and 2011 include amounts associated with the businesses transferred to AbbVie.

**Note 13 Taxes on Earnings from Continuing Operations**

Taxes on earnings from continuing operations reflect the annual effective rates, including charges for interest and penalties. Deferred income taxes reflect the tax consequences on future years of differences between the tax bases of assets and liabilities and their financial reporting amounts.

In 2013, taxes on earnings from continuing operations reflect the recognition of \$234 million of tax benefits as a result of the favorable resolution of various tax positions pertaining to prior years. Earnings from discontinued operations in 2013 include the recognition of \$193 million of tax benefits as a result of the resolution of various tax positions related to AbbVie's operations prior to the separation. In addition, as a result of the American Taxpayer Relief Act of 2012 signed into law in January 2013, Abbott recognized a tax benefit in the tax provision related to continuing operations of approximately \$103 million for the retroactive extension of the research tax credit and the look-through rules of section 954(c)(6) of the Internal Revenue Code to the beginning of 2012. The \$1.515 billion domestic loss before taxes in 2012 includes \$1.29 billion of net loss on the early extinguishment of debt.

U.S. income taxes are provided on those earnings of foreign subsidiaries which are intended to be remitted to the parent company. Abbott does not record deferred income taxes on earnings reinvested indefinitely in foreign subsidiaries. Undistributed earnings reinvested indefinitely in foreign subsidiaries as working capital and plant and equipment aggregated \$24.0 billion at December 31, 2013. It is not practicable to determine the amount of deferred income taxes not provided on these earnings. In the U.S., Abbott's federal income tax returns through 2010 are settled except for three items, and the income tax returns for years after 2010 are open. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. Reserves for interest and penalties are not significant.

Earnings from continuing operations before taxes, and the related provisions for taxes on earnings from continuing operations, were as follows:

| (in millions)                                            | 2013     | 2012       | 2011     |
|----------------------------------------------------------|----------|------------|----------|
| Earnings (Loss) From Continuing Operations Before Taxes: |          |            |          |
| Domestic                                                 | \$ 529   | \$ (1,515) | \$ (593) |
| Foreign                                                  | 1,992    | 1,820      | 1,829    |
| Total                                                    | \$ 2,521 | \$ 305     | \$ 1,236 |



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 13 Taxes on Earnings from Continuing Operations (Continued)

| (in millions)                                 | 2013   | 2012     | 2011     |
|-----------------------------------------------|--------|----------|----------|
| Taxes on Earnings From Continuing Operations: |        |          |          |
| Current:                                      |        |          |          |
| Domestic                                      | \$ 16  | \$ (21)  | \$ (888) |
| Foreign                                       | 555    | 979      | 797      |
| Total current                                 | 571    | 958      | (91)     |
| Deferred:                                     |        |          |          |
| Domestic                                      | (308)  | (572)    | 360      |
| Foreign                                       | (125)  | (660)    | (159)    |
| Total deferred                                | (433)  | (1,232)  | 201      |
| Total                                         | \$ 138 | \$ (274) | \$ 110   |

Differences between the effective income tax rate and the U.S. statutory tax rate were as follows:

|                                                                 | 2013   | 2012    | 2011   |
|-----------------------------------------------------------------|--------|---------|--------|
| Statutory tax rate on earnings from continuing operations       | 35.0%  | 35.0%   | 35.0%  |
| Benefit of lower tax rates and tax exemptions on foreign income | (18.0) | (75.7)  | (14.9) |
| Resolution of certain tax positions pertaining to prior years   | (9.3)  | (69.4)  | (14.0) |
| Effect of retroactive legislation                               | (4.1)  |         |        |
| State taxes, net of federal benefit                             | 1.7    | 3.4     | (0.3)  |
| All other, net                                                  | 0.2    | 17.0    | 3.1    |
| Effective tax rate on earnings from continuing operations       | 5.5%   | (89.7)% | 8.9%   |

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 13 Taxes on Earnings from Continuing Operations (Continued)

The tax effect of the differences that give rise to deferred tax assets and liabilities were as follows:

| (in millions)                                                                          | 2013     | 2012     |
|----------------------------------------------------------------------------------------|----------|----------|
| Deferred tax assets:                                                                   |          |          |
| Compensation and employee benefits                                                     | \$ 862   | \$ 1,936 |
| Other, primarily reserves not currently deductible, and NOL's and credit carryforwards | 2,908    | 3,278    |
| Trade receivable reserves                                                              | 155      | 557      |
| Inventory reserves                                                                     | 137      | 211      |
| Deferred intercompany profit                                                           | 274      | 1,095    |
| State income taxes                                                                     | 196      | 197      |
| Total deferred tax assets                                                              | 4,532    | 7,274    |
| Deferred tax liabilities:                                                              |          |          |
| Depreciation                                                                           | (72)     | (75)     |
| Other, primarily the excess of book basis over tax basis of intangible assets          | (1,774)  | (2,447)  |
| Total deferred tax liabilities                                                         | (1,846)  | (2,522)  |
| Total net deferred tax assets                                                          | \$ 2,686 | \$ 4,752 |

Abbott has incurred losses in a foreign jurisdiction where realization of the future economic benefit is so remote that the benefit is not reflected as a deferred tax asset. Valuation allowances for recorded deferred tax assets were not significant.

The following table summarizes the gross amounts of unrecognized tax benefits without regard to reduction in tax liabilities or additions to deferred tax assets and liabilities if such unrecognized tax benefits were settled:

| (in millions)                              | 2013     | 2012     |
|--------------------------------------------|----------|----------|
| January 1                                  | \$ 2,257 | \$ 2,123 |
| Increase due to current year tax positions | 244      | 673      |
| Increase due to prior year tax positions   | 152      | 62       |
| Decrease due to prior year tax positions   | (541)    | (438)    |
| Lapse of statute                           | (23)     |          |
| Settlements                                | (124)    | (163)    |
| December 31                                | \$ 1,965 | \$ 2,257 |

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

The total amount of unrecognized tax benefits that, if recognized, would impact the effective tax rate is approximately \$1.7 billion. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by \$350 million to \$425 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

**Abbott Laboratories and Subsidiaries**

**Notes to Consolidated Financial Statements (Continued)**

**Note 14 Segment and Geographic Area Information**

Abbott's principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott's products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies throughout the world. As a result of the separation of AbbVie, Abbott no longer has a Proprietary Pharmaceutical Products segment and this business has been removed from the 2012 and 2011 historical information presented below. Abbott's reportable segments are as follows:

*Established Pharmaceutical Products* International sales of a broad line of branded generic pharmaceutical products.

*Nutritional Products* Worldwide sales of a broad line of adult and pediatric nutritional products.

*Diagnostic Products* Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

*Vascular Products* Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

Abbott's underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, effective January 1, 2013, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment's assets. The segment information below for 2012 and 2011 has been adjusted to exclude intangible asset amortization from operating earnings and intangible assets and goodwill from the total segment asset information. The following segment information has been prepared in accordance with the

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 14 Segment and Geographic Area Information (Continued)

internal accounting policies of Abbott, as described above, and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

| (in millions)                    | Net Sales to External Customers (a) |                  |                  | Operating Earnings (a) |                 |                 |
|----------------------------------|-------------------------------------|------------------|------------------|------------------------|-----------------|-----------------|
|                                  | 2013                                | 2012             | 2011             | 2013                   | 2012            | 2011            |
| Established Pharmaceuticals      | \$ 4,974                            | \$ 5,121         | \$ 5,355         | \$ 1,182               | \$ 1,237        | \$ 1,254        |
| Nutritionals                     | 6,740                               | 6,461            | 5,989            | 1,263                  | 1,020           | 792             |
| Diagnostics                      | 4,545                               | 4,292            | 4,126            | 1,008                  | 825             | 794             |
| Vascular                         | 3,012                               | 3,071            | 3,333            | 962                    | 1,020           | 1,111           |
| <b>Total Reportable Segments</b> | <b>19,271</b>                       | <b>18,945</b>    | <b>18,803</b>    | <b>\$ 4,415</b>        | <b>\$ 4,102</b> | <b>\$ 3,951</b> |
| Other                            | 2,577                               | 2,549            | 2,604            |                        |                 |                 |
| <b>Total</b>                     | <b>\$ 21,848</b>                    | <b>\$ 21,494</b> | <b>\$ 21,407</b> |                        |                 |                 |

(a)

Net sales and operating earnings were unfavorably affected by the relatively stronger U.S. dollar in 2013 and 2012 and were favorably affected by the relatively weaker U.S. dollar in 2011.

|                                                         | 2013            | 2012          | 2011            |
|---------------------------------------------------------|-----------------|---------------|-----------------|
|                                                         | (in millions)   |               |                 |
| Total Reportable Segment Operating Earnings             | \$ 4,415        | \$ 4,102      | \$ 3,951        |
| Corporate functions and benefit plans costs             | (514)           | (598)         | (529)           |
| Non-reportable segments                                 | 423             | 443           | 457             |
| Net interest expense                                    | (90)            | (288)         | (294)           |
| Net loss on extinguishment of debt                      |                 | (1,351)       |                 |
| Share-based compensation                                | (262)           | (284)         | (256)           |
| Amortization of intangible assets                       | (791)           | (795)         | (884)           |
| Other, net (b)                                          | (660)           | (924)         | (1,209)         |
| <b>Earnings from Continuing Operations before Taxes</b> | <b>\$ 2,521</b> | <b>\$ 305</b> | <b>\$ 1,236</b> |



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

**Note 14 Segment and Geographic Area Information (Continued)**

(b)

Other, net includes: charges for cost reduction initiatives of approximately \$350 million in 2013 and \$430 million in 2012; and charges of \$240 million in 2011 for cost reduction initiatives and integration.

| (in millions)                    | Depreciation  |                 |                 | Additions to Long-term Assets |                 |                 | Total Assets     |                  |                  |
|----------------------------------|---------------|-----------------|-----------------|-------------------------------|-----------------|-----------------|------------------|------------------|------------------|
|                                  | 2013          | 2012            | 2011            | 2013                          | 2012            | 2011            | 2013             | 2012             | 2011             |
| Established Pharmaceuticals      | \$ 84         | \$ 156          | \$ 169          | \$ 128                        | \$ 237          | \$ 122          | \$ 2,637         | \$ 2,805         | \$ 4,348         |
| Nutritionals                     | 190           | 175             | 167             | 340                           | 428             | 205             | 3,518            | 3,211            | 2,939            |
| Diagnostics                      | 368           | 295             | 313             | 394                           | 349             | 394             | 3,312            | 3,286            | 3,218            |
| Vascular                         | 122           | 76              | 99              | 62                            | 69              | 109             | 1,711            | 1,834            | 1,400            |
| <b>Total Reportable Segments</b> | <b>764</b>    | <b>702</b>      | <b>748</b>      | <b>924</b>                    | <b>1,083</b>    | <b>830</b>      | <b>\$ 11,178</b> | <b>\$ 11,136</b> | <b>\$ 11,905</b> |
| Other                            | 164           | 661             | 647             | 982                           | 902             | 845             |                  |                  |                  |
| <b>Total</b>                     | <b>\$ 928</b> | <b>\$ 1,363</b> | <b>\$ 1,395</b> | <b>\$ 1,906</b>               | <b>\$ 1,985</b> | <b>\$ 1,675</b> |                  |                  |                  |

|                                            | 2013             | 2012             | 2011             |
|--------------------------------------------|------------------|------------------|------------------|
|                                            | (in millions)    |                  |                  |
| Total Reportable Segment Assets            | \$ 11,178        | \$ 11,136        | \$ 11,905        |
| Cash, investments and restricted funds (c) | 8,217            | 15,448           | 8,476            |
| Current deferred income taxes (c)          | 2,528            | 2,986            | 2,701            |
| Non-reportable segments                    | 1,181            | 1,167            | 1,148            |
| Goodwill and intangible assets (c)         | 15,507           | 24,362           | 25,695           |
| All other (c)                              | 4,342            | 12,136           | 10,352           |
| <b>Total Assets</b>                        | <b>\$ 42,953</b> | <b>\$ 67,235</b> | <b>\$ 60,277</b> |

(c)

In 2012 and 2011, the reported amounts include assets associated with the businesses transferred to AbbVie as part of the separation.

## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 14 Segment and Geographic Area Information (Continued)

|                     | Net Sales to External<br>Customers (d) |           |           | Long-term Assets (e) |           |           |
|---------------------|----------------------------------------|-----------|-----------|----------------------|-----------|-----------|
|                     | 2013                                   | 2012      | 2011      | 2013                 | 2012      | 2011      |
|                     | <i>(in millions)</i>                   |           |           |                      |           |           |
| United States       | \$ 6,269                               | \$ 6,349  | \$ 6,302  | \$ 7,884             | \$ 15,244 | \$ 15,867 |
| Japan               | 1,442                                  | 1,723     | 1,726     | 902                  | 1,169     | 1,225     |
| Germany             | 1,070                                  | 984       | 1,058     | 1,040                | 6,173     | 5,909     |
| The Netherlands     | 960                                    | 1,107     | 1,204     | 560                  | 532       | 462       |
| China               | 1,083                                  | 859       | 625       | 356                  | 259       | 127       |
| India               | 922                                    | 919       | 917       | 3,080                | 3,467     | 3,160     |
| Brazil              | 470                                    | 448       | 470       | 216                  | 200       | 186       |
| Switzerland         | 792                                    | 693       | 591       | 1,117                | 1,214     | 1,045     |
| Canada              | 734                                    | 753       | 652       | 368                  | 352       | 237       |
| Italy               | 726                                    | 719       | 761       | 100                  | 222       | 229       |
| France              | 680                                    | 667       | 781       | 213                  | 220       | 214       |
| Russia              | 525                                    | 485       | 427       | 30                   | 37        | 21        |
| Spain               | 413                                    | 417       | 447       | 326                  | 314       | 293       |
| United Kingdom      | 479                                    | 497       | 475       | 1,380                | 1,345     | 1,273     |
| All Other Countries | 5,283                                  | 4,874     | 4,971     | 6,133                | 5,164     | 6,260     |
| Consolidated        | \$ 21,848                              | \$ 21,494 | \$ 21,407 | \$ 23,705            | \$ 35,912 | \$ 36,508 |

(d) Sales by country are based on the country that sold the product.

(e) Amounts reported in 2012 and 2011 include assets associated with businesses transferred to AbbVie as part of the separation.



## Abbott Laboratories and Subsidiaries

## Notes to Consolidated Financial Statements (Continued)

## Note 15 Quarterly Results (Unaudited)

(in millions except per share data)

|                                            | 2013     | 2012     |
|--------------------------------------------|----------|----------|
| <b>First Quarter</b>                       |          |          |
| Continuing Operations:                     |          |          |
| Net Sales                                  | \$ 5,378 | \$ 5,284 |
| Gross Profit                               | 2,747    | 2,716    |
| Earnings from Continuing Operations        | 545      | 351      |
| Basic Earnings per Common Share            | 0.35     | 0.22     |
| Diluted Earnings per Common Share          | 0.34     | 0.22     |
| Net Earnings                               | 545      | 1,242    |
| Basic Earnings Per Common Share (a)        | 0.35     | 0.79     |
| Diluted Earnings Per Common Share (a)      | 0.34     | 0.78     |
| Market Price Per Share-High (b)            | 35.34    | 29.42    |
| Market Price Per Share-Low (b)             | 31.64    | 25.82    |
| <b>Second Quarter</b>                      |          |          |
| Continuing Operations:                     |          |          |
| Net Sales                                  | \$ 5,446 | \$ 5,313 |
| Gross Profit                               | 2,704    | 2,748    |
| Earnings from Continuing Operations        | 476      | 411      |
| Basic Earnings per Common Share            | 0.30     | 0.26     |
| Diluted Earnings per Common Share          | 0.30     | 0.26     |
| Net Earnings                               | 476      | 1,725    |
| Basic Earnings Per Common Share (a)        | 0.30     | 1.09     |
| Diluted Earnings Per Common Share (a)      | 0.30     | 1.08     |
| Market Price Per Share-High (b)            | 38.77    | 30.85    |
| Market Price Per Share-Low (b)             | 34.69    | 28.25    |
| <b>Third Quarter</b>                       |          |          |
| Continuing Operations:                     |          |          |
| Net Sales                                  | \$ 5,369 | \$ 5,265 |
| Gross Profit                               | 2,722    | 2,581    |
| Earnings from Continuing Operations        | 773      | 339      |
| Basic Earnings per Common Share            | 0.50     | 0.21     |
| Diluted Earnings per Common Share          | 0.49     | 0.21     |
| Net Earnings                               | 966      | 1,943    |
| Basic Earnings Per Common Share (a)        | 0.62     | 1.22     |
| Diluted Earnings Per Common Share (a)      | 0.61     | 1.21     |
| Market Price Per Share-High (b)            | 37.16    | 33.69    |
| Market Price Per Share-Low (b)             | 32.70    | 30.39    |
| <b>Fourth Quarter</b>                      |          |          |
| Continuing Operations:                     |          |          |
| Net Sales                                  | \$ 5,655 | \$ 5,632 |
| Gross Profit                               | 2,844    | 2,837    |
| Earnings (loss) from Continuing Operations | 589      | (522)    |
| Basic Earnings per Common Share            | 0.38     | (0.33)   |
| Diluted Earnings per Common Share          | 0.37     | (0.33)   |
| Net Earnings                               | 589      | 1,053    |
| Basic Earnings Per Common Share (a)        | 0.38     | 0.66     |
| Diluted Earnings Per Common Share (a)      | 0.37     | 0.66     |
| Market Price Per Share-High (b)            | 38.81    | 34.67    |
| Market Price Per Share-Low (b)             | 32.75    | 29.96    |

(a)

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

The sum of the four quarters' of earnings per share for 2013 and 2012 may not add to the full year earnings per share amount due to rounding and/or the use of quarter-to-date weighted average shares to calculate the earnings per share amount in each respective quarter.

(b)

The 2012 market prices per share reflect historical share prices that have been adjusted to reflect the separation of AbbVie.

**MANAGEMENT REPORT ON INTERNAL CONTROL  
OVER FINANCIAL REPORTING**

The management of Abbott Laboratories is responsible for establishing and maintaining adequate internal control over financial reporting. Abbott's internal control system was designed to provide reasonable assurance to the company's management and board of directors regarding the preparation and fair presentation of published financial statements.

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Abbott's management assessed the effectiveness of the company's internal control over financial reporting as of December 31, 2013. In making this assessment, it used the criteria set forth in *Internal Control - Integrated Framework (1992)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment, we believe that, as of December 31, 2013, the company's internal control over financial reporting was effective based on those criteria.

Abbott's independent registered public accounting firm has issued an audit report on their assessment of the effectiveness of the company's internal control over financial reporting. This report appears on page 86.

Miles D. White  
CHAIRMAN OF THE BOARD AND CHIEF EXECUTIVE OFFICER

Thomas C. Freyman  
EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER

Robert E. Funck  
VICE PRESIDENT, CONTROLLER

February 21, 2014

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Shareholders of Abbott Laboratories:

We have audited the accompanying consolidated balance sheets of Abbott Laboratories and subsidiaries (the "Company") as of December 31, 2013 and 2012, and the related consolidated statements of earnings, comprehensive income, shareholders' investment, and cash flows for each of the three years in the period ended December 31, 2013. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2013 and 2012, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2013, in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 2 to the consolidated financial statements, on January 1, 2013, the Company distributed all of the outstanding shares of AbbVie Inc., which encompasses the Company's research-based pharmaceuticals business, to the Company's shareholders. Also, as discussed in Note 1, in 2011 the Company changed the year end of its foreign subsidiaries from a November 30 fiscal year end to a December 31 calendar year end.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company's internal control over financial reporting as of December 31, 2013, based on criteria established in *Internal Control - Integrated Framework (1992)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 21, 2014 expressed an unqualified opinion on the Company's internal control over financial reporting.

/s/ Deloitte & Touche LLP

Chicago, Illinois  
February 21, 2014

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To The Board of Directors and Shareholders of Abbott Laboratories:

We have audited the internal control over financial reporting of Abbott Laboratories and subsidiaries (the "Company") as of December 31, 2013, based on criteria established in *Internal Control – Integrated Framework (1992)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying *Management Report on Internal Control over Financial Reporting*. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company's internal control over financial reporting is a process designed by, or under the supervision of, the company's principal executive and principal financial officers, or persons performing similar functions, and effected by the company's board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on the criteria established in *Internal Control – Integrated Framework (1992)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements of the Company as of and for the year ended December 31, 2013 and our report dated February 21, 2014 expressed an unqualified opinion on those financial statements and includes an explanatory paragraph regarding the distribution of the shares of AbbVie Inc. to the Company's shareholders and the Company's change to the year end of its foreign subsidiaries.

/s/ Deloitte & Touche LLP

Chicago, Illinois  
February 21, 2014

**ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

As previously reported on Abbott's Current Report on Form 8-K, dated December 14, 2012, the Audit Committee of Abbott's Board of Directors approved the dismissal of Deloitte & Touche LLP (Deloitte) as Abbott's independent registered public accountant, effective as of the date of Deloitte's completion of the audit services for the fiscal year ended December 31, 2013 and the filing of Abbott's 2013 Annual Report on Securities and Exchange Commission Form 10-K, and approved the appointment of Ernst & Young LLP as Abbott's independent registered public accounting firm to perform independent audit services beginning with the fiscal year ending December 31, 2014.

During the fiscal years ended December 31, 2013, 2012 and 2011, and through February 21, 2014, (i) there were no disagreements (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between Abbott and Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of Deloitte, would have caused Deloitte to make reference to the subject matter of the disagreement in connection with its reports on Abbott's consolidated financial statements for such years, and (ii) there were no "reportable events" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

**ITEM 9A. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

*Evaluation of disclosure controls and procedures.* The Chief Executive Officer, Miles D. White, and the Chief Financial Officer, Thomas C. Freyman, evaluated the effectiveness of Abbott Laboratories' disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories' disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 (the Exchange Act) is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

**Internal Control Over Financial Reporting**

*Management's annual report on internal control over financial reporting.* Management's report on Abbott's internal control over financial reporting is included on page 84 hereof. The report of Abbott's independent registered public accounting firm related to their assessment of the effectiveness of internal control over financial reporting is included on page 86 hereof.

*Changes in internal control over financial reporting.* During the quarter ended December 31, 2013, there were no changes in Abbott's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott's internal control over financial reporting.

**ITEM 9B. OTHER INFORMATION**

None.

## PART III

## ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Incorporated herein by reference are "Nominees for Election as Directors," "Committees of the Board of Directors," "Section 16(a) Beneficial Ownership Reporting Compliance," and "Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting" to be included in the 2014 Abbott Laboratories Proxy Statement. The 2014 Proxy Statement will be filed on or about March 14, 2014. Also incorporated herein by reference is the text found under the caption, "Executive Officers of the Registrant" on pages 19 through 21 hereof.

Abbott has adopted a code of ethics that applies to its principal executive officer, principal financial officer, and principal accounting officer and controller. That code is part of Abbott's code of business conduct which is available free of charge through Abbott's investor relations website ([www.abbottinvestor.com](http://www.abbottinvestor.com)). Abbott intends to include on its website any amendment to, or waiver from, a provision of its code of ethics that applies to Abbott's principal executive officer, principal financial officer, and principal accounting officer and controller that relates to any element of the code of ethics definition enumerated in Item 406(b) of Regulation S-K.

## ITEM 11. EXECUTIVE COMPENSATION

The material to be included in the 2014 Proxy Statement under the headings "2013 Director Compensation," and "Executive Compensation," and "Compensation Committee Report" is incorporated herein by reference. The 2014 Proxy Statement will be filed on or about March 14, 2014.

## ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

(a) *Equity Compensation Plan Information.*

The following table presents information as of December 31, 2013 about our compensation plans under which Abbott common shares have been authorized for issuance.

| Plan Category                                              | (a)<br>Number of<br>securities to be<br>issued upon<br>exercise of<br>outstanding<br>options,<br>warrants<br>and rights | (b)<br>Weighted-<br>average exercise<br>price of<br>outstanding<br>options,<br>warrants and<br>rights | (c)<br>Number of<br>securities<br>remaining<br>available for<br>future issuance<br>under equity<br>compensation<br>plans (excluding<br>securities<br>reflected in<br>column (a)) |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Equity compensation plans approved by security holders (1) | 42,757,340                                                                                                              | \$ 26.15                                                                                              | 137,024,619                                                                                                                                                                      |
| Equity compensation plans not approved by security holders | 0                                                                                                                       |                                                                                                       | 0                                                                                                                                                                                |
| Total (1)                                                  | 42,757,340                                                                                                              | \$ 26.15                                                                                              | 137,024,619                                                                                                                                                                      |

(1)

(i) *Abbott Laboratories 1996 Incentive Stock Program.* Benefits under the 1996 Program include stock options intended to qualify for special tax treatment under Section 422 of the Internal Revenue Code ("incentive stock options"), stock options that do not qualify for that special tax treatment ("non-qualified stock options"), restricted stock, restricted stock units, stock appreciation rights, performance awards, and foreign qualified benefits. The shares that remain available for issuance under the 1996 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards may be satisfied only from treasury shares).





## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 1996 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the 1996 Program. If shares are issued under any benefit under the 1996 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott, the shares subject to or reserved for that benefit, or so reacquired, may not again be used for new stock options, rights, or awards of any type authorized under the 1996 Program.

In April 2009, the 1996 Program was replaced by the Abbott Laboratories 2009 Incentive Stock Program. No further awards will be granted under the 1996 Program.

(ii) *Abbott Laboratories 2009 Incentive Stock Program.* Benefits under the 2009 Program include stock options that do not qualify for special tax treatment under Section 422 of the Internal Revenue Code ("non-qualified stock options"), restricted stock, restricted stock units, performance awards, other share-based awards (including stock appreciation rights, dividend equivalents and recognition awards), awards to non-employee directors, and foreign benefits. The shares that remain available for issuance under the 2009 Program may be issued in connection with any one of these benefits and may be either authorized but unissued shares or treasury shares (except that restricted stock awards are satisfied from treasury shares).

If there is a lapse, expiration, termination, forfeiture or cancellation of any benefit granted under the 2009 Program without the issuance of shares or payment of cash thereunder, the shares subject to or reserved for that benefit, or so reacquired, may again be used for new stock options, rights, or awards of any type authorized under the 2009 Program. If shares are issued under any benefit under the 2009 Program and thereafter are reacquired by Abbott pursuant to rights reserved upon their issuance, or pursuant to the payment of the purchase price of shares under stock options by delivery of other common shares of Abbott, the shares subject to or reserved for that benefit, or so reacquired, may not again be used for new stock options, rights, or awards of any type authorized under the 2009 Program.

(iii) *Abbott Laboratories 2009 Employee Stock Purchase Plan for Non-U.S. Employees.* Eligible employees of participating non-U.S. affiliates of Abbott may participate in this plan. An eligible employee may authorize payroll deductions at the rate of 1% to 10% of eligible compensation (in multiples of one percent) subject to a limit of US \$12,500 during any purchase cycle.

Purchase cycles are generally six months long and usually begin on August 1 and February 1. On the last day of each purchase cycle, Abbott uses participant contributions to acquire Abbott common shares. The shares acquired come from treasury shares. The purchase price is 85% of the lower of the fair market value of the shares on that date or on the first day of that purchase cycle.

(iv) *Advanced Medical Optics, Inc. Plans.* In 2009, in connection with its acquisition of Advanced Medical Optics, Inc., Abbott assumed options outstanding under the Amended and Restated Advanced Medical Optics, Inc. 2002 Incentive Compensation Plan, as amended; AMO's 2004 Stock Incentive Plan, as amended and restated; the Advanced Medical Optics, Inc. 2005 Incentive Compensation Plan; and the VISX, Incorporated 2000 Stock Plan. As of December 31, 2013, 1,125,820 options remained outstanding under the plans. These options have a weighted average purchase price of \$40.48. No further awards will be granted under the plans.

For additional information concerning the Abbott Laboratories 1996 Incentive Stock Program, the Abbott Laboratories 2009 Incentive Stock Program, and the Abbott Laboratories 2009 Employee Stock Purchase Plan for Non-U.S. Employees, see the discussion in Note 8 entitled "Incentive Stock Program" of the Notes to Consolidated Financial Statements included under Item 8, "Financial Statements and Supplementary Data."

(b)

*Information Concerning Security Ownership.* Incorporated herein by reference is the material under the heading "Security Ownership of Executive Officers and Directors" in the 2014 Proxy Statement. The 2014 Proxy Statement will be filed on or about March 14, 2014.

**ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The material to be included in the 2014 Proxy Statement under the headings "The Board of Directors," "Committees of the Board of Directors," "Leadership Structure," "Director Selection," "Board Diversity," "Corporate Governance Materials," and "Approval Process for Related Person Transactions" is incorporated herein by reference. The 2014 Proxy Statement will be filed on or about March 14, 2014.

**ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES**

The material to be included in the 2014 Proxy Statement under the headings "Audit Fees and Non-Audit Fees" and "Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Auditor" is incorporated herein by reference. The 2014 Proxy Statement will be filed on or about March 14, 2014.

**PART IV**

**ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES**

(a)

*Documents filed as part of this Form 10-K.*

(1)

*Financial Statements:* See Item 8, "Financial Statements and Supplementary Data," on page 45 hereof, for a list of financial statements.

(2)

*Financial Statement Schedules:* The required financial statement schedules are found on the pages indicated below. These schedules should be read in conjunction with the Consolidated Financial Statements of Abbott Laboratories:

**Abbott Laboratories Financial Statement Schedules**

**Page No.**

Valuation and Qualifying Accounts (Schedule II)

94

Schedules I, III, IV, and V are not submitted because they are not applicable or not required

Report of Independent Registered Public Accounting Firm

95

Individual Financial Statements of businesses acquired by the registrant have been omitted pursuant to Rule 3.05 of Regulation S-X

(3)

*Exhibits Required by Item 601 of Regulation S-K:* The information called for by this paragraph is incorporated herein by reference to the Exhibit Index on pages 96 through 101 of this Form 10-K.

(b)

*Exhibits filed (see Exhibit Index on pages 96 through 101).*

(c)

*Financial Statement Schedule filed (page 94).*

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Abbott Laboratories has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ABBOTT LABORATORIES

By /s/ MILES D. WHITE

Miles D. White  
Chairman of the Board and  
Chief Executive Officer

Date: February 21, 2014

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Abbott Laboratories on February 21, 2014 in the capacities indicated below.

/s/ MILES D. WHITE

Miles D. White  
Chairman of the Board, Chief Executive Officer  
and Director of Abbott Laboratories  
(principal executive officer)

/s/ THOMAS C. FREYMAN

Thomas C. Freyman  
Executive Vice President, Finance and Chief  
Financial Officer (principal financial officer)

/s/ ROBERT E. FUNCK

Robert E. Funck  
Vice President and Controller  
(principal accounting officer)

/s/ ROBERT J. ALPERN, M.D.

Robert J. Alpern, M.D.  
Director of Abbott Laboratories

/s/ ROXANNE S. AUSTIN

Roxanne S. Austin  
Director of Abbott Laboratories

/s/ SALLY E. BLOUNT, PH.D.

Sally E. Blount, Ph.D.  
Director of Abbott Laboratories

/s/ W. JAMES FARRELL

W. James Farrell  
Director of Abbott Laboratories

/s/ EDWARD M. LIDDY

Edward M. Liddy  
Director of Abbott Laboratories

/s/ NANCY MCKINSTRY

Nancy McKinstry  
Director of Abbott Laboratories

Edgar Filing: ABBOTT LABORATORIES - Form 10-K

/s/ PHEBE N. NOVAKOVIC

Phebe N. Novakovic  
Director of Abbott Laboratories

/s/ SAMUEL C. SCOTT III

Samuel C. Scott III  
Director of Abbott Laboratories

/s/ WILLIAM A. OSBORN

William A. Osborn  
Director of Abbott Laboratories

/s/ GLENN F. TILTON

Glenn F. Tilton  
Director of Abbott Laboratories

**ABBOTT LABORATORIES AND SUBSIDIARIES**  
**SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS**  
**FOR THE YEARS ENDED DECEMBER 31, 2013, 2012, AND 2011**  
(in millions of dollars)

| <b>Allowances for Doubtful<br/>Accounts and Product Returns</b> | <b>Balance<br/>at Beginning<br/>of Year</b> | <b>Provisions/<br/>Charges<br/>to Income</b> | <b>Amounts<br/>Charged Off<br/>and Other<br/>Deductions</b> | <b>Balance at<br/>End of Year</b> |
|-----------------------------------------------------------------|---------------------------------------------|----------------------------------------------|-------------------------------------------------------------|-----------------------------------|
| 2013                                                            | \$ 406                                      | \$ 163                                       | \$ (257)(1)                                                 | \$ 312                            |
| 2012                                                            | 421                                         | 343                                          | (358)                                                       | 406                               |
| 2011                                                            | 389                                         | 430                                          | (398)                                                       | 421                               |

(1)

Includes \$178 million transferred to AbbVie as part of the separation on January 1, 2013.

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Board of Directors and Shareholders of Abbott Laboratories:

We have audited the consolidated financial statements of Abbott Laboratories and subsidiaries (the "Company") as of December 31, 2013 and 2012, and for each of the three years in the period ended December 31, 2013, and the Company's internal control over financial reporting as of December 31, 2013, and have issued our reports thereon dated February 21, 2014, which report relating to the consolidated financial statements expresses an unqualified opinion and includes an explanatory paragraph regarding the distribution of the shares of AbbVie Inc. to the Company's shareholders and the Company's change to the year end of its foreign subsidiaries; such reports are included elsewhere in this Form 10-K. Our audits also included the consolidated financial statement schedule of the Company listed in Item 15. This consolidated financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion based on our audits. In our opinion, such consolidated financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ DELOITTE & TOUCHE LLP

Chicago, Illinois  
February 21, 2014

**EXHIBIT INDEX**  
**ABBOTT LABORATORIES**  
**ANNUAL REPORT**  
**FORM 10-K**  
**2013**

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be "filed under the Securities Exchange Act of 1934."

**10-K**  
**Exhibit**  
**Table**  
**Item No.**

- 2.1 \*Amendment No. 2 to Business Transfer Agreement dated January 29, 2011, by and among Abbott Healthcare Private Limited, Abbott Laboratories, Piramal Healthcare Limited ("Piramal") and certain shareholders of Piramal, filed as Exhibit 2 to the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.
- 2.2 \*Separation and Distribution Agreement, dated as of November 28, 2012, by and between Abbott Laboratories and AbbVie Inc., filed as Exhibit 2.1 to the Abbott Laboratories Current Report on Form 8-K dated November 28, 2012.  
 Certain schedules and exhibits have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Abbott will furnish supplemental copies of any such schedules or exhibits to the U.S. Securities and Exchange Commission upon request.
- 3.1 \*Articles of Incorporation, Abbott Laboratories, filed as Exhibit 3.1 to the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.
- 3.2 \*By-Laws of Abbott Laboratories, as amended and restated effective April 27, 2012, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K dated February 17, 2012.
- 4.1 \*Indenture dated as of February 9, 2001, between Abbott Laboratories and The Bank of New York Mellon Trust Company, N.A. (as successor to J.P. Morgan Trust Company, National Association, successor to Bank One Trust Company, N.A.) (including form of Security), filed as Exhibit 4.1 to the Abbott Laboratories Registration Statement on Form S-3 dated February 12, 2001.
- 4.2 \*Supplemental Indenture dated as of February 27, 2006, between Abbott Laboratories and The Bank of New York Mellon Trust Company, N.A. (as successor to J.P. Morgan Trust Company, National Association), filed as Exhibit 4.2 to the Abbott Laboratories Registration Statement on Form S-3 dated February 28, 2006.
- 4.3 \*Form of \$1,000,000,000 6.150% Note due 2037, filed as Exhibit 99.6 to the Abbott Laboratories Current Report on Form 8-K dated November 6, 2007.
- 4.4 \*Actions of the Authorized Officers with respect to Abbott's 5.150% Notes due 2012, 5.600% Notes due 2017 and 6.150% Notes due 2037, filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated November 6, 2007.
- 4.5 \*Form of \$2,000,000,000 5.125% Note due 2019, filed as Exhibit 99.4 to the Abbott Laboratories Current Report on Form 8-K dated February 26, 2009.
- 4.6 \*Form of \$1,000,000,000 6.000% Note due 2039, filed as Exhibit 99.5 to the Abbott Laboratories Current Report on Form 8-K dated February 26, 2009.



## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

### 10-K Exhibit Table Item No.

- 4.7 \*Actions of the Authorized Officers with respect to Abbott's 5.125% Note due 2019 and 6.000% Note due 2039, filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated February 26, 2009.
- 4.8 \*Form of 2020 Note, filed as Exhibit 99.5 to the Abbott Laboratories Current Report on Form 8-K dated May 27, 2010.
- 4.9 \*Form of 2040 Note, filed as Exhibit 99.6 to the Abbott Laboratories Current Report on Form 8-K dated May 27, 2010.
- 4.10 \*Actions of the Authorized Officers with respect to Abbott's 2.70% Notes, 4.125% Notes and 5.30% Notes, filed as Exhibit 99.3 to the Abbott Laboratories Current Report on Form 8-K dated May 27, 2010.  
Other debt instruments are omitted in accordance with Item 601(b)(4)(iii)(A) of Regulation S-K. Copies of such agreements will be furnished to the Securities and Exchange Commission upon request.
- 10.1 \*Supplemental Plan Abbott Laboratories Extended Disability Plan, filed as an exhibit (pages 50-51) to the 1992 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.2 \*Abbott Laboratories Deferred Compensation Plan, as amended effective January 1, 2008, filed as Exhibit 4.1 to the 2008 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.3 \*Abbott Laboratories 401(k) Supplemental Plan, as amended and restated, filed as Exhibit 10.3 to the 2013 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.4 \*Abbott Laboratories Supplemental Pension Plan, as amended and restated, filed as Exhibit 10.4 to the 2013 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.5 The 1986 Abbott Laboratories Management Incentive Plan, as amended and restated.\*\*
- 10.6 \*1998 Abbott Laboratories Performance Incentive Plan, as amended effective January 1, 2008, filed as Exhibit 10.7 to the 2008 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.7 \*Rules for the 1998 Abbott Laboratories Performance Incentive Plan, as amended and restated, filed as Exhibit 10.7 to the 2013 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.8 \*The Abbott Laboratories 1996 Incentive Stock Program, as amended and restated through the 6th Amendment February 20, 2009, filed as Exhibit 10.11 to the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2009.\*\*
- 10.9 \*Abbott Laboratories 2009 Incentive Stock Program, as amended and restated, filed as Exhibit 10.9 to the 2013 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.10 \*Abbott Laboratories Non-Employee Directors' Fee Plan, as amended and restated, filed as Exhibit 10.10 to the 2013 Abbott Laboratories Annual Report on Form 10-K.\*\*
- 10.11 \*Form of Non-Employee Director Stock Option Agreement under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 18, 2005, filed as Exhibit 10.7 to the Abbott Laboratories Current Report on Form 8-K dated February 18, 2005.\*\*
- 10.12 \*Form of Employee Stock Option Agreement for a Non-Qualified Stock Option granted with an Incentive Stock Option under the Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.1 to the Abbott Laboratories Current Report on Form 8-K dated August 20, 2004.\*\*

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

**10-K  
Exhibit  
Table  
Item No.**

- 10.13 \*Form of Employee Stock Option Agreement for a Non-Qualified Stock Option under the Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated August 20, 2004.\*\*
- 10.14 \*Form of Employee Stock Option Agreement for an Incentive Stock Option granted with a Non-Qualified Stock Option under the Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on Form 8-K dated August 20, 2004.\*\*
- 10.15 \*Form of Employee Stock Option Agreement for an Incentive Stock Option under the Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K dated August 20, 2004.\*\*
- 10.16 \*Form of Employee Stock Option Agreement for a Replacement Stock Option under the Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.5 to the Abbott Laboratories Current Report on Form 8-K dated August 20, 2004.\*\*
- 10.17 \*Form of Non-Employee Director Restricted Stock Unit Agreement under Abbott Laboratories 1996 Incentive Stock Program, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated December 10, 2004.\*\*
- 10.18 \*Form of Employee Stock Option Agreement for a Non-Qualified Stock Option granted with an Incentive Stock Option under the Abbott Laboratories 1996 Incentive Stock Program on or after February 18, 2005, filed as Exhibit 10.1 to the Abbott Laboratories Current Report on Form 8-K dated February 18, 2005.\*\*
- 10.19 \*Form of Employee Stock Option Agreement for a new Non-Qualified Stock Option under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 18, 2005, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated February 18, 2005.\*\*
- 10.20 \*Form of Employee Stock Option Agreement for an Incentive Stock Option granted with a Non-Qualified Stock Option under the Abbott Laboratories 1996 Incentive Stock Program on or after February 18, 2005, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on Form 8-K dated February 18, 2005.\*\*
- 10.21 \*Form of Employee Stock Option Agreement for an Incentive Stock Option under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 18, 2005, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K dated February 18, 2005.\*\*
- 10.22 \*Form of Non-Qualified Stock Option Agreement for an award of non-qualified stock options under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 17, 2006, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K dated February 16, 2006.\*\*
- 10.23 \*Form of Non-Qualified Stock Option Agreement for an award of non-qualified stock options under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 20, 2009, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on Form 8-K dated February 20, 2009.\*\*

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

**10-K  
Exhibit  
Table  
Item No.**

- 10.24 \*Form of Non-Qualified Replacement Stock Option Agreement for an award of non-qualified replacement stock options under the Abbott Laboratories 1996 Incentive Stock Program granted on or after February 20, 2009, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on 8-K dated February 20, 2009.\*\*
- 10.25 \*Form of Non-Employee Director Non-Qualified Stock Option Agreement, filed as Exhibit 10.2 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.26 \*Form of Non-Employee Director Restricted Stock Unit Agreement, filed as Exhibit 10.3 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.27 \*Form of Non-Employee Director Non-Qualified Replacement Stock Option Agreement, filed as Exhibit 10.4 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.28 \*Form of Non-Qualified Stock Option Agreement (ratably vested), filed as Exhibit 10.5 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.29 \*Form of Non-Qualified Replacement Stock Option Agreement, filed as Exhibit 10.6 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.30 \*Form of Performance Restricted Stock Agreement, filed as Exhibit 10.7 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.31 \*Form of Restricted Stock Agreement (ratably vested), filed as Exhibit 10.8 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.32 \*Form of Restricted Stock Agreement (cliff vested), filed as Exhibit 10.9 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.33 \*Form of Performance Restricted Stock Agreement (annual performance based), filed as Exhibit 10.10 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.34 \*Form of Performance Restricted Stock Agreement (interim performance based), filed as Exhibit 10.11 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.35 \*Form of Restricted Stock Unit Agreement (cliff vested), filed as Exhibit 10.12 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.36 \*Form of Restricted Stock Unit Agreement (ratably vested), filed as Exhibit 10.13 to the Abbott Laboratories Current Report on Form 8-K dated April 24, 2009.\*\*
- 10.37 Form of Restricted Stock Unit Agreement (ratably vested).
- 10.38 Form of Restricted Stock Unit Agreement for foreign employees (ratably vested).
- 10.39 Form of Performance Restricted Stock Unit Agreement for foreign employees (annual performance based).
- 10.40 Form of Performance Restricted Stock Unit Agreement for foreign executive officers (annual performance based).
- 10.41 Form of Performance Restricted Stock Unit Agreement for foreign employees (interim performance based).
- 10.42 Form of Performance Restricted Stock Unit Agreement for foreign executive officers (interim performance based).

## Edgar Filing: ABBOTT LABORATORIES - Form 10-K

**10-K  
Exhibit  
Table  
Item No.**

- 10.43 Form of Restricted Stock Unit Agreement (cliff vested).
- 10.44 Form of Restricted Stock Unit Agreement for executive officers (cliff vested).
- 10.45 Form of Restricted Stock Unit Agreement for foreign employees (cliff vested).
- 10.46 Form of Restricted Stock Unit Agreement for foreign executive officers (cliff vested).
- 10.47 Form of Non-Employee Director Restricted Stock Unit Agreement.
- 10.48 Form of Non-Employee Director Restricted Stock Unit Agreement for foreign non-employee directors.
- 10.49 Form of Restricted Stock Unit Agreement for Participants in France.
- 10.50 Form of Restricted Stock Agreement (ratably vested).
- 10.51 Form of Restricted Stock Agreement for executive officers (ratably vested).
- 10.52 Form of Performance Restricted Stock Agreement (annual performance based).
- 10.53 Form of Performance Restricted Stock Agreement for executive officers (annual performance based).
- 10.54 Form of Performance Restricted Stock Agreement (interim performance based).
- 10.55 Form of Performance Restricted Stock Agreement for executive officers (interim performance based).
- 10.56 Form of Restricted Stock Agreement (cliff vested).
- 10.57 Form of Restricted Stock Agreement for executive officers (cliff vested).
- 10.58 Form of Non-Qualified Stock Option Agreement.
- 10.59 Form of Non-Qualified Stock Option Agreement for executive officers.
- 10.60 Form of Non-Qualified Stock Option Agreement for foreign employees.
- 10.61 Form of Non-Qualified Stock Option Agreement for foreign executive officers.
- 10.62 Form of Non-Qualified Replacement Stock Option Agreement.
- 10.63 Form of Non-Qualified Replacement Stock Option Agreement for foreign employees.
- 10.64 Form of Non-Employee Director Non-Qualified Stock Option Agreement.
- 10.65 Form of Non-Employee Director Non-Qualified Stock Option Agreement for foreign non-employee directors.
- 10.66 Form of UK Option Award Agreement.
- 10.67 Form of UK Option Award Agreement for executive officers.
- 10.68 \*Form of Agreement Regarding Change in Control by and between Abbott Laboratories and certain named executive officers (other than Mr. White), filed as Exhibit 10.1 to the Abbott Laboratories Current Report on Form 8-K dated November 30, 2012.\*\*
- 10.69 \*Form of Time Sharing Agreement between Abbott Laboratories, Inc. and M.D. White and T.C. Freyman, filed as Exhibit 10.6 to the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended June 30, 2006.\*\*

# Edgar Filing: ABBOTT LABORATORIES - Form 10-K

## 10-K Exhibit Table Item No.

- 10.70 \*Amended and Restated Advanced Medical Optics, Inc. 2002 Incentive Compensation Plan, as amended, filed as Exhibit 4.3 to the Abbott Laboratories Registration Statement on Form S-8 dated March 20, 2009.\*\*
- 10.71 \*First Amendment to Amended and Restated Advanced Medical Optics, Inc. 2002 Incentive Compensation Plan, filed as Exhibit 4.4 to the Abbott Laboratories Registration Statement on Form S-8 dated March 20, 2009.\*\*
- 10.72 \*2004 Stock Incentive Plan, as amended and restated, filed as Exhibit 4.5 to the Abbott Laboratories Registration Statement on Form S-8 dated March 20, 2009.\*\*
- 10.73 \*Advanced Medical Optics, Inc. 2005 Incentive Compensation Plan, filed as Exhibit 4.6 to the Abbott Laboratories Registration Statement on Form S-8 dated March 20, 2009.\*\*
- 10.74 \*VISX, Incorporated 2000 Stock Plan, filed as Exhibit 4.8 to the Abbott Laboratories Registration Statement on Form S-8 dated March 20, 2009.\*\*
- 12 Computation of Ratio of Earnings to Fixed Charges.
- 21 Subsidiaries of Abbott Laboratories.
- 23.1 Consent of Independent Registered Public Accounting Firm.
- 31.1 Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
- 31.2 Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101 The following financial statements and notes from the Abbott Laboratories Annual Report on Form 10-K for the year ended December 31, 2013 filed on February 21, 2014, formatted in XBRL: (i) Consolidated Statement of Earnings; (ii) Consolidated Statement of Cash Flows; (iii) Consolidated Balance Sheet; (iv) Consolidated Statement of Shareholders' Investment; and (v) the notes to the consolidated financial statements.

The 2014 Abbott Laboratories Proxy Statement will be filed with the Securities and Exchange Commission under separate cover on or about March 14, 2014.

---

\*

Incorporated herein by reference. Commission file number 1-2189.

\*\*

Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.

Abbott will furnish copies of any of the above exhibits to a shareholder upon written request to the Secretary, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6400.